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The biopharmaceutical industry is at a crossroads, where changing industry and ethical 
demands means it must invest in research and development (R&D) to maintain a diverse 
pipeline of novel drugs, and simultaneously reduce the substantial risks and costs associated 
with this R&D. In the future, a complete toolkit of synthetic expression elements could be used 
to create a streamlined, rationalised next generation cell line development (CLD) process, 
maximising the benefits offered by synthetic biology. However, synthetic, predictable, 
titratable molecular biology tools have not yet been developed for all the desired steps of 
biopharmaceutical expression. In this thesis, I will present work endeavouring to expand this 
toolbox, by investigating synthetic control of glycoprotein expression through messenger 
RNA (mRNA) engineering.  
The tethering of various RNA-binding proteins to recombinant mRNA was tested, as a 
method of controlling mRNA processing, and stimulating intronless mRNA export. C1orf35 
and HuR were identified as target effector genes to increase transient protein production. 
However, inconsistency in their effect disqualified them as effective molecular biology tools. 
Two families of 3’ untranslated region (UTR) RNA elements were screened for their ability to 
control productivity through enhancement of mRNA stability. Though triple helices failed to 
increase expression, a stability element was discovered to increase transient SEAP 
productivity by 1.28-fold, via a mechanism of extension of SEAP mRNA half-life from 0.68h 
to 4.04h, compared to an industry-standard vector. 
5’ terminal oligo-pyrimidine (TOP) motifs were investigated for their ability to control 
productivity through translation initiation. Enhancement of transient titre was demonstrated 
with various recombinant proteins and culture conditions, chemical supplements screened 
for their ability to specifically affect 5’TOP activation, mechanism of titre control investigated, 
and 5’TOP motifs integrated with synthetic proximal and core promoters. Different 5’TOP 
motifs were shown to control titre of a biotherapeutic fusion protein in an industry transient 
production process, up to a 2.12-fold increase compared to an industry-standard vector. 
These synthetic elements were screened together for their modularity, demonstrating 
titratable control of SEAP titre, from a 0.82-fold decrease to a 5.23-fold increase compared to 
an industry-standard vector. Further steps were then recommended, to render these tools 
truly predictable, and contribute maximally towards a rationalised, next-generation CLD 
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1. Introduction and Literature Review 
1.1. Introduction  
1.1.1. What are Biopharmaceuticals? 
Tracing its intellectual lineage back to therapeutics as early as the invention of the cowpox 
vaccine in the 18th century by Edward Jenner (Riedel, 2005), the use of biologically inspired 
pharmaceuticals is a powerful tool in the fight for human health. The nomenclature and 
definitions attached to this area of medicine are wide, with products sometimes 
interchangeably referred to as biologics, biopharmaceuticals, and biological medicines. 
Regulatory bodies tend to define biopharmaceuticals by their production, for example the 
European Medicines Agency (EMA), defining them simply as ‘A medicine whose active 
substance is made by a living organism’ (EMA, 2019). Others argue for a more encompassing 
definition, pointing out that products such as oligonucleotides and peptides, while 
synthetically made, are clearly biologically derived, and should be classified as such (Rader, 
2008). Even laying this broader definition aside, drugs regulated as biopharmaceuticals are a 
very large field, accounting for 25% of products and 49% of sales in pharmaceuticals in 2017, 
projected to increase to 31% and 52% respectively by 2024 (Evaluate Pharma, 2018). In the 
United States, the biopharmaceutical sector accounts for 854,000 jobs, and 3.8% of total 
economic output (Thakor et al., 2017).  
The debate in nomenclature stems partially from the number of diverse biopharmaceutical 
products and fields. Most famous, for their stunning success in disease prevention, and in 
some cases extinction, are vaccines, which can take credit for the elimination of diseases such 
as polio, smallpox, and rubella as critical public health concerns (Stern and Markel, 2005). 
Another area, gene therapy is finally beginning to deliver on its initial promise (Naldini, 2015), 
with promising new technologies such as genome editing via CRISPR/Cas9 (Long et al., 2014; 
Maeder and Gersbach, 2016), and delivery by novel mechanisms, such as nebulisation and 
inhalation of mRNA (messenger ribonucleotide) (Patel et al., 2019). Elsewhere, lyophilized gut 
microbiota are administered as ‘live therapeutics’, specifically supplementing microbe 
populations and biosynthetic pathways affected by disease (Delday et al., 2018; O’Toole et al., 
2017; Raftis et al., 2018; Yuille et al., 2018). The field of cell therapy has varied applications, 
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such as treatment of Parkinson’s disease (Fu et al., 2015), and at the fulcrum between gene and 
cell therapy, CAR-T cell therapy, involving the removal, genetic engineering, and re-
introduction of immune cells is a field generating significant excitement (Yip and Webster, 
2018). However, in a prominent theme in biopharmaceuticals, CAR-T cell therapy is 
hampered by very high costs, which complicate the excitement based on its’ efficacy (Leech 
and Dusetzina, 2018; Xie, 2018). Whilst acknowledging the scope and breadth of the broader 
biopharmaceutical field, this review and thesis will be focusing on therapeutic glycoproteins, 
and specifically their upstream production in Chinese Hamster Ovary (CHO) cells. 
1.1.2. Therapeutic Glycoproteins 
As vaccines can trace their lineage back to Edward Jenner, so too can therapeutic 
glycoproteins trace theirs back to Banting and Macleod, and the first successful purification 
and administration of insulin, to a diabetic patient in 1922 (Joshi et al., 2007). Starting in 1982 
with the release of Humulin, the first recombinant insulin drug (Kinch, 2015), the original 
paradigm of production (extraction and purification from animals) has been supplanted by 
the expression of recombinant proteins. This paradigm, in which cultured cells containing 
recombinant DNA are used to synthesize an extracted product, remains by far the dominant 
industry methodology, despite the emergence of alternative expression platforms, such as 
cell-free expression systems, transgenic plants, and ‘pharming’ from genetically modified 
animals (Kesik-Brodacka, 2018; Lalonde and Durocher, 2017).  
As desire to produce more complex products arose, the correct folding and post-translational 
modification, such as glycosylation, of these proteins became paramount, in order that they 
be bioactive, long-lasting, and non-immunogenic in humans (Lalonde and Durocher, 2017). 
Thus, established first by the release of tissue plasminogen activator (t-PA),  produced in CHO 
cells in 1987 (Jayapal et al., 2007), mammalian cell cultures became the leading technology for 
the production of these glycoproteins. 
1.1.3. CHO Cells 
Multiple mammalian cell types are available for biopharmaceutical production, such as CHO, 
Human Embryonic Kidney (HEK-293), Myeloma, and Baby Hamster Kidney (BHK) (Jostock 
and Knopf, 2012; Sarantos and Cleo, 2013). Despite this breadth of available cell types, CHO 
cells are the dominant type used in this field, for example accounting for 61.5% of 
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biopharmaceutical production in the European Union (Sarantos and Cleo, 2013), and 75% of 
published research papers concerning biopharmaceutical production (Kunert and Reinhart, 
2016).  
Since they were first cultured in 1957 (Tjio and Puck, 1958), CHO cells have been a mainstay 
for mammalian genetic studies, sometimes referred to as the mammalian equivalent of the 
model bacteria E.coli (Jayapal et al., 2007). Most modern CHO cell lines for industrial 
glycoprotein production can trace their ancestry back to the CHO-K1 proline auxotroph 
created in 1967 (Puck and Kao, 1967), and subsequent addition of dihydrofolate-deficient 
mutations, creating the DXB11 and DG44 cell lines (Urlaub and Chasin, 1980; Urlaub et al., 
1983), allowing for widespread use of selective media in CHO cell culture, which will be 
discussed later in this review.  
CHO cells have a number of favourable characteristics, which have led to their dominance. 
CHO cells are able to grow in suspension media, making them ideal for industrial scaling. 
Few viruses can propagate in CHO cells, lessening risk of contamination. CHO cells can grow 
in serum-free, chemically defined media, contributing towards batch-reproducibility and 
regulatory compliance. The protein glycosylation pattern observed in CHO cells resembles 
that of human proteins, for instance with absence of the immunogenic α-galactose epitope 
(Lai et al., 2013). Strategies such as Dihydrofolate Reductase (DHFR)-linked and more recently 
Glutamine Synthetase (GS)-linked gene amplification have also been developed in CHO cells, 
allowing for high cell-specific productivity (Gaughan, 2016; Noh et al., 2018). Finally, the 
highly developed platform of CHO protein production is recognised by regulatory bodies, 
and can therefore streamline regulatory approval (Kim et al., 2012).  
1.1.4. Industry Landscape and Challenges 
For most of the history of mammalian cell-based glycoprotein production, the industry has 
been dominated by the ‘blockbuster’ model. Patent-protected biopharmaceuticals faced no 
competition, and could dominate markets. Humira, an anti-tumour necrosis factor alpha 
(TNFα) monoclonal antibody (mAb), has led worldwide sales since its’ FDA approval in 2002 
(Jayapal et al., 2007), continuing with global sales of $11bn in 2013 (Barnard et al., 2015), $16bn 
in 2016 (Moorkens et al., 2017), and is projected to remain the world’s highest selling 
biopharmaceutical until 2024 (Evaluate Pharma, 2018).  
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This landscape, however, is beginning to shift. A number of patents for high selling drugs, 
such as Remicade, are set to expire (Sarantos and Cleo, 2013). Biosimilars, duplicates of 
already approved drugs, with subtly different manufacturing processes, are being granted 
streamlined approval pipelines by regulatory bodies, to decrease costs and time to market, 
and to increase competition (Morrison, 2018). In the face of these changes, biopharmaceutical 
companies must diversify from this blockbuster modality. Companies are already being 
undercut by introduction of biosimilars, such as Sanofi introducing Admelog, a biosimilar of 
Eli Lilly’s Humalog (Morrison, 2018). Humira is only projected to remain at the top of 
biopharmaceutical sales because of legal challenges delaying the release of Adalimumab 
biosimilars until 2023 (Evaluate Pharma, 2018), and its manufacturer AbbVie’s reliance on the 
blockbuster model, as shown in Figure 1.1, potentially leaves it vulnerable to Humira being 
challenged on the market. 
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Figure 1.1 - Showing AbbVie’s proportional reliance on its flagship blockbuster drug, Humira. The proportion of 
total revenue derived from sales of Humira has increased from 45.47% in 2011 to 64.67% in 2017, which may 
leave AbbVie vulnerable to being undercut by Adalimumab biosimilars. Data gathered from 
https://www.macrotrends.net/stocks/charts/ABBV/abbvie/revenue. bn: billion. 
However, biopharmaceutical companies can neither financially, nor ethically, rely solely on 
these undercutting biosimilars to prosper. Orphan drugs, defined by the EMA as drugs that 
do not affect more than five in 10,000 people within the European Union, are already 
underrepresented in biopharmaceutical approvals, representing only 10 of 212 
biopharmaceuticals approved by the EMA by 2013 (Sarantos and Cleo, 2013). Furthermore, 
with patient pressure to justify exorbitantly high prices for such rare drugs rising (Evaluate 
Pharma, 2018; Xie, 2018), biopharmaceutical companies cannot continue to rely on the general 
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price-inelasticity of drugs to recoup their costs. Relying entirely on production of biosimilars 
mimicking already released drugs ducks this ethical issue, and deprives patient groups of 
potentially effective therapies. Financially, due to their competitive nature, biosimilars cannot 
act as flagship drugs (Morrison, 2018), and companies with the healthiest outlooks are those 
which have a diverse pipeline of novel therapeutics (Evaluate Pharma, 2018; Moorkens et al., 
2017).  
This innovation driven approach, though, is high in risk. Vector optimisation and cell line 
development for an industrial glycoprotein-producing cell line can take up to 20 weeks 
(Barnard et al., 2015; Rajendra et al., 2016), contributing to the cost of developing new 
biopharmaceuticals sometimes nearing $3bn (DiMasi et al., 2016). Risk remains high even after 
production, where only an estimated 9.6% of biopharmaceuticals will make it from phase I 
trials to regulatory approval (David W. Thomas et al., 2016). Some progress is being made, 
with a record 49 biopharmaceutical approvals in 2017, back up from a dip in 2016, although 5 
of those approvals were for biosimilars (Morrison, 2018). However, the biopharmaceutical 
industry remains a highly volatile one, at constant risk of making losses, due to the 
idiosyncratic risk of R&D failure. In fact, even the risk that has been considered systematic in 
biopharmaceutical industry is largely composed of the anticipated and systematised losses 
from this stochastic R&D leverage (Thakor et al., 2017).  
Put briefly, the challenge facing the biopharmaceutical industry is to continue to innovate, 
investing in R&D in pursuit of a diverse, novel pipeline, and to simultaneously find ways to 
mitigate the cost, time, and risk associated with its current R&D practices.  
1.2. Cell Line Development 
Once a therapeutic glycoprotein has been identified and designated for development, for 
instance after humanization of a clinically relevant mAb (Gaughan, 2016), or design of next-
generation antibody-drug conjugate (LoRusso et al., 2011), it moves into the process of cell line 
development (CLD). This is the process by which a product is taken from a gene to a 
manufacturing cell line suitable for clinical and market supply, which has been extensively 
screened and selected for critical parameters most relevant to biopharmaceutical production: 
high production levels and cell growth, amenability to scale-up, correct post-translational 
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modifications, and good safety profile (Rita Costa et al., 2010). This is an expensive and time-
consuming R&D process, historically taking up to a year (Jayapal et al., 2007; Lai et al., 2013), 
although this has since improved to general timescales of around 6 months (Jostock and 
Knopf, 2012; Rajendra et al., 2016). The archetypal CLD process will first be discussed, 
followed by the advances which have led to this progress, and the inefficiencies that remain. 
1.2.1. The Archetypal CLD Process 
The archetypal CLD process can be broken down into 8 steps:  
1. An expression plasmid containing the coding sequence (CDS) of interest and a 
selection maker is delivered to the host cell nucleus. This can be performed by a variety 
of methods, such as lipofection or electroporation. The vector is integrated randomly 
into the host cell chromosomes, and can land in transcriptionally active or inactive 
sites. 
2. The stably transfected cells are grown in selective media. For instance in the case of 
DHFR-deficient cells, cells are grown in medium deficient in glycine, hypoxanthine 
and thymidine, for which they are auxotrophic. Linkage of a DHFR gene with the 
vector allows selection of successfully transfected cells. GS-based selection can also be 
used, although this differs from DHFR selection in that most industrial CHO cell lines, 
such as DG44 are not GS-deficient, necessitating selection by inclusion of methionine 
sulfoximine (MSX), a GS inhibitor, in the medium (Jostock and Knopf, 2012). However, 
GS-deficient cell lines exhibiting high selection stringency have recently been 
developed to overcome this problem (Noh et al., 2018). Selection can also be mediated 
through antibiotic agents, such as a hygromycin resistance gene.  
3. Selected cells are scaled-up and recovered. 
4. Amplification is performed, in which an inhibitor of a vector-linked selection gene is 
added in increasing quantities, in order to encourage replication of the vector across 
the genome. Two options are commonly used for this step: DHFR and more recently 
GS (Lai et al., 2013). The two systems are similar, in that they use an inhibitor of an 
essential biosynthetic pathway, methotrexate (MTX) for DHFR and MSX for GS, for 
amplification, as shown in Figure 1. GS-linked amplification tends to require fewer 
steps in concentration, shortening CLD timelines (Noh et al., 2018). 
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5. A number of single-clone populations in the order of ~102 are isolated from these 
heterologous pools of amplified cells, and screened for favourable production 
characteristics in multi-well plates. 
6. A number of clonal populations in the order of ~101 are chosen and taken forward 
through expansion. 
7. Each clone is assessed in lab-scale bioreactors, designed to replicate conditions in 
industrial production, and screened again for favourable characteristics. 
8. A ‘winner’ clonal cell line is selected, and cryopreserved in cell banks, to be revived 





1.2.2. Developments in the CLD Process 
Transforming yields of therapeutic glycoproteins from milligram to gram per litre scales 
(Jayapal et al., 2007), whilst retaining the same generalised process, CLD has seen a great deal 
of development (Kim et al., 2012). Acknowledging the important role that advancements in 
extrinsic process factors has played, such as with development of culture media (Kunert and 
Reinhart, 2016; Kuo et al., 2018; Sellick et al., 2011) and high-throughput cell-screening 
technologies (Kim et al., 2012; Lai et al., 2013; Nielsen and Borth, 2015), this review will focus 
on development of factors intrinsic to the molecular biology of the cell expression system.  
During this review of developments in the CLD process, molecular biology tools will be 
assessed by several desirable attributes for efficient, rationalised CLD, which for the purposes 
of this thesis will be defined here: 
  
Figure 1.2 - Showing the two 
biosynthetic pathways and their 
essential products most often 
targeted by selection and 
amplification steps in CLD.  
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• Synthetic will refer to manmade, as opposed to natural, molecular biology tools. It 
should be noted that very few molecular biology tools are ‘truly’ synthetic, i.e. 
designed from scratch with no basis in natural elements. With this in mind, care should 
be taken to understand which tool is being referred to as synthetic. For example, a 
‘synthetic’ expression cassette could be constructed by artificial arrangement of 
‘natural’ vector elements, such as promoters and terminators.  
• Predictable will refer to tools whose effect in an experimental setting can be accurately 
user-defined and modelled beforehand, as shown in Figure 1.3a.  
• Titratable will refer to tools whose effect can be predictably titrated across a range of 
strengths, as shown in Figure 1.3b. 
 
Figure 1.3 – Showing the generalised desirable qualities of synthetic molecular biology tools. Predictable tools, 
shown in 3a, have user-defined functionalities that accurately predict their observed experimental effect. Titratable 
tools, shown in 3b, have a broad range of predictable effect strengths, controlled by their input strength.  
1.2.3. Vector Engineering 
Taking the basal glycoprotein expression vector as a design space, containing a selection 
marker for molecular cloning via E.coli (e.g. ampicillin or kanamycin resistance), a marker for 
selection and amplification in CHO cells (e.g. DHFR, GS), and a cassette expressing the desired 
product, multiple improvements have been made, both adding new elements, as well as 
controlling and optimising those already in place, summarised in Figure 1.4. 
1.2.3.1. Promoters 
As shown by experiments measuring significant changes in titre and expression 
characteristics of GFP (green fluorescent protein) and EPO (erythropoietin) (Wang et al., 2017), 
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promoters exercise a significant degree of control over the expression of recombinant proteins. 
Thus, predictable control of their transcriptional strength is desirable, not only for its 
maximisation, but also in cases such as mAbs, where two polypeptide chains have to be 
transcribed at a precise stoichiometry for optimal expression (Pybus et al., 2014). For strong 
transcription of therapeutic glycoproteins, the most commonly used promoter is the human 
cytomegalovirus major (CMV) immediate early gene promoter (Wang et al., 2017), followed 
by  the elongation factor 1-alpha (EF1α) and  simian virus 40 (SV40) promoters,  the latter of 
which has a lower transcription activity than the other two, but may maintain its expression 
more robustly over long-term cultures (Ho et al., 2014; Wang et al., 2016).  
Promoters commonly used in the biopharmaceutical industry can generally be divided into 
two regions: the core, containing the transcription start site, and the upstream proximal 
promoter region, containing transcription factor recognition elements (TFREs) (Lenhard et al., 
2012). Work towards creating synthetic promoters with differential strengths has largely 
focused on this proximal promoter region. For example, in Schlabach et al., 2010, a library of 
every possible DNA 10-mer, concatemerised to 100 base pairs (bp), was screened for its ability 
to upregulate the transcriptional activity of a CMV core promoter when placed upstream. By 
combining activating 10-mers together, the transcriptional activity of wild-type (WT) CMV 
could be doubled in some cell lines. Crucially though, this change in transcriptional strength 
was neither predictable, nor titratable (Schlabach et al., 2010).  
Since this, an approach to design through modular placement of TFREs along a synthetic 
proximal promoter has yielded greater such control (Brown and James, 2015). In the first 
tranche of such work, TFREs known to be active in CHO cells were first concatemerised 
upstream of a CMV core promoter, then randomly combined, before expression data from 
these constructs was used to create a final library of 44 proximal promoters,  showcasing a 
broad, titratable range of transcriptional strength, up to double the activity of the WT CMV 
promoter. These promoters were shown to be consistent across multiple cell types, and across 
different transient culture lengths (Brown et al., 2014a).  Further mechanistic understanding 
of these synthetic promoters has since been achieved, firstly by characterisation of TFREs in 
the CMV proximal promoter, in particular the functionally critical NF-κB and CRE elements 
(Brown et al., 2015). Secondly, highly transcriptionally active TFREs have been screened for 
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their context and spacing independence, allowing for creation of synthetic, predictable, 
titratable promoter libraries with transcriptional strengths over two orders of magnitude, as 
well as design of synthetic promoters in silico with truly modular, predictably titratable 
elements (Brown et al., 2017). Finally, omics datasets from different culture stages and 
conditions have allowed discovery of previously unidentified highly active TFREs, and 
creation of synthetic promoters insensitive to changing culture conditions, such as 
hypothermia (Johari et al., 2019).  
1.2.3.2. Codon Optimisation and Translational Control 
Since mRNA codons are a degenerate code for the amino acid residues they recruit, myriad 
different CDSs can be used to produce the same protein. Codon optimisation refers to the 
practice of designing an mRNA CDS that will most efficiently be translated into protein. Most 
commonly, this involves the adaptation of transcripts to fit the relative abundance of donor 
transfer RNAs (tRNAs) within the particular cell line of production, ensuring an optimal rate 
and accuracy of translational elongation (Hung et al., 2010). In Kotsopoulou et al., 2010, it was 
found that titre of a mAb could be significantly increased by optimisation of the heavy chain 
transcription codon adaptation index (CAI), a measure of the proportion of codons within a 
transcript that are ‘optimal’ within the codon bias of the cell (Kotsopoulou et al., 2010). 
Through this optimisation of codon adaption, the half-life of cytoplasmic mRNA is also 
increased (Presnyak et al., 2015), due to the emerging mechanistic link between slow ribosome 
translocation and targeted mRNA degradation (Bicknell and Ricci, 2017; Łabno et al., 2016). 
Other methods of codon optimisation have been developed, such as minimisation of 
secondary structure elements in the mRNA, and maximisation of GC content, although even 
a multiparameter optimisation of these factors, utilising a sliding scale along an mRNA, was 
unable to significantly outperform the holistic optimisation of CAI (Brown et al., 2019).  
Besides design of the CDS for elongation efficiency, relatively few options are available for 
controlling mRNA translation rate. Translation initiation, rather than elongation, is usually 
the rate limiting step of the process (Aitken and Lorsch, 2012). The near-ubiquitous Kozak 
consensus sequence (Kozak, 1987) is commonly used to enhance this rate, and some tools are 
available to predict the translation initiation rate of transcripts in E.coli (Reeve et al., 2014), but 
no predictable or titratable control has yet been exercised in CHO cells. As such, and in 
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contrast to other elements, very few synthetic elements for the 5’ and 3’ untranslated region 
(UTR), which control translation initiation of the CDS, are available for vector design (Brown 
et al., 2019).  
1.2.3.3. Signal Peptides 
A crucial, sometimes rate-limiting, stage in the expression of secreted recombinant proteins is 
the translocation of the nascent polypeptide to the endoplasmic reticulum (ER), through 
recognition of the signal peptide (SP), by the signal recognition particle (SRP), for the purposes 
of protein folding and secretion. For example, (Kober et al., 2013), showed that a panel of 
natural SPs fused to both polypeptide chains of a mAb led to fold change in cell-specific 
productivity over an order of magnitude. Some progress towards synthetic SPs has been 
made, for instance with the creation of Secrecon, a SP optimised for expression by a hidden 
Markov model, discriminating for SP-like features (Barash et al., 2002), which remains one of 
the highest-performing signal peptides to date (Brown et al., 2019; Güler-Gane et al., 2016). 
Some further mechanistic understanding has since been gained, such as the introduction of 
one and two alanine residues to the end of the signal peptide slightly improving protein titre 
(Güler-Gane et al., 2016), and the ability to discriminate in silico between signal and non-signal 
peptides (Petersen et al., 2011). However, no comprehensive explanation of cell line to cell line 
or product to product variation has yet been made, and no generally applicable predictable 
design principles have yet been produced. The best available tool is currently to screen a large 
library of randomly generated SPs, choosing those predicted to perform best. These SPs can 
slightly, if not significantly, outperform Secrecon, and their strengths are neither predictable 
nor titratable (Brown et al., 2019).  
1.2.3.4. IRES 
Classically, pre-initiation complexes (PICs) recruit mRNAs for translation via their 5’ methyl-
guanosine cap, in a mechanism which will be further discussed later in this review (Aitken 
and Lorsch, 2012). However, cis-elements, such as the internal ribosome entry site (IRES) 
enable binding of the PIC for translation inside the mRNA transcript (Hinnebusch et al., 2016), 
through recruitment of initiation factors by a diverse family of secondary structure elements 
(Leppek et al., 2018; Martinez-Salas et al., 2018). In a recombinant production setting, these 
IRES features allow for creation of multi-cistronic mRNA transcripts, from which multiple 
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polypeptides can be translated. These IRES-mediated vectors have become a common tool in 
biotechnology studies (Dreesen and Fussenegger, 2011; Ho et al., 2014; Wang et al., 2017, 2018). 
In one study, an IRES-mediated tricistronic expression cassette was constructed, containing a 
mAb light chain (LC), heavy chain (HC), and selection gene. Lower mAb titres were achieved 
in transient transfection, compared to a multi-promoter plasmid control, since IRES sites 
perform less efficient PIC recruitment than 5’caps. However, stably transfected pools showed 
the tricistronic vector achieving markedly higher titres than the control. This was partially 
because polypeptide stoichiometry could be controlled by order of the CDSs inside the 
transcript. More importantly, since the LC and HC CDSs could no longer become genetically 
unlinked from the selection marker, or one another, a far greater proportion of clones that 
survived selection were producing both the LC and HC polypeptide, compared to the 
standard multi-promoter design. Thus, IRES systems can reduce the number of low/non-
expressing clones in transfected populations, prevent product dislinkage from the selection 
marker, and allow for defined stoichiometric control over multiple polypeptides, though this 
can come at the cost of a reduced maximal titre (Ho et al., 2012). A modicum of predictable, 
synthetic control has since been exercised over IRES, such as by mutation of functionally 
critical AUG triplets in the commonly used Encephalomyocarditis virus (EMCV) IRES, to 
create a library of 24 differential-strength sites, which were validated as consistent across 
multiple cell lines, and in their ability to produce LC and HC polypeptides at differing 
stoichiometries. Notably, none of these were able to increase translation efficiency, and 
therefore expression levels, compared to the wild-type IRES (Koh et al., 2013).  
1.2.3.5. Selection Marker Attenuation 
The amplification step of CLD is predicated on the expectation that a higher concentration of 
selective agent (e.g. MSX, MTX) will necessitate cells increasing the expression of their 
selection marker to survive, thereby concurrently increasingly the expression of the 
genomically or cistronically-linked gene of interest. By attenuating the selection marker, 
making it less effective or more difficult to express, the cell is forced to amplify it to a greater 
extent, concomitantly increasing the gene of interest’s expression to the same degree (Lai et 
al., 2013). Various strategies of attenuation have been performed. In one study, a DHFR 
selection marker under the control of a strong Ef1α promoter was codon-deoptimised by 
minimisation of its CAI, leading to an up to 2-fold increase in the expression of a fusion 
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reporter protein, with a positive correlation observed between the extent of codon-
deoptimisation, selection stringency, and resultant fold change in yield (Westwood et al., 
2010). In another, it was shown that expression of a recombinant gene could be attenuated by 
inclusion of negatively-regulated micro RNA (miRNA) binding sites in its 3’UTR, and that 
attenuation of a DHFR selection marker by this method led to an increase in mAb production 
after selection in 10nM MTX (Jossé et al., 2018). Combination of selection marker attenuation 
with IRES expression systems is popular, as the relative resistance of IRES cassettes to 
selection marker dislinkage and gene fragmentation make them ideal systems for a tool 
predicated on linkage between the selection marker and gene of interest (Chin et al., 2015; Ho 
et al., 2012; Ng et al., 2012). This effect has been predictably titrated, with differentially 
attenuated IRES sites placed upstream of a variety of selection markers leading to a broad 
range of resultant mAb titres from transfected stable pools of cells (Yeo et al., 2017). One 
disadvantage of utilising selection marker attenuation is that effectively increasing the 
stringency of selection intrinsically means that fewer cells will survive the process (Westwood 
et al., 2010). Though the resultant surviving cells may be express the gene of interest more 
highly, this reduction in selection survival may complicate clonal isolation and expansion, 
and reduce the overall expression level of heterologous transfected pools if the stringency is 
too high (Yeo et al., 2017).  
1.2.3.6. Chromatin Modulating Elements 
In the archetypal CLD process, the glycoprotein expression vector is randomly integrated and 
dispersed through the host genome. This means it can land in either transcriptionally active 
euchromatin sites, or inactive heterochromatin sites, leading to reduced expression, and 
disrupting the correlation between gene copy number and expression levels required for 
predictable amplification (Lai et al., 2013). Moreover, regulation of chromatin state is a 
dynamic system, and even transcriptionally active cassettes can become silenced over time by 
methylation (Yang et al., 2010), especially when selection pressure is removed, as is often 
required for industrial production (Saunders et al., 2015). This problem can be approached by 
the non-random integration of the vector into a predetermined genomic site, which will be 
discussed in section 1.2.7. of this review, or by the inclusion of cis elements in the vector to 
control the surrounding chromatin state. A number of different chromatin modulating 
elements are used for this purpose, which largely fall into two functional groups: those which 
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function as borders, preventing the spread of the surrounding chromatin state into the vector, 
and those which actively function through dominant chromatin remodelling mechanisms 
(Neville et al., 2017).  
The most commonly used element from the first category is the matrix attachment region 
(MAR): a sequence of DNA that acts as an attachment point to anchor chromatin to the nuclear 
matrix during interphase, and can prevent spread of heterochromatin (Zhao et al., 2017). 
Introduction of MARs into vectors can sometimes yield mixed results, for example in one 
study, where popular MARs derived from chicken lysozyme and human interferon β were 
used to flank a GFP reporter under the control of SV40, EF1α, and CMV promoters. Both 
MARs were able to increase GFP expression in stably transfected pools, but only with the 
SV40 promoter, the weakest of the three. Furthermore, this MAR-SV40 construct retained 
significantly less of its GFP expression compared to an SV40 control after 8 weeks of culture 
in non-selective medium (Ho et al., 2014).  More positive results have since been found, such 
as flanking combinations of interferon β and β-globin MARs increasing expression of GFP in 
stably transfected pools, with both SV40 and CMV promoters, whilst also demonstrating 
strikingly higher numbers of successfully transfected clones, a higher proportion of positive 
GFP expressors within those clones, and higher retention of GFP expression than controls 
lacking a MAR (Zhao et al., 2017). Development of MARs in a recombinant production setting 
is continuing, for instance with the recent discovery of a new MAR, that with a CMV has been 
shown to increase GFP expression 4.5-fold, with a markedly higher expression retention after 
40 generations than non-MAR controls (Tian et al., 2018).   
In contrast to MARs, ubiquitous chromatin opening elements (UCOEs), characterised by 
methylation-free CpG islands, dominantly remodel chromatin to an active state, and do not 
need to flank both ends of an expression cassette. Discovered in the human HNRPA2B1-CBX3 
locus, A2UCOE is the most commonly utilised variant, with fragments of 8, 4, and 1.5 
kilobases (kb) conferring chromatin remodelling upon a construct when paired with a CMV 
promoter (Neville et al., 2017). A series of studies pairing the 8kb A2UCOE initially with a 
GFP-expressing vector have well defined their attributes. Stable transfection of CHO-DG44 
cells led to a higher average level of GFP expression than non-UCOE controls. Although 
UCOE-containing transfected cells could then be amplified using a higher initial 
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concentration of MTX (250nM), UCOE cell lines had lower expression than controls after this 
amplification process, whilst showing similar retention of expression with and without 
continued selection. Notably, this small difference in expression (<1.5 fold) occurred despite 
a marked decrease in gene copy number (>6 fold), implying more efficient transcription at 
integration sites (Betts et al., 2015). Improved results were then found in a similar system with 
an EPO reporter, with UCOE cell lines maintaining an increased titre after amplification, once 
more despite a markedly lower gene copy number, whilst simultaneously showing a stronger 
correlation between copy number and titre, indicating the abolition of position-mediated 
effects (Betts and Dickson, 2015). Finally, it was observed that selected UCOE cell lines 
contained vectors integrated in a more dispersed manner across their karyotype, again 
suggesting abolition of position-dependent effects (Betts and Dickson, 2016).  
A modicum of cross-element comparison has been made between chromatin modulating 
factors, such as a comparison of four elements, each with various positional variants, for 
production of a mAb in CHO cell culture. Of the four, including a MAR element, the 1.5kb 
core A2UCOE element performed the best by far, boosting expression by 6.5 and 7.5 fold in 
stable pools and clonal cell lines respectively, and demonstrating greater retention of 
expression after 120 generations than controls (Saunders et al., 2015). Finally, some titratable 
synthetic systems utilising chromatin modulating elements have been developed, such as the 
integration of a minimised production-enhancing DNA element into an accumulative site 
specific integration system, demonstrating predictable increases in expression, and a clear 
correlation between gene copy number and recombinant protein production (Kawabe et al., 
2017).  
 
Figure 1.4 - Showing the basal therapeutic glycoprotein vector, and the developments that have been made to each 
of its’ constituent parts. Regions critical to expression, the 5’ and 3’UTRs, for which no synthetic systems of 
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control in glycoprotein-expressing CHO cells have been implemented, are highlighted. AmpR: ampicillin 
resistance; UTR: untranslated region; SP: signal peptide; CDS: coding sequence. 
1.2.3.7. MPRA 
As stated in Figure 4, no synthetic vector elements have yet been implemented in the 5’UTR 
and 3’UTR for industrial glycoprotein expression in CHO cells. However, the technology of 
massively parallel reporter assays (MPRAs) is rapidly becoming more established and could 
represent a powerful solution for the rational engineering of 5’ and 3’ UTRs for industrial 
control of biopharmaceutical expression. Made possible by advances in high-throughput 
oligonucleotide synthesis, sequencing, and reporter technologies, MPRA is an experimental 
method, involving the parallel testing of thousands of genetic variants. An example MPRA 
assay might involve the production and transfection of a library of reporters with thousands 
of randomly generated 3’UTR sequences, before analysis by deep sequencing, inferring from 
their relative abundance the effect of each sequence feature on mRNA accumulation 
(Melnikov et al., 2014). In one example, a library of rationally designed 3’UTRs enabled the 
dissection of 3’UTR regulatory sequences into three categories of regulation, and the rational 
design of 58 constructs, whose stability to could be accurately predicted by regression analysis 
of the original dataset (Rabani et al., 2017).  
In terms of 5’UTR design, several studies have been carried out. For example, by partnering a 
library of 280,000 random 5’UTRs with polysome profiling in HEK-293T cells, the effect of 
various sequences on translational activation was analysed, facilitating 5’UTR design by a 
deep-learning algorithm, accurately prescribing different levels of polysome loading (Sample 
et al., 2019). In another study, a library of all possible translation initiation site variants (from 
-6 to +5, 65,536 sequence variants), was partnered with fluorescence-associated cell sorting 
(FACS) to model and accurately predict genome-wide translation initiation efficiencies of 
human mRNAs (Noderer et al., 2014).   In a similar study in yeast, 2,000 sequence variants of 
the 10bp upstream of the translation start site were used in yeast, to inform a model which 
could predict 70% of the variation in translation initiation across 5’UTRs, including those with 
nucleotide compositions not included in the original dataset (Dvir et al., 2013).  
Similar studies have been carried out in the 3’UTR. In one study, 13,000 rationally designed 
3’UTR variants were screened for their ability to effect expression dynamics in yeast, giving 
the observation that most mutations had minimal effect on expression, and allowing the 
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identification of a critical TA-rich element, which could then be molecularly characterized 
(Shalem et al., 2015). In another study for functional annotation, >450kb of 3’UTR sequence 
from human genes were screened with a GFP reporter, allowing for the discovery of 87 novel 
3’UTR-regulatory elements (Zhao et al., 2014). Finally, a cell-based expression screen was used 
in one study to identify 8mers associated with regulation of protein expression. This facilitated 
the discovery of hundreds of mostly expression-activating sequences, which was a surprising 
result in the 3’UTR, a feature mostly associated with negative regulation (Wissink et al., 2016).  
As demonstrated above, the MPRA methodology represents a potentially powerful tool in the 
functional dissection, and thereby the design, of 5’ and 3’UTRs for biopharmaceutical 
expression. The potential of applying sequences discovered by this platform to vector design, 
specifically sequences discovered by Oikonomou et al., 2014, will be discussed and 
investigated in chapter 4 of this thesis. The wholesale application of MPRA technology to each 
new industrial product and vector, as part of the CLD process could be a potent tool to 
rationalise vector design. Its’ implementation would also depend on the development of 
timescale and resource-appropriate CHO MPRA platforms, which may be a valuable 
investigation to undertake in future.  
1.2.4. Transient Gene Expression  
As the isolation of clonal high-producing cell lines is a time and labour intensive process, other 
methods, primarily transient gene expression (TGE), are often used to produce smaller 
quantities of recombinant protein for pre-production processes (Lalonde and Durocher, 2017). 
Quantities of protein on the g/l scale can be produced by a process spanning as little as 7 days 
(Barnard et al., 2015; Daramola et al., 2014), in contrast to months of CLD, giving an indication 
of steps to improve their eventual stable manufacturability (Mason et al., 2012), and providing 
material for pre-clinical studies, such as toxicology investigations, all without confronting the 
potentially confounding effect of clonal cell line variation (Pybus et al., 2014).  
TGE comprises the delivery of intact plasmid DNA (pDNA), the basal vector containing only 
the expression cassette and E.coli selection marker, into a heterogenous pool of cells. This 
pDNA  is harboured episomally in the nucleus, but not integrated into host chromosomes, 
and is transcribed, and thereby expressed, from this episomal space (Geisse and Fux, 2009). 
Historically, TGE has mostly been performed in HEK-293 cells, due to their higher yields and 
45 
 
earlier development of stimulatory systems such as EBNA-linked replication than CHO cells. 
However, more development has recently been performed on transient CHO systems, to 
ensure maximal relevance of the material gathered to stable production (Hacker et al., 2013), 
and with developments, CHO cells have been shown to produce higher titres of industrially-
relevant molecules such as mAbs, than HEK-293 cells (Zhong et al., 2018). A variety of delivery 
methods are available, the three most widely used systems being lipofection, electroporation, 
and polyethyleneimine (PEI) – mediated transfection. Transfection efficiency, a measure of 
the percentage of cells expressing the transfected gene, is notably higher for lipofection and 
electroporation, with reported efficiencies as high as 93.65% (Wang et al., 2018) and 96% 
(Steger et al., 2015) in CHO cells respectively, with PEI-mediated transfection usually 
achieving efficiencies of 50-60% (Hacker et al., 2013), and up to 80% (Rajendra et al., 2015a). 
However, due to ease of scale-up compared to electroporation, a significant cost-reduction 
compared to lipofection, and optimisation of transfection protocols, PEI is the most common 
method of pDNA delivery for larger-scale industrial TGE (Gutiérrez-Granados et al., 2018).  
A significant limitation of basal TGE is that episomal DNA is not replicated upon cell division, 
leading to dilution of pDNA from cells, as cultures grow and divide. A solution to this 
problem that has been implemented in HEK-293 cells for a number of years is Epstein-Barr 
virus (EBV) nuclear antigen 1 (EBNA-1)-based stimulation of plasmid replication. EBNA-1 is 
a gene that stimulates replication of plasmids carrying the EBV origin of replication, oriP. 
Transfection of pDNA containing oriP into a cell line stably expressing the EBNA-1 gene leads 
to replication of the pDNA with cell division, maintaining its levels inside cells as cell density 
grows (Carpentier et al., 2007; Yates et al., 2002). A major development for TGE in CHO cells 
was the implementation of this system. Stable integration of EBNA-1 into CHO cells led to 
significant increases in transient titre of a mAb when transfected in a vector containing oriP 
using PEI. Titre was further increased by the stable cotransfection of EBNA-1 and GS, allowing 
for MSX-mediated selection. Combined with the optimisation of the PEI transfection 
protocols, and of the culture platform and feeding regime, transient mAb titres of 2g/l could 
be achieved (Daramola et al., 2014).  
Through extensive characterisation of TGE in CHO cells, further cell-line adaptations have 
sought to overcome bottlenecks identified at the transcriptional and post-transcriptional steps 
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in expression (Mason et al., 2012; Rajendra et al., 2015a). For instance, stable cotransfection of 
the transcription factor X-box Binding Protein 1 (XBP1) has been shown by multiple studies 
to increase TGE titre of varied reporter proteins (Brown et al., 2019; Cain et al., 2013; Johari et 
al., 2015; Pybus et al., 2014; Rajendra et al., 2015b). A number of other proteins, such as 
Activating Transcription Factor 6 (ATF6) and the chaperone Binding Immunoglobulin Protein 
(BiP) (Brown et al., 2019; Johari et al., 2015; Pybus et al., 2014), have also been identified for this 
purpose. In the converse methodology, knockout of two apoptotic-factor genes (Bax and Bak), 
has been shown to create a cell line capable of a 3-4 fold increase in TGE yield of a mAb, 
mediated through an increase in cell density and viability, and increased uptake of pDNA 
(Macaraeg et al., 2013).   
A number of advances in transfection and culture technique have also been made, and 
optimised protocols for TGE in CHO cells published (Hacker et al., 2013). Further 
improvements are being made, such as the development of a high cell density PEI transfection 
system, allowing for >1g/l titres of a mAb (Rajendra et al., 2015c), and subsequent pairing with 
a downstream purification system, enabling transient production of ~1mg quantities of mAb 
from a 24 deep-well plate (Barnard et al., 2015). Development of other transfection methods 
continue apace, such as with the creation of a flow-electroporation based system, leading to 
~1g/l mAb titres, in cell culture up to the litre scale (Steger et al., 2015). 
Some work has been performed for the predictable, titratable control of TGE.  For example, in 
Johari et al., 2015, a number of TGE-enhancing techniques (overexpression of chaperone 
proteins, chemical supplements, temperature shifts), were screened and combined, to create 
an optimised Biphasic 12-day production process, increasing titre of a difficult to express 
(DTE) fusion protein 6-fold. Similarly, in Brown et al., 2019, different cell lines, overexpressed 
proteins, and vector features were combined, leading to a titratable range of up to 10-fold 
increase compared to controls of a Secreted Alkaline Phosphatase (SEAP) reporter.  
1.2.5. Cell Chassis Development 
Regardless of vector design and DNA delivery platform, the chassis through which 
therapeutic glycoproteins are ultimately manufactured and exported is the CHO cell. 
Therefore, control of their expression profile will ultimately be mediated through the cell’s 
capacity to grow, survive, and express recombinant protein. As demonstrated by the 
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comparison of the typical maximum cell-specific production rate of CHO cells, 50-90 
picograms per cell per day (pcd), and the output of secretory plasma cells producing 
Immunoglobulin M (IgM), up to 400pcd, this cell-chassis has not been maximally exploited, 
and thus much work has been invested to develop its abilities (Hansen et al., 2017).  The chassis 
is generally manipulated by either overexpression of favourable genes, or disruption of 
unfavourable genes, by knockout, or RNA interference-based methods (Fischer et al., 2015). 
Many genes have been successfully targeted by this methodology, reviewed comprehensively 
by Fischer et al., 2015, such as the translation-controlling Mammalian Target of Rapamycin 
(mTOR) (Dreesen and Fussenegger, 2011), and the transcription factor Yin Yang 1 (YY1) 
(Tastanova et al., 2016). However, this review will focus on the two most commonly targeted 
functions: expression capacity, and anti-apoptosis engineering.  
1.2.5.1. Expression Capacity Engineering 
In CHO cell lines expressing recalcitrant recombinant proteins, dislinkage is often observed 
between heightened gene copy number, mRNA levels, intracellular polypeptide levels, and 
secreted protein titre, which fails to concomitantly increase (Chromikova et al., 2015; Reinhart 
et al., 2014). This indicates an expression bottleneck at the stages of protein folding, post-
translational modification, trafficking and secretion. A key contributor towards this 
bottleneck is the unfolded protein response (UPR). Sensing unfolded protein accumulation 
via BiP, the UPR is a signalling cascade, which inhibits translation, degrades mRNA, and 
upregulates expression of chaperone proteins, in an attempt to bring levels of unfolded 
protein back to homeostatic levels. If unable to do so, the UPR will trigger autophagy or 
apoptosis (Hussain et al., 2014). A cell’s ability to upregulate UPR-responsive genes, thus 
mitigating these negative changes, has been shown to positively correlate with their ability to 
produce recombinant protein (Kober et al., 2012). Accumulation of unfolded and misfolded 
protein in the endoplasmic reticulum also leads to ER-associated degradation (ERAD) of 
proteins by the proteasome, and aggregation of recombinant protein, further compromising 
expression (Zhou et al., 2018).  
One tactic to mitigate this response is to overexpress chaperone proteins, which bind to 
polypeptides and prevent the formation and aggregation of unfolded protein. The two most 
commonly targeted of these proteins are BiP and Protein Disulphide-Isomerase (PDI), and 
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overexpression of both has been shown to increase the expression of secreted proteins (Johari 
et al., 2015; Pybus et al., 2014), though for reasons that will shortly be discussed, this effect is 
not universal across cell lines and recombinant proteins (Mohan et al., 2008). Another tactic is 
to overexpress proteins directly implicated in the UPR. XBP1, and its splicing variant XBP1S, 
are UPR-activated proteins, contributing towards endoplasmic reticulum biogenesis when 
overexpressed, and thereby increasing the capacity of the cell to process translating and 
folding protein (Hussain et al., 2014). Overexpression of XBP1/XBP1S has been shown to 
increase recombinant protein titre in multiple studies, under both transient (Johari et al., 2015; 
Pybus et al., 2014; Rajendra et al., 2015b) and stable expression (Cain et al., 2013; Gulis et al., 
2014). ATF6, previously mentioned for its’ ability to increase recombinant protein expression 
across multiple studies (Brown et al., 2019; Johari et al., 2015; Pybus et al., 2014), is also a target 
of this strategy, being a UPR-inducible transcription factor associated with the expression of 
multiple foldases and chaperones. Finally, secretion factors can be overexpressed, such as 
Vesicle-associated membrane protein 8 (VAMP8) and Synaptosomal-associated protein 23 
(SNAP23), which have been shown to increase production of a mAb, when overexpressed 
both episomally and stably, by altering the ratio of intracellular to extracellular (secreted) 
recombinant protein (Peng et al., 2011). Overexpression of SRPs, primarily SRP14, has also 
been shown to increase titre of a difficult to express mAb, by a similar mechanism (Le Fourn 
et al., 2014).  
Despite substantial overlap in identified effector genes between different studies, very little 
predictable control over expression can be exercised by this method. For example, separate 
studies on the co-expression of PDI with a reporter protein have found changes in reporter 
specific productivity (qP) ranging from a 1.6-fold decrease, to a 1.37-fold increase. This is 
partially attributable to a lack of standardised methodology: differences in transfection 
method, origin of the effector gene (CHO, human, mouse), and effector gene dosage can all 
impact the resultant changes in expression (Hansen et al., 2017). The main source of this 
unpredictability, however, is the genetic instability of immortalised cell lines. Because of this 
instability, pools of cells carry an intrinsically high genetic heterogeneity. When clonal cell 
lines are isolated from transfected pools, the cells may or may not be susceptible to 
manipulation of a certain effector gene, and may have high or low reporter expression for a 
number of genetic reasons. Therefore, to reliably test an effector gene’s consequence on 
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expression, multiple clonal lines must be assessed as a population, or heterologous pools of 
transiently transfected cells can be used. In turn, these results may not be applicable to a 
particular isolated clonal cell line. Due to this seemingly intractable incongruity, effector genes 
must be assessed on a case-by-case basis, rather than in a systematic, predictable fashion 
(Hansen et al., 2017).  
1.2.5.2. Anti-Apoptosis Engineering 
As the titre of a transfected culture is necessarily a factor of how many cells are producing 
protein for how long, substantial work has been invested into improving cell culture 
performance, particularly in delaying the cell death phase, through anti-apoptosis 
engineering (Kim et al., 2012; Mohan et al., 2008). This can be achieved through either 
overexpression of anti-apoptotic genes, or disruption of apoptotic genes. The two most 
common targets for the former approach have been the overexpression of B-cell lymphoma 
(BCL) proteins BCL-XL and BCL2 (Fischer et al., 2015), both of which have been shown to 
increase apoptosis resistance. This technique has also recently been advanced by the 
mutagenesis and directed evolution of BCL-XL, selecting for apoptosis resistance, to create a 
hyper-active form of the gene, conferring greater cell culture performance (Majors et al., 2012). 
More novel targets for this strategy include Heat-shock protein 27 (HSP27), overexpression of 
which led to increased maximum cell density and apoptosis resistance by downregulation of 
various caspases (Tan et al., 2015), and mTOR, which when overexpressed via an IRES cassette, 
led to increases in cell proliferation and viability (Dreesen and Fussenegger, 2011).  
By far the most prevalent target of gene disruption for anti-apoptosis engineering are Bcl-2-
associated X protein (Bax) and Bcl-2 homologous antagonist killer (Bak) genes, the knockout 
of which has been shown to increase cell culture performance and titre in both stable and 
transient expression systems (Fischer et al., 2015; Macaraeg et al., 2013). Comprehensive 
knockdown of apoptotic pathways has recently been made more tractable by the advent of 
CRISPR/Cas9 gene editing technology, for instance in the single-step multiplexed disruption 
of FUT8, Bax, and Bak, leading to reduced apoptosis activity and increased productivity (Grav 




Figure 1.5 -Showing the generalised cell culture performance of  non-engineered (solid line) and anti-apoptosis 
engineered (dotted line) CHO cells. The area under this curve, measuring the number of cell days in each culture 
is referred to as the integral of viable cell density (IVCD), and correlates with recombinant protein titre.    
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1.2.6. miRNA Engineering 
miRNAs are small (~22nt) regulatory RNAs, which control the critical and energy-consuming 
process of translation. They are usually transcribed by RNA polymerase II, as either a 
dedicated pri-miRNA, or as part of an mRNA intron, a pri-mintron, before cleavage into a 
precursor-miRNA hairpin by either Drosha, or the spliceosome, respectively. After processing 
by Dicer, mature miRNAs bind Ago2, which can then bind mRNAs with regions of 
complementarity to the miRNA as part of the RISC complex, inhibiting translation, and 
upregulating deadenylation and decay of the mRNA (Hammond, 2015). As the obligatory 
region of complementarity is very small (~6nt seed sequence), miRNAs target multiple 
mRNAs, often within a functionally related family, making them attractive targets for cell 
engineering, since the effectiveness of single gene engineering is often mitigated by the genetic 
redundancy of CHO cells (Hackl et al., 2012; Zhou et al., 2018). Additionally, unlike protein-
based cell engineering, they impose no translational burden on the cell (Hackl et al., 2012; 
Stolfa et al., 2018).  
Identification of CHO miRNAs has been expediated by sequencing of the CHO genome (Xu 
et al., 2011), in combination with other omics datasets, such as RNA-seq (Stolfa et al., 2018).  
Public databases of these miRNAs are available, such as miRbase, which currently lists 351 
mature CHO miRNAs, significantly less than the 2654 identified in the better annotated 
human genome, though this difference may be partially explained by genetic factors, such as 
the lower chromosome number in CHO cells (22 vs 46) (Fischer et al., 2015). Target miRNAs 
can also be identified by omics datasets, such as by comparing the miRNA expression of high 
to low expressing cell lines (Maccani et al., 2014). Numerous synthetic strategies exist to 
control miRNAs in CHO cells, such as transient overexpression by miRNA mimics, or the use 
of Antagomirs to inhibit endogenous miRNAs (Fischer et al., 2015; Jadhav et al., 2013).  
In Fischer et al., 2017, it was shown that transient transfection of mir-557 led to a significant, 
~40% increase in product expression in seven established cell lines, producing a variety of 
products (mAbs, bispecific antibodies, scFv), amplified by both GS and DHFR methods, with 
both high and low levels of expression. A cell line stably overexpressing mir-557 was then 
created, and taken through a CLD process with a difficult to express mAb, against a control 
overexpressing a nontargeting miRNA. The mir-557 cell line produced higher-expressing 
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stable pools, a much higher proportion of high-expressing clones (41.5% vs 1.2%), and the top 
3 selected clones produced 2-fold more of the mAb in a fed-batch culture, with no compromise 
in product quality (Fischer et al., 2017). In an alternative approach to miRNA engineering, 
Jossé et al. introduced miRNA target sites into the 3’ UTR of a DHFR cassette, as a means of 
selection marker attenuation (Jossé et al., 2018). A great variety of miRNAs have been targeted 
as a means of engineering. Common strategies have been developed, including knockdown 
of miR-7a to reduce growth and enhance proliferation, and overexpression of let-7 to supress 
apoptosis (Fischer et al., 2015; Jadhav et al., 2013), rendering this synthetic tool somewhat, if 
not entirely, predictable.   
1.2.7. Site-Specific Integration 
In the canonical CLD process, the expression cassette is integrated randomly into the host-cell 
genome, before amplification, again into random genomic loci (Jayapal et al., 2007). The 
underlying assumption of this methodology is that as gene copy number rises, expression 
levels will concurrently increase. However, due to a myriad of genomic factors, such as 
chromatin state and presence of upstream or distal enhancer regions, different integration 
sites in the genome show markedly different levels of cassette transcription. As such, 
integration and amplification steps are rendered heterologous and unpredictable, as the 
assumed correlation between copy number and expression levels does not always arise (Alves 
and Dobrowsky, 2017).  
To circumvent this problem, various strategies have been developed to insert the expression 
cassette into transcriptionally active known genomic sites, or ‘hotspots’, ensuring more 
consistent transgene expression, and better correlation between copy number and expression. 
The first step in this process is to identify a genomic hotspot to be targeted. A number of 
traditional screening methods have been employed for this, such as in Cheng et al., 2016, 
where a GFP-expressing cassette was randomly integrated into mammalian HT1080 cells. 
After clonal isolation, the location of 10 high-producing clones was assessed by sequencing, 
identifying 8 distinct genomic sites. Site-specific integration of a SEAP reporter into one of 
these sites led to both more consistent and higher reporter expression than random 
integration. Such exhaustive methods may become unnecessary in the future, as the growing 
availability and depth of genomic, epigenomic, and transcriptomic datasets (to be discussed 
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later) begin to allow for in silico selection of hotspots (Alves and Dobrowsky, 2017; Stolfa et al., 
2018).  
Following identification of an integration site, three leading options are available for targeted 
delivery of the cassette: site-specific recombination, genome editing, or transposase-mediated 
integration.  
In site-specific recombinase systems, a recombination site in the genome and cassette are 
recognised and recombined by an enzyme. The two most common systems for this purpose 
are Cre/loxP and Flp/FRT (Lai et al., 2013), both offering a highly specific integration event at a 
single predetermined site. The technology has been further developed by the creation of 
Recombination-Mediated Cassette Exchange (RMCE) systems, wherein a master cell line, 
containing a cassette flanked by recombination sites in a known genomic hotspot, is 
exchanged for the desired expression cassette. This cassette exchange can be used to screen 
for transfected clones, through removal of a fluorescent protein, or addition of an antibiotic 
resistance gene. Integration of cassettes at these sites has led to high expression, high 
expression stability across multiple generations, and better correlation between gene copy 
number and expression levels (Zhang et al., 2015). The system has further evolved, with the 
development of an Flp/FRT-mediated binary RMCE system, comprising two independently 
integrated cassettes, with predictable, additive expression profiles, allowing for site-specific 
co-integration and expression of two reporters (Baser et al., 2016). Similarly, an accumulative 
Cre/loxP integration system has been designed, whereby a number of independent RMCE 
events take place, as each successive cassette is flanked by a new distinct loxP site, specific for 
the recombination of the next cassette. This system allows for predictable and additive 
integration of up to 8 cassettes at a single genomic site, creating titratable control of expression 
(Kameyama et al., 2010; Kawabe et al., 2017).   
One disadvantage of Cre/loxP and Flp/FRT technology is that integration events leave the 
recombination site unaltered, leaving open the possibility of reversibility, and that such 
constructs may experience genomic instability. Hence, the analogous Φ31 integrase system 
has been developed, utilising a viral integrase, and endogenous attP/attB sites within the 
genome, which are altered upon an integration event. This also allows for higher copy number 
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than recombinase-mediated systems, but at the cost of an inability to select a hotspot 
integration site (Alves and Dobrowsky, 2017; Campbell et al., 2010).  
 The emerging technologies of genome editing are a potentially powerful tool for site-specific 
recombination. These technologies pair a DNA recognition mechanism with nuclease activity 
to perform site-specific double-strand breaks, and providing genetic material for homology-
directed repair (HDR) or non-homologous end joining (NHEJ) allowing for concurrent knock-
in of DNA (Gaj et al., 2013). Optimised vectors for Transcription Activator-like Effector 
Nuclease (TALEN)-mediated genome editing have been developed, allowing for efficient 
integration and expression of a single-chain Fv-Fc (scFv-Fc) protein in CHO cells at a 
predetermined genomic site (Sakuma et al., 2015). TALEN technology is limited its’ 
mechanism of DNA recognition, by modular DNA-binding protein domains, the 
development and design of which is a difficult process. As such, more excitement is being 
drawn by the far more easily programmable CRISPR/Cas9 genome editing system (Lee et al., 
2015a), which targets DNA via a small guide RNA (gRNA). Methods have been developed in 
CHO cells for the stable integration of expression cassettes, both by HDR (Lee et al., 2015b, 
2016b), and by NHEJ (Bachu et al., 2015), both with levels of efficiency allowing for selection 
via one round of limiting dilution into a 96 well plate, resulting in a much more consistent 
expression level across multiple clones than in random integration (Lee et al., 2015b).  
Finally, transposon-mediated integration systems, such as sleeping-beauty and piggyBAC, 
are well established in molecular biology studies (Narayanavari et al., 2017), but have only 
recently been applied to production of biopharmaceuticals. Promisingly, it has been 
demonstrated that stable cell pools generated using the piggyBAC system, as opposed to 
random integration, exhibited around 4-fold higher productivity of a panel of mAbs, up to an 
impressive 7.6g/l in a 16-day production process (Rajendra et al., 2016). These encouraging 
results should merit further investigation of transposons for biopharmaceutical production. 
1.2.8. Omics 
‘Omics’ is an umbrella term, encompassing the various emerging techniques of gathering and 
analysing large datasets, broadly describing the state of a cell.  A genomics dataset might be 
a sequenced genome, a transcriptomic dataset could be an RNA-seq file describing global 
RNA abundance, a metabolomic dataset could be a data-driven model of the metabolic flux 
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performed by a cell, and so on. Sequencing of the CHO-K1 genome (Xu et al., 2011), combined 
with the advent of technologies such as RNA-seq, and mass spectrometry, and freely-available 
tools such as CHOgenome.org (containing an annotated CHO-K1 genome), CHOmine (a 
repository of publicly available CHO omics datasets), and CRISPy (a CRISPR/Cas9 target 
finder for CHO-K1 cells), are facilitating the use of omics technology in biopharmaceutical 
research and development (Stolfa et al., 2018).  
The potential benefits of omics technology include the in silico screening of genomes for 
transcriptional hotspots, appropriate for site-specific integration of a transgene (Kuo et al., 
2018; Stolfa et al., 2018), such as in Zhang et al., 2015, where clonal cell lines exhibiting high 
product expression, expression stability over 100 generations, and strong correlation between 
copy number and expression levels, were created by insertion of a mAb-expressing cassette 
at in silico determined hotspots using RMCE (Zhang et al., 2015).  
Another application of omics technologies is to analyse the properties of cell lines with 
desirable production qualities, learning which attributes tend to make cells highly productive, 
and even utilising the power of emerging synthetic biology technologies, to apply these 
solutions with a more systems-based approach than had been attempted before, for example 
with the downregulation of an entire pathway via miRNA signalling (Fischer et al., 2015; Kuo 
et al., 2018), or multiplexed knockout of genes by CRISPR/Cas9 (Grav et al., 2015). Multiple 
studies with this premise have been published, such as the transcriptomic and proteomic 
analysis of cell lines with a wide range of productivities, allowing identification of genes most 
correlated with product secretion, which led to the counterintuitive insight that in some cases, 
intracellular expression of the product was not strongly linked to overall secreted productivity 
(Kang et al., 2014). The CHO translatome has also been analysed, to identify genes most 
essential for cellular growth and proliferation, the data also suggesting that transcription and 
translation level are uncoupled for 95% of genes in the CHO genome (Courtes et al., 2013). 
Omics data used to reconstruct the protein secretion pathway in mice has been successfully 
applied to CHO cells, predicted several novel targets for increasing secretion capacity (Lund 
et al., 2017). Through use of omics datasets, all three of these studies offer striking insights to 
understanding glycoprotein production characteristics in CHO cells, unattainable by more 
conventional means. Omics datasets can also be used to inform more traditional molecular 
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biology practices, such as in the omics-based identification of a correlation between deletion 
of a telomeric region of CHO chromosome 8, and an increase in productivity (Ritter et al., 
2016a). Using this result to inform more traditional molecular biology, quantitative PCR 
(qPCR) and small interfering RNA (siRNA) screens were used to identify the causative 
C12orf35 gene within this locus, and to show that its’ knockdown reproduced the phenotype 
of increased productivity (Ritter et al., 2016b).  
Most ambitiously, some have aimed to use omics datasets, in combination with various tools 
for machine learning, to develop an in silico accurate, predictive model of CHO cell behaviour. 
This problem has already been approached on a slightly smaller scale, such as with 
reconstruction of the CHO protein secretory pathway (Lund et al., 2017), and creation of a 
model of the CHO metabolome (Hefzi et al., 2016). With such tools and the appropriate data, 
the application of synthetic biology parts to a certain bioproduction process could be made 
truly predictable and rational.  
The major roadblock to this data-driven rationalisation of CHO-cell engineering remains the 
relative paucity of available datasets, for example with only a handful of publicly available 
CHO genomes (Lalonde and Durocher, 2017; Stolfa et al., 2018). Furthermore, considering that 
the inherent genomic plasticity of CHO cells leads to high genetic heterogeneity between 
parental and clonal cell lines, it can become uninformative, or even misleading, to apply to 
them omics datasets obtained from ancestral cell lines, such as CHO-K1 (Datta et al., 2013). 
With the continuing advance of technology, shown for instance in Figure 1.6 by the cost of 
sequencing DNA per megabase falling by several order of magnitude in less than 20 years, it 
may be only a matter of time before this roadblock is cleared, as omics datasets become more 
readily available, and affordably gathered.  
 
Figure 1.6 - Demonstrating the increasing availability 
and ease of gathering Omics datasets by the showing the 
decreasing cost per megabase of DNA sequencing from 
2001-2017. Data gathered from www.genome.gov

















1.3. Pitch: A Molecular Toolkit of Synthetic Expression 
Elements 
As has been shown by the varied examples within this review, bottlenecks in 
biopharmaceutical expression can occur at almost any of the distinct molecular junctures 
through which genetic information must pass before it can be harvested as a secreted 
glycoprotein. Different studies have observed limitations in productivity stemming from 
inefficient transcription (Brown et al., 2014a), inadequate processing and translation of mRNA 
(Mason et al., 2012; Rajendra et al., 2015a), polypeptide aggregation and ER stress (Reinhart et 
al., 2014), inability to traffic protein to the Golgi apparatus (Mathias et al., 2018), incapability 
of secreting protein from the Golgi apparatus (Kaneyoshi et al., 2019), and limitation in cellular 
capacity (Dreesen and Fussenegger, 2011).  
Production of glycoproteins is product, cell, and process-specific expression characteristics, 
and each example requires a specifically targeted solution. Synthetically maximised 
transcription could not alleviate a bottleneck stemming from protein aggregation, and 
conversely, enhanced secretion machinery could not effectively stimulate the titre of a product 
suffering from improper mRNA processing. In short, no generalised, one-size-fits-all 
solutions or platforms can be applied to producing therapeutic glycoproteins as a whole.  
Rather, to shorten CLD timelines and costs, and to ensure that more therapeutic glycoproteins 
can be brought forward through production with as few inefficiencies as possible, 
biopharmaceutical companies should have access to a broad toolbox of synthetic molecular 
biology elements. These elements should provide control over every possible stage in 
glycoprotein expression, containing for example promoters for transcription, signal peptides 
for secretion, and effector genes for cell performance. Ideally these elements should be 
predictable, and titratable in their strength.  
Paired with a rapid and high-throughput transient expression system, this toolbox would 
allow for a more efficient and streamlined CLD screening process, whereby expression 
characteristics are quickly identified, rationally designed against, and screened again, as 
shown in Figure 1.7. Expression platforms optimised via this system could then be taken 
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forward to stable cell line generation, carrying with them a far greater assurance that the 
labour-intensive process will yield clonal cell lines with favourable expression profiles.  
 
Figure 1.7 – Showing the generalised schematic of a CLD platform designed to reduce risk, and ensure a high rate 
of success in creating stable glycoprotein-expressing cell lines, by utilising rational design via a toolbox of 
synthetic molecular biology elements.  
Work to create this molecular toolkit is well underway, with its most comprehensive 
realisation so far published by Brown et al., 2019. In this study, synthetic variants of promoters, 
signal peptides, codon optimised transcripts, cell lines, and effector genes, were all screened 
for their effect on SEAP expression in a high-throughput transient system, compared to an 
‘industry standard’ construct. It shows the many strengths that this approach currently brings: 
at least one variant of each synthetic element led to a significant increase in SEAP expression, 
when elements were combined together increases in titre were always predictable and often 
titratable, and combining the most favourable of every element created a construct with ~10-
fold higher SEAP expression than the industry standard control (Brown et al., 2019).  
However, this study also demonstrates the current limitations of this platform. The study was 
exclusively performed using the well-characterised and easy to express SEAP reporter, and 
the ‘design’ of elements such as the variant signal peptides was based primarily in prior 
understanding and study of SEAP, which would not be available when optimising the 
expression of a new, novel glycoprotein. Moreover, multiple expression elements, such as the 
5’ and 3’ UTRs had no synthetic variants. If SEAP expression suffered from inefficient 
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translation initiation, mRNA stability, or nuclear export, as these elements control, it could 
not have been relieved.  
Rather than presenting a fully developed platform, Brown et al., 2019 acts as an ideal template 
for how to perform next-generation CLD. As work continues into discovering new synthetic 
systems of expression control, and predictable understanding of those that exist grows, a 
landscape can be approached where this paradigm is applicable and useful for the 
development of every novel glycoprotein-producing cell line.  In this thesis, I hope to further 
this paradigm, by the discovery and characterisation of synthetic expression elements for 




1.4. The Molecular Journey of  a Biopharmaceutical mRNA 
In defiance of the historical ‘central dogma’ of molecular biology (Shapiro, 2009), diverse 
families of RNA have been discovered, exhibiting myriad functions beyond codon-based 
information transfer from DNA to protein: regulation of gene expression by miRNA, catalysis 
of splicing by snRNA, and sequence-specific guidance of endonucleases by crRNA and 
tracrRNA, to name a few (Doudna and Charpentier, 2014; Köhler and Hurt, 2007).  Rather, 
this responsibility is given specifically to mRNA, which transports and translates genetic 
information from a storage capacity in DNA to a functional capacity in protein. As with all 
stages of gene expression, these processes are tightly regulated, and their synthetic control is 
as pertinent to optimal biopharmaceutical development and production as any other stage in 
expression. In the following section, the processing of a biopharmaceutical mRNA will be 
reviewed, tracing the flow of genetic information from the end of transcription to translation, 
and discussing potential junctures for the development of effective, novel, synthetic 
expression tools. The development of tools to address these proposed junctures will then form 
the experimental basis of this thesis.   
1.4.1. Transfection 
Whilst the transfection of recombinant DNA is far removed from the mRNA processing 
pathways the rest of this literature review will focus on, elements essential to those processes 
impact recombinant protein expression through their effect on transfection. 
Gene expression cassette copy number is a fundamental factor in the efficient expression of 
recombinant protein. The more sites that are available for transcription of recombinant DNA, 
the more recombinant mRNA will be transcribed, leading to improved expression. As such, 
recombinant protein expression levels correlate positively with recombinant DNA copy 
number (Rajendra et al., 2015c). This positive correlation is slightly complicated by factors such 
as the increase in transfection efficiency associated with addition of any DNA, including 
noncoding ‘filler’ DNA (Rajendra et al., 2015a). Furthermore, like any other enhancing factor, 
increases in copy number may still be rendered ineffective by expression bottlenecks further 
downstream in the expression pathway, such as in translation or protein folding (Rajendra et 
al., 2015b). Nonetheless, a synthetic system must optimise every element of its’ expression 
construct, and ensuring a high copy number is an important part of this.  
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Despite copy number being the metric best suited to align recombinant DNA quantity with 
expression, cellular ability to uptake DNA across all transfection strategies (e.g. 
electroporation, lipofection, PEI) is fundamentally limited and defined by its total weight 
(Hacker et al., 2013; Steger et al., 2015; Wang et al., 2018). Beyond a certain threshold of 
recombinant DNA mass per cell, for instance 1mg of pDNA per litre of culture at 1*106 cells/ml 
(Daramola et al., 2014), no more DNA can be taken up by cells without incurring a significant 
cytotoxic penalty and resultant loss of titre.  
As shown in Figure 1.8, DNA copy number per constant weight of DNA is negatively 
correlated with the size of the DNA cassette. As copy number is a fundamental factor in 
recombinant protein expression, it is desirable for glycoprotein expression cassettes to be as 
small as possible. Thus, the creation of minimised cassettes by the removal or modification of 
sizable mRNA elements, such as introns, without losing their expression benefits, may help 
to maximise copy number per transfection.  
Figure 1.8 – Showing the change in  recombinant DNA copy number per µg over a representative range of 
plasmid sizes. 
1.4.2. Processing and Export 
Before a nascently transcribed pre-mRNA can be translated into protein, it must first be 
processed, modified, and exported from the nucleus to the cytoplasm. There are multiple 
regulated steps in this process, each critical to efficient export of translation-competent mRNA 


























1.4.2.1. 5’ Capping 
The first stages of mRNA maturation occur co-transcriptionally (Hsin and Manley, 2012). One 
of these stages is 5’ capping, which involves the reversible addition of a 7-methylguanosine 
cap by 5-5 linkage to the 5’ end of the pre-mRNA (Bentley, 2014).  This reaction occurs when 
the nascent transcript emerging from the RNA Polymerase II is only 20-30bp long (Rasmussen 
and Lis, 1993). Rather than being a ubiquitous, universal reaction, complicating evidence of 
such quality control mechanisms (Fernandez-Sanchez et al., 2009) and cytoplasmic capping 
(Otsuka et al., 2009) suggest that capping is regulated in a nuanced fashion (Bentley, 2014).  
The methyltransferase enzyme responsible for this reaction is recruited to nascent RNA via 
the CTD domain of RNA Polymerase II (Hsin and Manley, 2012), which is a common 
mechanism in transcriptional coupling. After this step, the Cap Binding Complex (CBC) binds 
the 5’ end of the mRNA (Heath et al., 2016).  
1.4.2.2. 3’ End Processing 
Concurrently in pre-mRNA maturation is 3’ end cleavage and polyadenylation, giving mature 
mRNAs (and other long noncoding RNAs) their characteristic PolyA tail. These two 
processes, whereby transcribed RNA beyond the polyadenylation signal is cleaved and 
degraded, and a PolyA tail is added to the mRNA, are coupled, both to one another, and to 
transcription (Bentley, 2014; Proudfoot, 2011). The reaction is carried out by a multisubunit 
complex, comprising cleavage stimulation factor (CstF), cleavage and polyadenylation 
specificity factor (CPSF) bearing the necessary endonuclease, and cleavage factors I and II 
(CFIm and CFIIm) (Bentley, 2014). In order to prevent premature cleavage, coding sequence is 
protected by the U1snRNP, which inhibits cleavage and polyadenylation (Kaida et al., 2010).  
Since the 3’ UTR is used as a binding platform for a number of regulatory factors (Mazumder 
et al., 2003), alternative sites of cleavage and polyadenylation, resulting in different lengths of 
the 3’ UTR, can have an impact on gene expression and regulation (Elkon et al., 2013). For 
instance, proliferating cancer cells have been shown to increase cleavage at upstream 
polyadenylation sites, leading to reduced regulation by miRNA binding to the 3’ UTR 
(Sandberg et al., 2008a). In another example, the long 3’ UTR isoform of the CD47 mRNA has 
been shown to increase membrane localisation of CD47, by recruiting the 3’ UTR binding 




Splicing is the process by which noncoding introns are excised from pre-mRNA, leaving 
ligated exons, which together form the mature mRNA, to be translated into protein. This is 
carried out by a large multimeric complex, known as the spliceosome (Sperling et al., 2008). 
The core components of this complex are U1, U2, and U4-6 small nuclear RNAs (snRNAs). 
These RNPs require a complex biogenesis, with the RNA components of each undergoing 5’ 
capping and 3’ end processing, before U1, 2, 4 and 5 snRNAs are exported to the cytoplasm 
for processing, and re-imported to the nucleus (Köhler and Hurt, 2007). These snRNA 
components are essential, as through their rearrangements, they catalyse the splicing reaction 
itself (Madhani and Guthrie, 1994). The process of splicing begins with assembly of the 
spliceosome, as U1 snRNP binds the 5’ splice site (5’ss) via base-pairing reactions, and 
interaction with the Pol II CTD (Matera and Wang, 2014; Spiluttini et al., 2010). The 3’ splice 
site (3’ss) is then bound by U2 snRNP, along with associated factors. A conformational change 
then occurs, bringing U2 snRNP into contact with the branchpoint adenosine. After this exon 
definition complex has been made, a pre-formed tri-snRNP consisting of U4-6 binds the 
complex. Conformational changes, catalysed by several Prp ATPase helicase proteins, and 
involving the loss of U1 and U4 snRNPs, then facilitate the two splicing reactions, shown in 
Figure 1.9. Whilst the reactions are directly carried out by U2 and U6 snRNPs, U5 is also 
essential to this process (Matera and Wang, 2014). 
Splicing components are highly enriched in nuclear organelles, known as nuclear speckles 
(Lamond and Spector, 2003). It is thought that most splicing activity occurs on the borders 
between these compartments and the surrounding nuclear space (Girard et al., 2012). Splicing 
has been shown to be substantially co-transcriptional, occurring as the nascent mRNA 





Figure 1.9 - Showing the mechanism of intron 
splicing, whereby an intron is cleaved out of an 
mRNA, leaving an exon-exon junction and an excised 
intron lariat. This reaction is catalysed by dynamic 






The Exon Junction Complex (EJC), consisting of the four proteins Y14, Magoh, EI4A3 and BTZ, 
is a key protein signature of splicing, and has multiple roles in regulation of gene expression 
(Boehm and Gehring, 2016). EIF4A3 is the main RNA-binding protein of the complex, binding 
via the phosphate backbone, ensuring a lack of sequence specificity (Bono et al., 2006). 
However, it is only recruited to pre-mRNA in a splicing-dependent manner, via a transient 
association with the spliceosome, and therefore mostly appears in canonical sites 20-24 bases 
upstream of exon junctions. The EJC can also be deposited at non-canonical sites, in a 
mechanism that is not fully understood. It is speculated that this is related to the EJCs 
enrichment at purine-rich sequences of RNA, particularly a GAAGAA motif (Saulière et al., 
2012).  
One of the strongest effects the EJC has on gene expression is through its’ activation of 
nonsense mediated decay (NMD) of mRNA. The general model for this effect is that NMD is 
triggered when the EJC is detected downstream of translation termination, which could 
indicate incorrect splicing, or an early translation stop site (Boehm and Gehring, 2016; Nagy 
and Maquat, 1998). The EJC can also increase gene expression, by facilitating binding of RNA 
export factors, such as ALYREF and DDX39B to a messenger ribonucleoprotein (mRNP) 
(Gromadzka et al., 2016; Heath et al., 2016). This recruitment of mRNA export factors 
contributes towards the improved expression associated with intron-containing genes (Lu 
and Cullen, 2003). These are just two of the myriad of ways in which the EJC can affect gene 
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expression, including  splicing regulation, and enhancement of translation initiation (Boehm 
and Gehring, 2016). 
1.4.2.5. TREX 
The bulk of mammalian mRNA export from the nucleus requires the transcription export 
(TREX) complex and the heterodimeric nuclear receptor NXF1-NXT1 (Viphakone et al., 2012). 
At each point during the maturation pathway key components of the TREX, such as THO1,2,5-
7 (Masuda et al., 2005) are recruited. Alternative forms of TREX consist of various 
interchangeable proteins in addition to this stoichiometric core, such as ALYREF, DDX39B or 
CHTOP (Chang et al., 2013; Chi et al., 2013). Unlike in yeast, where TREX recruitment is 
primarily coupled to transcription, metazoan TREX recruitment is primarily coupled to 
splicing (Masuda et al., 2005), though some inefficient EJC and export factor deposition has 
been observed in intronless transcripts, possibly deposited via co-transcriptional scanning for 
introns (Viphakone et al., 2019).  Metazoan TREX recruitment is also coupled to mRNA 
processing through its’ interactions with the RNAPII CTD, the CBC, the EJC, and Prp19 
(Gromadzka et al., 2016; Heath et al., 2016; Hsin and Manley, 2012). In particular, the critical 
export factors ALYREF and CHTOP are deposited preferentially at the 5’ and 3’ ends of pre-
mRNA respectively, the former by utilising the CBC as a transient landing pad before 
associating more stably with EJCs and influencing splicing events, and the latter through 
preferential association with Ser2-phosphorylated RNA Polymerase 2 (which occurs more 
frequently toward the 3’ end of transcription), from where it can influence 3’ end processing 
(Viphakone et al., 2019).  
After early recruitment to these protein signals, TREX subunit deposition on the mRNA is 
mostly mediated through the DDX39A/B RNA helicases, which load export factors such as 
ALYREF, CHTOP, and UIF using it’s helicase ATPase cycle (Dufu et al., 2010). Unlike the THO 
core, all of these proteins strongly bind RNA. This, in combination with the substantially 
greater concentration of  these proteins than THO components (Schwanhausser et al., 2011) 
have led to speculation that THO’s major role is as a chaperone for export factors binding 
mRNA, and it is unclear whether these export factors remain bound to THO after their 
deposition (Heath et al., 2016).  
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Once export factors have bound to the mRNA, its’ primary export ability comes from 
recruitment of the NXF1 protein to the mRNA, which then facilitates nuclear export through 
the nuclear pore complex (NPC) (Okamura et al., 2014). Through an NTF2-like (NT2FL) 
domain, NXF1 binds the NXT1 protein, forming a heterodimer required for its’ stability and 
function (Liker et al., 2000; Okamura et al., 2014). Through various protein interactions, chiefly 
mediated by ALYREF, autoinhibition of NXF1’s RNA-binding capacity is relieved, facilitating 
mRNA binding and nuclear export (Viphakone et al., 2012).  
1.4.2.6. Nuclear Export 
Once NXF1-NXT1 has bound the mRNA, a conformational change in the mRNP occurs, 
known as remodelling, which is orchestrated by DDX39B,  and it is taken to the nuclear 
membrane for export through the NPC (Okamura et al., 2014). Through interaction with FG 
repeats, NXF1 helps the mRNP to overcome the permeability barrier of the NPC, facilitating 
export into the cytoplasm (Köhler and Hurt, 2007).  
Inefficient processing and export of recombinant transcripts can be a limiting factor in 
biopharmaceutical expression, with higher quantities of pDNA delivered into the nucleus not 
leading to higher quantities of exported mRNA (Rajendra et al., 2015a). This is especially 
relevant in regard to solving the problem of excess vector size discussed in section 1.4.1. As 
much of the mRNA processing and export machinery is recruited by splicing (Heath et al., 
2016; Masuda et al., 2005), the creation of minimised transcripts by removal of introns may 
impair efficient mRNA delivery into the cytoplasm (Lu and Cullen, 2003). Tools targeted 
toward this problem will be investigated in chapter 3 of this thesis.  
1.4.3. Translation 
Translation, in which mRNA codons are decoded by interactions with specific aminoacyl-
tRNAs, facilitated by the polypeptide factory of the ribosome, is the final stage of gene 
expression with which a biopharmaceutical mRNA is involved. It is heavily energy 
consuming, and its’ four stages are thus all tightly regulated (Jackson et al., 2010; Valvezan 




The first stage of translation is initiation, starting with a processed and exported mRNP in the 
cytoplasm, and ending when that mRNP has been bound by a full 80S ribosome, the start 
codon positioned at the peptidyl decoding site, and the methionyl-initiator transfer RNA 
(Met-tRNAi) bound to it, ready for polypeptide elongation to begin (Aylett and Ban, 2017). 
Initiation is the most strictly regulated of all four steps in translation, and is thus often a 
bottleneck in protein production (Aitken and Lorsch, 2012; Jackson et al., 2010). 
To begin translation initiation, an exported mRNP is bound by eukaryotic initiation factor 4F 
(eIF4F), a trimer consisting of eIF4E, eIF4A1, and eIF4G, and by eIF4B at its 5’ terminus. The 
mRNP is also bound by PolyA-binding protein (PABP), at its PolyA tail. PABP binds to eIF4G, 
forming a circularised mRNP. Assisted by binding from eIF4G and eIF4B, eIF4A1 then begins 
to unwind any 5’UTR mRNA secondary structures, via its ATP-dependent helicase activity, 
rendering an activated mRNP, ready for ribosome binding (Aitken and Lorsch, 2012; Jackson 
et al., 2010). Evidence gathered from assays in the presence and absence of these various 
factors indicate that not every factor is strictly essential for this mRNA activation, rather, they 
form a network of redundant interactions, perturbations of which are used to regulate 
dynamics of initiation (Mayberry et al., 2009), for instance in the observation that abrogation 
of the PABP-eIF4G interaction only significantly downregulates translation initiation under 
conditions of high competition for translational apparatus (Svitkin et al., 2009). 
This activating mRNP is then bound by the 43S pre-initiation complex (PIC), consisting of the 
40S ribosome, eIF1A, eIF1, eIF5, eIF3, and Met-rRNAi-eIF2-GTP. Using the processive helicase 
activity of eIF4A1, the mRNA is then scanned for the AUG start codon, to which Met-tRNAi 
can bind. To enable scanning along the mRNA, eIF1 and eIF1a bind to inhibit ribosomal RNA 
(rRNA)-mRNA interactions, which might otherwise inhibit the processivity of scanning. 
When the start codon, most efficiently within the ideal context of a Kozak sequence 
(GCC(A/G)CCAUGG), passes thought the P site, it is arrested by binding to Met-tRNAi, 
causing a conformational change that expels eIF1, and hydrolyses the GTP bound to eIF2, 
before it is expelled from the complex (Aylett and Ban, 2017), forming the ‘closed’ 48S PIC. 
Finally, aided by GTP-bound eIF5B, the 60S ribosome binds, and upon hydrolysis of GTP-
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eIF5B, all initiation factors are ejected, and the complete 80S initiation complex, ready for 
elongation, is formed (Jackson et al., 2010).  
Translation initiation can be regulated by a number of mechanisms. Firstly, global regulation 
can occur by the phosphorylation or otherwise manipulation of translation initiation factors. 
For example, eIF2a is phosphorylated by PERK to downregulate translation in response to 
triggering of the UPR (Jackson et al., 2010), and mTOR dynamically regulates the 
phosphorylation of 4E-BP1/2/3 in response to nutrients and growth signals, which when 
hyperphosphorylated, sequester eIF4E, inhibiting translation (Roux and Topisirovic, 2018; 
Valvezan and Manning, 2019). Initiation can also be regulated by sequence-specific protein-
RNA binding events. Examples of this include the regulation of adenine/uridine-rich elements 
(ARE) in the 3’UTR by specific binding of HuR (Mazan-Mamczarz et al., 2003; Wu et al., 2015), 
or the nutrient/growth factor dependant regulation of ribosomal proteins containing a 5’TOP 
sequence, specifically bound by LARP1, rendering transcripts hypersensitive to regulation by 
mTOR (Fonseca et al., 2018; Hong et al., 2017). 
Initiation is the most tightly regulated stage of translation, acting as the primary bottleneck of 
its rate, outside of cases with notably suboptimal codons (Aitken and Lorsch, 2012; Jackson et 
al., 2010). Abundance of protein in mammalian cells is fundamentally controlled by 
translation (Schwanhausser et al., 2011), and expression deficits can occur at translation, failing 
to efficiently convert abundant mRNA into recombinant protein (Rajendra et al., 2015a). 
Despite this, beyond the ubiquitous Kozak sequence, there are no synthetic, predictable, or 
titratable elements for controlling the efficiency of translation initiation. Potential tools 
targeting this step in expression will be explored in Chapter 5 of this thesis.  
1.4.3.2. Elongation 
Translation elongation involves the processive ratcheting of mRNA through three sites in 80S 
ribosome (Aminoacyl site, Peptidyl site, Exit site), matching each codon with its cognate 
aminoacyl-tRNA to form peptide bonds between each residue of the open reading frame 
(ORF), and ends when a stop codon is reached. It is a cycle, composed of three steps: tRNA 
selection, peptide-bond formation, and translocation of the mRNA-tRNA complex. During 
tRNA selection, aminoacyl-tRNAs are delivered to the A site by eEF1a, in complex in GTP. 
Upon binding of a cognate codon and tRNA, eEF1a utilises its GTPase activity to hydrolyse 
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its bound GTP and fully accommodates the tRNA at the A site. As the peptide bond is formed 
by nucleophilic attack, a conformational change occurs, such that the two bound tRNAs 
occupy both the P/E and A/P sites respectively: the so-called hybrid-state. This hybrid state is 
the substrate for eEF2, which hydrolyses GTP to translocate the tRNA-mRNA complex 
through the ribosome, to the E and P sites (Schuller and Green, 2018).  
Several mechanisms are used to regulate elongation. For example, the peptide bond formation 
kinetics are less favourable for some residue pairs than others, for instance, a proline-proline 
pair can cause translation to stall. This stalling can be rescued by eIF5a, originally thought to 
be an initiation factor, now with growing calls to be renamed as an elongation factor, which 
stimulates peptide bond formation (Browning and Bailey-Serres, 2015). Ribosome stalling can 
also occur due to poor rates of A site occupancy, caused by low levels of aminoacyl-tRNAs 
cognate to a specific codon. This stalling is most often resolved by either a frameshift in codon 
reading, or misincorporation of a near-cognate tRNA (Schuller and Green, 2018). These 
resolutions are obviously problematic for the expression of a supposedly homogenous 
biopharmaceutical protein, meaning that codon optimality is important both for increasing 
product expression, and product quality (Hanson and Coller, 2018; Lalonde and Durocher, 
2017). 
1.4.3.3. Termination and Recycling 
Translation termination begins when the stop codon enters the A site of the 80S ribosome. 
This stop codon is recognised by eRF1, a protein which resembles an amino-acyl tRNA in 
structure, binding through a highly conserved NIKS domain, with codon-anticodon like 
interactions. In this position, eRF1 extends into the site previously occupied by tRNA acceptor 
stems, promoting peptide hydrolysis of the nascent polypeptide. eRF1 also recruits eRF3 to 
the ribosome, which facilitates peptide release through its GTPase activity. Termination is 
typically regulated by the detection that the stop codon is the appropriate distance from the 
appropriate 3’UTR binding proteins, particularly PABP. Inappropriate distances between 
proteins, as well as detection of proteins positioned incorrectly, most canonically an EJC 
downstream of the stop codon, contribute toward inefficient termination, and even NMD of 
the transcript (Schuller and Green, 2018).  
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After this termination, the mRNA and eRF1 remain bound to the 80S ribosome. This complex 
is separated and recycled by the ABCE1 protein, which utilises energy generated by ATP 
hydrolysis to separate the constituent parts, recycling them for the next round of translation 
(Dever and Green, 2012). ABCE1 and even the mRNA can sometimes remain bound to the 40S 
ribosome after this process, facilitating reinitiation of translation, utilising mRNA 
circularisation to re-bind and re-scan the transcript (Schuller and Green, 2017).  
1.4.4. mRNA Stability 
Highly regulated rates of turnover and mRNA half-lives are critical to the concentration of an 
mRNA in the cytoplasm, as stable mRNAs may be translated many times, leading to high 
protein expression, whereas certain transcripts may even be co-translationally degraded upon 
their first round of translation (Bicknell and Ricci, 2017). Therefore, mRNA stability is a critical 
determinant of expression characteristics (Fukao and Fujiwara, 2017; Presnyak et al., 2015).  
1.4.4.1. Global Decay Pathways 
Degradation of mRNA is generally performed by either 5’-3’ decay (which in some cases can 
occur co-translationally (Bicknell and Ricci, 2017)), or by exosome-mediated 3’-5’ decay.  
5’-3’ decay begins with deadenylation of the PolyA tail, mediated through the PAN2/PAN3 
and CCR4/NOT complexes, partially dissociating PABP from the transcript, thereby inhibiting 
translation. The decapping complex of DCP1/DCP2 is recruited by this process, via 
interactions with decapping coactivators DDX6 and Edc3. Upon binding, a conformational 
change in the catalytic DCP2 and binding of cofactors such as Edc1 allow hydrolysis of the 5’ 
cap, thus rendering the 5’ end of the transcript vulnerable to rapid, processive exonucleolytic 
degradation by Xrn1 (Mugridge et al., 2018). This process is inhibited by both translation 
initiation and elongation, with PABP association and codon optimality thought to be the main 
factors linking the two processes (Chan et al., 2018; Hanson and Coller, 2018; Presnyak et al., 
2015). In the case of 3’-5’ degradation, deadenylated transcripts are bound by the 1044 exosome, 
consisting of a 9-subunit core, which binds RNA and regulates the exoribonuclease activity of 
Rrp44, which processivity degrades the mRNA in a 3’-5’ direction (Januszyk and Lima, 2014).  
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1.4.4.2. mRNA Surveillance 
To prevent the production of aberrant protein, mRNA in the cytoplasm is subject to three 
main quality control mechanisms: nonsense-mediated, nonstop, and no-go decay (NMD, 
NSD, NGD), which are known collectively as mRNA surveillance (Bicknell and Ricci, 2017).  
NMD detects transcripts with premature stop codons (PTCs), canonically identified by 
detection of an EJC downstream of a stop codon. The efficient NMD pathways of organisms 
containing largely intronless genes have since called the simplicity of this model into question, 
and a new model has emerged, in which proximity of the stop codon to PABP and abundance 
of 3’UTR-binding proteins such as Upf1 are also integrated into the detection signal 
(Shoemaker and Green, 2012), reinforced by evidence that 3’UTRs can influence mRNA 
stability by forming secondary structures to change physical stop codon proximity to the 
PolyA sequence (Wu and Bartel, 2017). 
NSD and NGD detect transcripts lacking a stop codon, and transcripts on which the ribosome 
permanently stalls whilst inside the CDS, respectively. In all cases the ribosome will stall: on 
the end of a truncated transcript, at a site of stable mRNA secondary structure, at a site of 
inefficient peptide-linkage, or at a PolyA tail, all of which are detected by Dom34/Hsb1. The 
shared mechanism of ribosome stalling has somewhat blurred the sharp line between NSD 
and NGD, for instance in cases of stalling on a PolyA tail, which may be due as much to 
formation of energetically unfavourable Poly-Lys peptides (causing NGD) as to reaching the 
end of the transcript (causing NSD) (Radhakrishnan and Green, 2016; Shoemaker and Green, 
2012).  
Upon detection by any of the mRNA surveillance pathways, transcripts are split by an 
endonuclease upstream of the detection site, and the 5’ and 3’ fragments degraded by the 
exosome and Xrn1, respectively (Bicknell and Ricci, 2017).  
1.4.4.3. mRNA Stability Regulation 
The stability of cytoplasmic mRNA is regulated by a number of factors, such as 5’ cap 
methylation (Mauer et al., 2017), binding of AREs by RNA-binding proteins (Łabno et al., 2016; 
Schoenberg and Maquat, 2012), the potential use of which will be discussed in chapter 3, and 
targeted regulation by miRNAs (Hammond, 2015), which has already been discussed. 
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However, the most relevant mechanism of stability regulation for a biopharmaceutical 
transcript is the link between mRNA half-life and codon optimality.  
A striking genome-wide correlation has been observed between codon optimality and mRNA 
stability, with transcripts containing >70% optimal codons having around four-fold longer 
half-lives than those containing <40% in budding yeast. This mechanistic link was 
strengthened by the observation that substitution of WT codons with optimised and 
unoptimised codons had significant effects on mRNA half-life, and an implication of codon 
optimality as a secondary genetic code made by observation of the optimal codon enrichment 
in functional groups such as ribosomal protein mRNAs, and depletion in other groups, such 
as tRNA modification genes (Presnyak et al., 2015).  This correlation has been replicated both 
in higher eukaryotic zebrafish (Mishima and Tomari, 2016), and in mammalian NIH3T3 cells 
(Radhakrishnan and Green, 2016). This link is thought to be mediated through slower 
ribosomal processivity on suboptimal transcripts, sensed by the DEAD-box protein DDX6 
(functionally associated with mRNA decapping), which preferentially associates with slow-
moving ribosomes to induce enhanced degradation (Hanson and Coller, 2018; Heck and 
Wilusz, 2018).  
The efficiency of recombinant protein expression is tied to the availability of translation-
competent mRNA in the cytoplasm, and high rates of mRNA turnover can compromise this, 
with studies showing deficiencies in production stemming from low concentrations of 
mRNA, not caused by transcription deficiencies (Mason et al., 2012). In cases that led to high 
mRNA turnover that cannot be resolved by codon optimisation, such as undesirable peptide 
linkages, it is desirable to control mRNA stability through other means. Potential solutions 






Figure 1.10 – Showing the four main stages of, and most key factors in, the journey of a biopharmaceutical mRNA. 
First is mRNA maturation, including the addition of a 5’ cap, splicing of introns, and 3’ end maturation, followed 
by loading with factors and exportation from the nucleus (it should be noted that there is no clear chronological 
divide between these first two stages, and RNA export factors may even influence RNA maturation (Viphakone 
et al., 2019)). Next is translation in the cytoplasm, followed finally by degradation. The four molecular junctures 





In response to changing ethical and economic needs, the CLD process for production of 
therapeutic glycoproteins has undergone a myriad of synthetic developments in molecular 
biology, from various vector engineering strategies, to cell line manipulation, to transfection 
and culture strategy. In order to meet the current demands, a streamlined development 
platform, with reduced risk and increased screening capabilities must be developed, whereby 
rapidly transiently screened solutions can be rationally engineered toward optimality. In 
order to create this system, a molecular toolkit of synthetic biology parts, covering every step 
of product expression in both the vector and cell line must be developed. The work presented 
in this thesis will contribute towards this unmet need, by investigating synthetic tools for 
controlling biopharmaceutical titre by manipulation of mRNA, forming opportunities for 
synthetic control.   
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2. Materials and Methods 
2.1. Buffers and Solutions 
Buffer/Solution Composition 
5x TBE – Tris/Borate/EDTA 0.45M Tris Base, 0.45M Boric Acid, 10mM EDTA pH8.0.  
LB Media 10g Bacto-tryptone, 5g yeast extract, 170mM NaCl. pH 7.5 
with NaOH. Water to 1l.  
Nutrient Agar 2.3% Agar.  
10x PBS –Phosphate Buffered Saline 1.4M NaCl, 25mM KCl, 0.1M Na2HPO4, 18mM KH2HPO4, 
pH to 7.4 with NaOH. 
Lysis Buffer 50mM HEPES pH7.5, 100mM NaCl. 
4x Upper Buffer 100mM Tris-HCl (pH 6.8), 4% SDS, 0.2% bromophenol blue, 
20% glycerol, 200mM β-mercaptoethanol. 
4x Lower Buffer 1.15M Tris HCl pH8.8, 14mM SDS.  
Transfer Buffer 25mM Tris, 190mM glycine, 20% glycine. 
Blocking Buffer 0.5x TBS, 2% Tween, 2.5g   Milk Powder, Water to 50ml. 
Wash Buffer 1x TBS, 0.2% Tween. 
ECL1 0.1M Tris pH 8.5, 2.5mM Luminol, 0.4M p-Coumaric acid. 
ECL2 0.1M Tris pH 8.5, 18µM H2O2. 
Colouring substrate 2M Diethanolamine, 1mM MgCl2, 0.5mM ZnCl2. 
10x TBS – Tris Buffered Saline 1M Tris, 6.84M NaCl. pH to 7.6 with HCl. 
5x Running Buffer 0.125M Tris, 1.25M Glycine, 17mM SDS.  
FIX Solution 4% Formaldehyde, 1% PBS. 
TX Solution 0.5% Triton X-100 (vol/vol), 1% PBS. 
ELISA Wash Buffer 1X PBS, 0.05% Tween (vol/vol). 
 
The generic chemicals in these buffers and solutions were purchased from: 
• Thermo Fisher, Massachusetts, USA 
• Sigma Aldrich, Missouri, USA 
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2.2. Vector Construction 
2.2.1. PP7d-Fusion Proteins 
In order to create PP7d-fusion proteins, a CHO codon optimised Kozak-PP7d sequence was 
inserted by Gibson assembly (NEB, Massachusetts, USA) into a pcDNA5 FRT TO expression 
vector (Thermo Fisher, Massachusetts, USA, USA), directly downstream of the CMV 
promoter. Fusion proteins were then created by Gibson assembly, removing the PP7d stop 
codon in the process, by mismatching of primer-template base pairing.  
2.2.2. TU 
Expression of CHO codon optimised reporter and non-fusion test genes were driven from an 
in-house AstraZeneca proprietary transcription-unit (TU) vector, under a CMV promoter 
(Patel et al., in press). For studies using the Ef1α promoter, the CMV promoter and 5’UTR 
were removed from TU, and replaced by their counterpart Ef1α sequences.  
2.2.3. MGVT 
For expression of reporters utilising OriP-mediated amplification (Daramola et al., 2014), TU 
expression cassettes were transferred by golden gate cloning to an in-house multi-gene vector 
backbone (MGVT), containing the required OriP sequence (Patel et al., in press).  
2.3. Molecular Cloning 
2.3.1. PCR 
PCR was performed with the NEB Q5 2X Master Mix kit (NEB, Massachusetts, USA), as per 
the manufacturer’s instructions, with the following generic reaction mixture: 
• 12.5µl Q5 2X Master Mix 
• 9µl Nuclease-free water 
• 1.25µl 10µM Forward Primer 
• 1.25µl 10µM Reverse Primer 
• 1µl 10ng/µl Template DNA 





To perform Site-Directed Mutagenesis, the NEB Q5 Site-Directed Mutagenesis kit (NEB, 
Massachusetts, USA) was used, following manufacturer instructions, with primers designed 
using the NEBaseChanger online tool. After PCR amplification, reaction mixes were taken 
forward into the Kinase-Ligase-DpnI reaction, with the following generic reaction mixture: 
• 2.5µl 2X KLD Buffer 
• 1.5µl Nuclease-free Water 
• 0.5µl PCR mix 
• 0.5µl KLD enzyme mix 
Each 5µl KLD reaction mix was then transformed into competent DH5α E.coli (NEB, 
Massachusetts, USA), as described below. 
2.3.3. Gibson Assembly  
To perform Gibson Assembly, DNA backbone and inserts were first amplified by PCR, adding 
linkers with primers designed using the NEBuilder online tool. Template DNA was then 
degraded by addition of 1µl DpnI restriction enzyme (NEB, Massachusetts, USA) and 
incubation at 37˚C for 1 hour. PCR mixes were then run on an agarose electrophoresis gel, and 
the appropriate bands extracted using the QIAquick Gel Extraction kit (Qiagen, Hilden, 
Germany). Finally, each fragment was taken forward to NEB Gibson Assembly (NEB, 
Massachusetts, USA), with the following generic reaction mixture: 
• ~100ng of DNA fragments (3:1 insert:backbone molar ratio) 
• 5µl Gibson Assembly 2X Master Mix 
• Nuclease-free water to 10µl 
This reaction mixture was incubated at 50˚C for 1 hour, before being transformed into 
competent DH5α E.coli (NEB, Massachusetts, USA), as described in section 2.3.7. 
2.3.4. Colony PCR 
Transformed E.coli were screened for the correctly constructed plasmid by colony PCR. This 




• 2µl 10x Biotaq Buffer 
• 0.6µl 50mM MgCl2 
• 2µl dNTPs 
• 0.6µl 10µM For Primer 
• 0.6µl 10µM Rev Primer 
• 0.5µl Biotaq Polymerase 
• 13.7µl dH2O 
The template was added by picking a numbered E.coli colony with a P10 pipette tip, and 
dipping it inside the PCR tube. The reaction scheme involved an initial denaturation at 95°C 
for 3 minutes, extending at 72°C for 1 minute/kb with 30 cycles, and a final extension at 72°C 
for 5 minutes. 
2.3.5. Golden Gate Cloning 
For insertion of a transcription unit into the in-house MGEV backbone, the NEB Golden Gate 
Assembly kit (NEB, Massachusetts, USA) was used, as per the manufacturer’s instructions, 
with the following generic reaction mix: 
• 75ng MGEV backbone 
• 75ng insert 
• 2µl 10X NEB Golden Gate Buffer 
• 1µl NEB Golden Gate Assembly  
• Nuclease-free water to 20µl 
The reaction mixture was incubated at 37˚C for 1 hour, followed by 60˚C for 5 minutes, before 
10µl was transformed into competent DH5α E.coli (NEB, Massachusetts, USA), as described 
in section 2.3.7. 
2.3.6. Ligation 
In order to clone by ligation, DNA was first digested by the appropriate NEB restriction 
enzyme (NEB, Massachusetts, USA), with the following generic reaction mixture.  
• 3µl CutSmart 10X Buffer 
• 1µl Restriction Enzyme 1 
• 1µl Restriction Enzyme 2 
• 1-3µg DNA 
• Nuclease-free water to 30µl  
101 
 
Following digestion, reaction mixes were run on an agarose electrophoresis gel, before being 
gel extracted with the MinElute Gel Extraction Kit (Qiagen, Hilden, Germany). Gel extracted 
fragments were then ligated using the NEB Quick Ligation Kit (NEB, Massachusetts, USA), as 
per the manufacturer’s instructions, with the following generic reaction mix: 
• 10µl 2X Quick Ligation Buffer 
• ~100ng DNA fragments (3:1 insert:backbone molar ratio) 
• 1µl Quick Ligase 
• Nuclease-free water to 20µl 
This reaction mixture was incubated at room temperature for 10 minutes, before 10µl was 
transformed into competent DH5α E.coli (NEB, Massachusetts, USA), as described in section 
2.3.7.  
2.3.7. DH5α Transformation 
Competent DH5α were transformed with DNA by heat shock. To do this, 50µl frozen DH5α 
E.coli (NEB, Massachusetts, USA) were mixed with the appropriate volume of DNA, and left 
on ice for 30 minutes. They were then heated to 42°C for 30 seconds, before being returned to 
ice for 2 minutes. 950µl of SOC media (NEB, Massachusetts, USA) was then added, and the 
cells incubated in a shaking incubator at 37°C for 1 hour. After this, the cells were spun at 
6000rcf for 3 minutes, the supernatant removed, and the cells resuspended in 100µl LB 
medium (Thermo Fisher, Massachusetts, USA) for plating. E.coli were plated on agar plates, 
containing 100µg/ml Ampicillin (Thermo Fisher, Massachusetts, USA) or 50µg/ml Kanamycin 
(Thermo Fisher, Massachusetts, USA), as appropriate. 
2.3.8. Plasmid Preparation 
E.coli transformed with DNA were inoculated in liquid LB media (Thermo Fisher, 
Massachusetts, USA), containing either 100µg/ml Ampicillin (Thermo Fisher, Massachusetts, 
USA) or 50µg/ml Kanamycin (Thermo Fisher, Massachusetts, USA), and incubated with 
shaking at 37°C overnight. The cells were harvested by spinning at 6000rcf, for a time 
appropriate to the volume of medium. Plasmids were then isolated using Qiagen 





Correct molecular cloning was verified by the Sheffield Medical School Sanger sequencing 
service. DNA to be sequenced was diluted to 100ng/µl, primers to be used were diluted to 
1µM and both were sent in an envelope to be sequenced. 
2.4. Cell Culture 
2.4.1. HEK-293T 
HEK293T cells were subcultured every 3-4 days in T-75 and T-25 flasks (Corning, New York, 
USA) and kept in a static incubator at 37°C and 5% CO2. Cells were washed in warm 1x PBS 
and trypsinised (Thermo Fisher, Massachusetts, USA), before being passaged into new 
medium, at approximately a 1:4 ratio, depending on their confluence. Cells were counted 
using a haemocytometer when plating cells for experiments.  
Appropriate volumes of cell culture were used when incubated in various culture platforms, 
as displayed below: 
Culture Platform Culture Volume / ml 
T-75 Flask (Corning, New York, USA) 20 
T-25 Flask (Corning, New York, USA) 6 
6cm Dish (Corning, New York, USA) 5 
24-Well Plate (Corning, New York, USA) 0.5 
 
2.4.2. CHO 
CHO cells were subcultured every 3-4 days in chemically defined CD-CHO medium (Gibco, 
Massachusetts, USA), their viable cell densities measured using a ViCell XR machine 
(Beckman Coulter, California, USA), and seeded at 0.2*106cells/ml. Cells were incubated at 
37⁰C and 5% CO2, being shaken at 140RPM in Erlenmeyer flasks (Corning, New York, USA), 
240RPM in cultiflasks (Sartorius, Göttingen, Germany) and 320RPM in plates. Different CHO 




Cell Line CD-CHO Supplement 
Transient Host 25µM MSX, 100µg/ml Hygromycin B (Sigma Aldrich, 
Missouri, USA) 
ETE mAb Stable Producer 50µM MSX 
 
Appropriate volumes of cell culture were used when incubated in various culture platforms, 
as displayed below: 
Culture Platform Culture Volume / ml 
250ml Erlenmeyer Flask (Corning, New York, USA) 60 
125ml Erlenmeyer Flask (Corning, New York, USA) 30 
Cultiflask (Sartorius, Göttingen, Germany) 10 
24 Deep-Well Plate (Greiner Bio-One, Kremsmünster, Austria) 3 
24 Shallow-Well Plate (Thermo Fisher, Massachusetts, USA) 0.6 
96 Deep-Well Plate (Greiner Bio-One, Kremsmünster, Austria) 0.5 
 
2.4.3. Cell Culture Feeding 
For the transient fed-batch process described in Chapter 5 of this thesis, cells were treated with 
proprietary AstraZeneca feeds (AstraZeneca, Cambridge, UK). Day 0 feeds were applied 4 
hours post-transfection. Each Feed was administered individually by direct pipetting into the 
culture vessel. 
2.4.4. Multi-well Cell Growth Measurement 
For experiments performed in multi-well plates, presenting too small a culture volume for 
measurement by ViCell, one of three methods were performed to monitor cell culture growth. 
2.4.4.1. Bradford Assay 
To measure cellular protein abundance as a proxy for cell growth, cell lysates of HEK-293T 
cells were first collected, as described in section 2.7.1. 10µl of this cell lysate was mixed with 
990µl Bradford 1X dye reagent (Bio-Rad, California, USA). After 1 minute incubation, the 
absorbance of the sample was measured at 595nm, on a spectrophotometer blanked with 1ml 
Bradford 1x dye reagent.  
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After substitution of the of the blank sample’s aborbance, fold change in protein concentration 
was directly inferred from fold change in absorbance.   
2.4.4.2. Prestoblue Assay 
To measure fold-change in viable cell density by Prestoblue assay, a 1:1 volume:volume mix 
of Prestoblue Cell Viability Reagent (Thermo Fisher, Massachusetts, USA) and CD-CHO 
medium (Gibco, Massachusetts) was created. After shaking, 100µl of cell culture was 
aspirated from the culture vessel, transferred to a clear-bottom 96-well plate (Thermo Fisher, 
Massachusetts, USA), and 100µl CD-CHO added to two ‘blank’ wells. 22.5µl of 
Prestoblue:CD-CHO mix was then added to each well of the plate, which was shaken for 20 
seconds, and placed in a static 37°C 5% CO2 incubator. After incubation for 30 minutes, 
fluorescence of each well was measured in a plate reader, with a 560nm excitation wavelength, 
and 590nm emission wavelength.  
After substitution of the average of the blank well’s fluorescence, fold change in cell growth 
was directly inferred from fold change in fluorescence across the plate.  
2.4.4.3. Iprasense 
To measure viable cell density and viability in multi-well culture platforms, the Iprasense 
Norma HT (Iprasense, Montpellier, France) cell counter was used, as per manufacturer’s 
instructions. Where necessary, CD-CHO was used to dilute cell culture to the appropriate 
density for each slide, as described below.   
 
Iprasense Slide Depth Minimum Cell Density Maximum Cell Density 
100µm 0 cells/ml 4*106 cells/ml 
20µm 4*106 cells/ml 8*106 cells/ml 
 
2.5. Transfection 
2.5.1. HEK-293T PEI 
HEK-293T cells were transiently transfected using PEI (Thermo Fisher, Massachusetts, USA, 
USA) at 1µg/ml. In 24 well plates, 1*105 cells per well were used, and 1*106 cells per 6cm dish. 
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A weight ratio of 1:5 DNA:PEI was mixed with serum-free medium (Sigma Aldrich, Missouri, 
USA), to a volume equal to 1/6 of the total medium volume of the dish being transfected. This 
was mixed, centrifuged down using a pulse, and incubated for 20 minutes. The mixture was 
then added to the cells in medium, dropwise. 
2.5.2. CHO Electroporation 
To transfect CHO cells using electroporation, cells were first split into unsupplemented CD-
CHO medium (Gibco, Massachusetts, USA) for the two passages prior to transfection. 
Electroporation was performed with the Nucleofector 2B Device, with both electroporation 
cuvettes, and a 96-well shuttle (Lonza, Basel, Switzerland). On the day of transfection, the 
appropriate volume of unsupplemented medium was added into the culture platform, and 
incubated in a 37˚C 5% CO2  shaking incubator.  
DNA mixes were created by diluting the appropriate quantity of DNA (800ng for 96 deep-
well plates, 10µg for cultiflasks) 1:4 in nucleofector solution. 5*10^6 cells per ml of desired 
transfected culture were spun down at 200G for 5 minutes, and the supernatant aspirated and 
discarded. The cells were resuspended in the appropriate volume of Nucleofector solution 
(15µl for 96 deep-well plates, 100µl for cultiflasks). This cell suspension was then added to the 
DNA mix, and electroporated.  
Electroporated cells were diluted in the appropriate volume of unsupplemented CD-CHO for 
the desired cell density, seeded in the pre-gassed culture platform, and placed in the 
incubator.  
2.5.3. CHO PEI 
To transfect CHO cells using PEI, cells were first split into unsupplemented CD-CHO medium 
(Gibco, Massachusetts, USA) for the two passages prior to transfection. On the day of 
transfection, cells were seeded at 1*10^6 cells/ml in unsupplemented medium, in the 
appropriate culture platform. For the 7-day fed-batch process described in Chapter 5, cells 
were seeded at 4*10^6cells/ml. Cells were transfected with DNA with a maximum quantity of 
1.2µg per 1*10^6 cells. The appropriate volume of DNA was mixed at a 1:1 ratio with 300mM 
NaCl (Sigma Aldrich, Missouri, USA). 25kDa PEI (Thermo Fisher, Massachusetts, USA, USA) 
was also mixed 1:1 with 300mM NaCl, with a 5:1 DNA:PEI ratio of PEI to DNA transfected. 
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The DNA/NaCl and PEI/NaCl mixes were then combined, and mixed by pipetting up and 
down. After 1-minute incubation, the transfection mixes were added to cell culture.  
2.6. SEAP Assays 
To assay for concentration of SEAP, two different methodologies were used: an in-house 
method for supernatant collected from HEK-293T cells, and the Sensolyte pNPP SEAP 
detection kit (Anaspec, Fremont, USA) for supernatant collected from CHO cells.  
2.6.1. In-House 
One tablet of P-nitrophenyl phosphate (Sigma Aldrich, Missouri, USA) was added to 20ml of 
colouring substrate, and mixed on a shaking plate for 20 minutes.  
Medium was aspirated from adherent cells by pipette. It was then spun at 500G at 4˚C for 4 
minutes. The supernatant was then aspirated, leaving at least 50µl medium along with the 
pellet at the bottom of the tube. The appropriate amount of supernatant was then added to a 
1:10 mixture of 0.05% CHAPS in PBS (Thermo Fisher, Massachusetts, USA, USA) with mixed 
colouring substrate. The reaction was incubated in the dark for 2-4 hours. After this, the 
absorbance of the mixture was measured in a spectrophotometer at 405nm.  
If supernatant was not assayed on the day of collection, it was flash-frozen in liquid nitrogen, 
followed by storage in a -80˚C freezer, before being thawed on ice on the day of assaying. 
2.6.2. Sensolyte 
Cell culture was harvested, and centrifuged at 1000G for 5 minutes, before supernatant was 
aspirated. If necessary, harvested supernatant was diluted using CD-CHO (Gibco, 
Massachusetts, USA). 50µl of supernatant was aliquoted into a 96-well plate (Thermo Fisher, 
Massachusetts, USA), before 50µl of Sensolyte component A (Anaspec, Fremont, USA) was 
added. Absorbance at 405nm was measured after 15 minutes incubation in a plate reader, 
using a well containing only CD-CHO and component A as a blank.  
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2.7. Western Blot 
2.7.1. Cell Lysis 
Medium was aspirated from adherent cells, or from centrifuged cell pellets. The cells were 
washed with 1% PBS (Thermo Fisher, Massachusetts, USA, USA) of equivalent volume to the 
medium, before 1/6 of this volume of Lysis buffer was added. The buffer/cell mixture was 
then collected and centrifuged at 500G for 5 minutes, before the cell lysate supernatant was 
taken. The protein concentration in the cell lysate was then assessed by Bradford assay (Bio-
Rad, California, USA).  
2.7.2. Protein Gel 
Proteins were run on a Polyacrylamide gel, of which the percentage depended on the size of 
the protein being probed for. The Polyacrylamide gel consisted of a 5% upper gel, and a 10-
15% lower gel. Constituents for different gel percentages are listed below: 
5% Loading Gel 
4x Upper Buffer 4ml 
30% Acrylamide/0.8% Bisacrylamide (Bio-
Rad, California, USA) 
1.2ml 
10% APS (Sigma Aldrich, Missouri, USA) 110µl 
TEMED (Sigma Alrdich, Missouri, USA) 20µl 
Water Up to 10ml 
10-15% Running Gel 
4x Lower Buffer 4ml 
30% Acrylamide/0.8% Bisacrylamide 3.3-5ml 
10% APS 110µl 
TEMED 20µl 
Water Up to 10ml 
 
Proteins were denatured before gel loading by boiling at 95°C for three minutes and exposure 
to 1/6 diluted 2-mercaptoethanol (Sigma Aldrich, Missouri, USA). Samples were loaded onto 
gel using a gel-loading tip, and Thermo Scientific PAGEruler (Thermo Fisher, Massachusetts, 
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USA, USA). Gels were run in running buffer at 30mA, until the PAGEruler had sufficiently 
progressed down the gel.  
2.7.3. Transfer and Blotting 
Transfer to nitrocellulose membrane (Bio-Rad, California, USA) was performed by a Trans 
Blot Turbo machine (Bio-Rad, California, USA). The nitrocellulose and filter papers were 
soaked in transfer buffer, before the sandwich was stacked, and the protein was transferred 
at 25V for 7 minutes. After transfer, the nitrocellulose was briefly stained with Ponceau S 
(Sigma Aldrich, Missouri, USA), to check that proteins had transferred, before being washed 
with water. 
Nitrocellulose blots were blocked with blocking buffer on a shaker, for one hour. They were 
then exposed to the primary antibody in blocking buffer at the appropriate concentration, and 
left on a shaker for at least an hour. After three short (10 seconds) and three long (10 minutes) 
washes with Wash Buffer, the secondary antibody is added in blocking buffer at the 
appropriate concentration, on a shaker for 1 hour. After three more short and long washes, 
the gel was visualised by chemiluminescence, after addition of a 1:1 mixture of ECL1 and 
ECL2 solutions. 
2.8. Immunofluorescence 
To perform immunofluorescence, cells were first seeded in a well of a 24-well plate containing 
a coverslip.  
To fix the cells, medium was removed from the well, before the well was washed twice in 1X 
PBS. After this, 200µl FIX solution was added, and left at room temperature for 30 minutes.  
To permeabilise the cells, the FIX solution was removed, before the well was washed with 1X 
PBS (Sigma Aldrich, Massachusetts, USA). 200µl of TX solution was then added, before the 
wells were incubated on ice for 10 minutes. TX solution was then removed, before the cells 
were washed twice more in 1X PBS.  
After this, the cells were incubated with 100µl 1% BSA (Sigma Aldrich, Massachusetts, USA) 
in 1X PBS for 1 hour. This solution was removed, before the well was incubated with the 
primary antibody, diluted in 100µl 1% BSA in 1X PBS for 1 hour. The well was then washed a 
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further three times in 1X PBS. The well was then incubated with secondary fluorescent 
antibody, diluted 1/800 with 100µl 1% BSA in 1X PBS, covered in foil, for 30 minutes. 
Following this, the well was washed three final times with 1X PBS. The coverslip was then 
removed from the well, dried, and mounted with DAPI. Nail varnish was used to seal the 
coverslip, which could be stored at 4°C in the dark. 
2.9. RT-qPCR 
2.9.1. HEK-293T 
In order to extract RNA from cells, medium was first aspirated from cells, before they were 
washed with 1X PBS. Cells were then lysed in a volume of lysis mix equivalent to 5% of the 
total medium in the dish. The components for 1.2ml lysis mix are as follows: 
• 1150µl Lysis Buffer 
• 48µl Protease Inhibitors (Thermo Fisher, Massachusetts, USA, USA) 
• 1µl DTT (Thermo Fisher, Massachusetts, USA, USA) 
• 1µl Ribosafe RNase Inhibitor (Bioline, London, UK) 
After lysis cells were scraped off the plate, and pipetted into an Eppendorf tube, they were 
centrifuged at 16,100G for 5 minutes at 4°C, the supernatant aspirated, and the pellet 
discarded. A 3:1 ratio of TRIzol LS (Thermo Fisher, Massachusetts, USA, USA) was added to 
the lysis mix, and the solution was homogenised by pipetting up and down. The samples were 
left at room temperature for 10 minutes, before 200µl chloroform (Sigma Aldrich, Missouri, 
USA) was added, the tubes were hand-shaken for 30 seconds, and left at room temperature 
for a further 10 minutes.  
Samples were centrifuged at 12,000G for 15 minutes at 4°C, before the colourless supernatant 
was added to a CrystalClear tube (Starlab, Milton Keynes, UK) containing 1µl of Glycogen 
(Sigma Aldrich, Missouri, USA). A 1:1 ratio of isopropanol (Thermo Fisher, Massachusetts, 
USA, USA) was then added, before the sample was mixed by inversion and left at room 
temperature for 10 minutes. Following this, samples were centrifuged at 12,000G for 15 
minutes at 4°C. The supernatant was aspirated and discarded, leaving a white RNA pellet. 
This pellet was washed with 1.2ml of ice-cold 75% ethanol (Thermo Fisher, Massachusetts, 
USA, USA), by vortexing, and centrifuged at 7,500G for 5 minutes at 4°C. The supernatant 
was removed, leaving a white RNA pellet, which was left to air-dry in an open tube in a fume 
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cupboard. Once the white RNA pellet became colourless and translucent, it was stored at -
80°C.  
To treat RNA samples with DNase, RNA pellets were first re-suspended in 43µl in H2ORNase-
free, by vortexing, incubating on ice for 10 minutes, and vortexing again. The following Turbo 
DNase (Thermo Fisher, Massachusetts, USA, USA) mix was then added per sample: 
• 5µl 10X DNase Buffer 
• 2µl Turbo DNase  
• 1µl Ribosafe RNase Inhibitor 
This reaction mix was incubated at 37°C for 1 hour, shaking gently, at no more than 350RPM. 
50µl H2ORNase-free, and 100µl acidic phenol (Thermo Fisher, Massachusetts, USA, USA) were 
then added, before the sample was hand-shaken for 30 seconds, and left at room temperature 
for 5 minutes. The samples were centrifuged at 12,000G for 5 minutes at 4°C. 90µl supernatant 
was then aspirated, added to 1µl Glycogen (Sigma Aldrich, Missouri, USA) and 10µl Na-
Acetate (Sigma Aldrich, Missouri, USA) (3M, pH5.8), and mixed by inversion. 250µl 100% 
ethanol was then added, and mixed again by inversion. The sample was then incubated for at 
least 20 minutes at -24°C in a freezer.  
Samples were then centrifuged at 12,000G for 30 minutes at 4°C, and supernatant removed, 
revealing a white RNA pellet. This pellet was washed with 1.2ml of ice-cold 75% ethanol, by 
vortexing, and centrifuged at 7,500G for 5 minutes at 4°C. The supernatant was removed, 
leaving a white RNA pellet, which was left to air-dry in an open tube in a fume cupboard. 
The pellets were then re-suspended in 40-50µl H2ORNase-free, by vortexing, incubating on ice for 
10 minutes, and vortexing again. RNA concentration of the sample was then assessed by 
Nanodrop (Thermo Fisher, Massachusetts, USA, USA).  
cDNA synthesis was performed on 1µg of RNA, using a Bioscript reverse transcription kit 
(Bioline, London, UK), as instructed by the manufacturer. The resultant cDNA was then 
stored at -24°C. 
To perform qPCR, cDNA was diluted 5X in H2ORNase-free. If comparative qPCR against 18S 
rRNA was used, a further 100X dilution in H2ORNase-free of this diluted cDNA was prepared in 
a separate tube for the 18S rRNA qPCR tubes. A Sensimix kit (Bioline, London, UK) was then 
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used to performed qPCR, as per manufacturer instructions, with the following run 
parameters: 
• Anneal at 59°C or more for 15 seconds. 
• Extend for 25 seconds. 
• Cycle 45 times. 
Relative RNA levels were calculated by the -ΔΔCt method, against 18S rRNA as a 
housekeeping gene.  
2.9.2. CHO 
To begin RT-qPCR, 1*10^6 cells were centrifuged at 200G for 5 minutes, before being 
resuspended and passed through a QIAshredder column (Qiagen, Hilden, Germany). RNA 
was extracted from the pellets using an RNeasy Miniprep kit (Qiagen, Hilden, Germany), as 
per manufacturer’s instruction, and eluted in 30µl RNAse-free water. The concentration of 
this RNA was then measured using a Nanodrop One machine (Thermo Fisher, Massachusetts, 
USA, USA). 800ng of each RNA sample was then brought forward to cDNA synthesis using 
the QuantiTect Reverse Transcription kit (Qiagen, Hilden, Germany), as per manufacturer’s 
instructions. cDNA was diluted to the appropriate concentration in RNAse-free water, 
followed by qPCR, using the Quantifast SYBR Green PCR kit (Qiagen, Hilden, Germany), 
using the following generic reaction mix: 
• 8ul Nuclear-free water 
• 2.5ul Primer Mix (1µM of each primer) 
• 2ul cDNA 
• 12.5ul SYBR Green Master Mix 2X 
All qPCR reactions were run with the following settings: 
• Anneal at 60˚C for 15 seconds 
• Extend for 20 seconds  
• Cycle 40 times 
Relative RNA levels were calculated by the -ΔΔCt method, against Fkbp1a RNA as a 
housekeeping gene, as recommended by Brown et al., 2018.  
Primers were designed using the Primer-BLAST online tool, and validated by serial dilution 
of cDNA before qPCR, allowing calculation of primer efficiency using the Thermo Fisher 
qPCR Efficiency Calculator online tool.  
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2.10. Titre Assays 
2.10.1. IgG 
IgG concentration in cell supernatant was assessed by firstly centrifuging CHO cells at 200G 
for 5 minutes, before removing the supernatant from the pellet. Concentration of IgG within 
this supernatant was then measured using the FastELISA Human IgG Quantification kit 
(2BScientific, Upper Heyford, UK), using the manufacturer’s instructions.  
2.10.2. EPO 
To measure concentration of EPO in cell supernatant, CHO cells were centrifuged at 200G for 
5 minutes, and the supernatant removed from the pellet. Concentration of EPO within this 
supernatant was then assessed with the Human Erythropoietin simplestepELISA Kit 
(ab211647) (Abcam, Cambridge, UK), as per the manufacturer’s instructions.  
2.10.3. Sc-FP 
To measure titre of sc-FP proteins, CHO cells were centrifuged at 1000G for 5 minutes, and 
the supernatant removed from the pellet. Concentration of sc-FP within this supernatant was 
then assessed using the Octet HTX Machine (Molecular Devices, California, USA), as per the 
manufacturer’s instructions. 
2.11. Culture Supplementation 
For experiments in which cell culture was supplemented with chemical agents, cells in 96 
deep-well plates (Greiner Bio-One, Kremsmünster, Austria) were treated 24 hours post-
transfection. Plates were removed from the shaking incubator, and left to stand for 5 minutes 
in a static 37°C 5% CO2 incubator, allowing cells to settle in the bottom of each well. 100µl of 
conditioned medium was then aspirated slowly from the meniscus of each well. Finally, 100µl 
of one of Leucine/Arginine/Glutamine (Thermo Fisher, Massachusetts, USA, USA), Efficient 
Feed (Gibco, Massachusetts, USA), or Rapamycin (Sigma Aldrich, Missouri, USA) dissolved 
to the appropriate concentration in pre-warmed CD-CHO medium (Gibco, Massachusetts, 
USA), was added to each well. Control cells were treated in the same way, and supplemented 
with CD-CHO alone.  
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Master stocks of chemicals were prepared by dissolving the appropriate concentration of each 
supplement in CD-CHO medium, and sterilised by passing through a 0.22µM filter (Cole-
Palmer, Illinois, USA). For chemicals requiring DMSO as a diluent (e.g. Rapamycin), control 
cells were treated with CD-CHO containing the equivalent concentration of DMSO (Sigma 
Aldrich, Missouri, USA).  
2.12. mRNA Stability Assay  
To measure stability of mRNA transcripts, cells were first transfected with the gene to be 
measured, using the PEI method detailed in section 2.5.3.  
For timepoint 0h, 1*106 cells were spun down at 200G for 5 minutes, and cell pellets harvested 
as per the CHO RT-qPCR protocol detailed in section 2.9.2. 48h-post transfection, cells were 
treated with 20µg/ml Actinomycin D (Sigma Aldrich, Missouri, USA), administered via 
addition to cell culture of 1mg/ml Actinomycin D stock in DMSO (Sigma Aldrich, Missouri, 
USA). Cell pellets were similarly harvested at every appropriate timepoint following 
Actinomycin D treatment. RT-qPCR was then performed on each sample, in accordance with 
the method detailed above, with the quantity of each transcript of interest measured by 
relative abundance compared to the housekeeping gene fkbp1a, as recommended by Brown et 
al., 2018. mRNA half-life was calculated by non-linear regression of each transcripts’ relative 
abundance against time points post-Actinomycin D treatment, utilising a one-phase 




2.13. Sequence Elements  
The following is a list of all cis sequence elements used in this thesis, with a short summary 
of how they were sourced, and incorporated into their vectors.  
2.13.1. Coat Protein Binding Sites 
Coat protein binding sites sequence are well established in literature (Chao et al., 2008, 2012). 
Modules, containing 3 repeats of sequences of 2 stem-loops (totalling 6 binding sites), were 
isolated by PCR from a pre-existing in-house laboratory plasmid based on these sequences, 
and placed downstream of the 3’UTR, directly upstream of the PolyA signal in the 













2.13.2. Triple Helices 
CHO MALAT1 and MENβ triple helices sequences were identified by aligning established 
human triple helices sequences (Brown et al., 2012, 2014b), with the CHO-K1 genome, taking 
the region of homology as the CHO triple helices. The PAN triple helix sequence was taken 
from literature (Mitton-Fry et al., 2010; Tycowski et al., 2012). Triple helices were placed 
directly downstream of the 3’UTR, in the AstraZeneca in-house TU1 vector, inserted between 
the SbfI and NotI restriction sites, both with and without a PolyA sequence downstream, 
















2.13.3. Stability Elements 
34nt stability elements were extracted from the data of Oikonomou et al., 2014, and placed 
directly downstream of the reporter CDS-bordering SbfI restriction site in the AstraZeneca in-
house TU1 vector, upstream of the 3’UTR, by site-directed mutagenesis. How stability 
elements were selected from the large database is described in detail in Chapter 4.  
Name Oikonomou et al., 2014 
SequenceID 
Sequence 
SE1 C3U-seq15901 TTTGTTTTAGATGGAATAGCACAAGGAGAAAAAT 
SE2 C3U-seq10578 GTTTTTTGAGGAATCTCAAGATGTGATATATTGG 
SE3 C3U-seq4185 ATGTCTCCAGTTACAACTCCGCAGTGGATGTGAA 
SE4 C3U-seq8401 GCAATTTAGCATGTTGGAACGTCTAGGGAGAAGG 
SE5 C3U-seq12424 TCTCATTCCAGTAAGGCAGTTAGACACTTGAGTT 
SE6 C3U-seq5465 CAGTTGAGATGAAGCACGTCGTTAGAACGTTGTT 
SE7 C3U-seq212 AAAATGTAAAAATGTAACTATAGCATATGAATTG 
SE8 C3U-seq1204 AAGTGGAGGTCTGGTTTGTAACTTTCCTTGTACT 
SE9 C3U-seq8665 GCCTTAGGAGACTGGAAGTTTAAAAATGTACAAG 
SE10 C3U-seq3598 ATAGCTGTACAAATATAAGAATAAAATGTTGAAA 
SE11 C3U-seq9065 GGAGAAAGCTTCTCTATTTTGGATGCATTTCAGA 
SE12 C3U-seq477 AAAGTTGCAAGATAAACAGCTGTAATTCGGACAA 
SE13 C3U-seq10512 GTTTTAAGTAACTTTTTATAGCAAGATGATACAA 
SE14 C3U-seq16091 TTTTGACTATTTTTATATATAAAGAAGAACTCAA 
SE15 C3U-seq14491 TTATTGTGGATAACAAAGATATCTTTTCTTTAGA 
SE16 C3U-seq13367 TGGCAGGTATTCCCATGATTCACAGAGTTACATT 
SE17 C3U-seq248 AAACAAAAGCCTGGCTGAGTTGATGTTTTACATT 
SE18 C3U-seq5093 CACAGTATTCGTGAATAAGTTGATTCTGTCCCCC 
SE19 C3U-seq5184 CACTGAAGAGGTGGAAAAATAATCGTGTCAATCT 
SE20 C3U-seq2244 ACTATAAATGCTTTGCAAAAATGGTTTCACGTTT 
SE21 C3U-seq13645 TGTAGATCATAGGATAGCTGACTTTGACAGTCAC 
SE22 C3U-seq1502 AATGGAACACAGACAGTGTAGAAGAATTCCTGAG 




2.13.4. 5’TOP Motifs 
The criteria by which 5’TOP-containing genes were identified is described in detail in Chapter 
5. Once genes were selected, 5’TOP sequences were identified by scanning for motifs in their 
CHO-K1 genome sequence (2014), with the following process: 
1. Identify a sequence that satisfies the following criteria: 
a. Upstream of the start codon. 
b. Nearest to the start of the annotated gene. 
c. Begins with a Cytidine.  
d. Comprises an exclusive tract of 5+ pyrimidines. 
2. If no such sequence can be identified, restart this process with the highest ranked gene 
of the next list.  
5’TOP motifs were substituted with the natural sequence from the Ef1α 5’TOP sequence in 
both the Ef1α and modified CMV-TCT promoters, by site-directed mutagenesis. The motif 
was removed from both of these promoters as a NON-TOP control.  
Source Name Sequence 
EF1a TOP1 CTTTTTC 
NON-TOP TOP2   
ACTB TOP3 CTCTTTCTTC 
RPLP2 TOP4 CTTCCTTTC 
RPL11 TOP5 CCTCCT 
RPS14 TOP6 CCTCCCCT 
GAPDH TOP7 CTCTCT 
RPL13A TOP8 CCTCCTCCTTTCCC 
RPL14 TOP9 CCTTCTTCCTTCTC 
RPS10 TOP10 CTTCTC 
RPS25 TOP11 CTCCTCCC 
RPS23 TOP12 CCTTCCT 
RPS24 TOP13 CCTTCC 
RPS7 TOP14 CCTCTTTCT 
RPL31 TOP15 CTTCCCTTCCC 
RPL18A TOP16 CTTCCTTTT 
RPS3A TOP17 CTCCCC 
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RPS3A#2 TOP18 CCCTTTT 
HSP90AB1 TOP19 CTTCTC 
TUBB TOP20 CCTTCCCTCCT 
RPS27A TOP21 CCTCTCTTCTC 
VIM TOP22 CCTCT 
RPS8 TOP23 CCTTCCC 
EEF1G TOP24 CCTTTT 
EEF2 TOP25 CTCTTCTCCT 
HSPD1 TOP26 CCCTCCC 
IPO5 TOP27 CTCCCTCCTCCTTCTCTCTCTC 
RPL7 TOP28 CTTCCTCTCTCT 
RPL10 TOP29 CTTTTCCTCC 
EIF2S3 TOP30 CCTTCCTCTCT 
HNRNPF TOP31 CCTCTTCCTCCTC 
RPL3 TOP32 CCTCT 
RPL30 TOP33 CTTCCTTTCT 
RPS2 TOP34 CCTTCCCC 
RPL23A TOP35 CCTTTT 
EEF2 TOP36 CTCTTCTCC 
ENO2 TOP37 CTTTCTCCTTCCTCC 
DDX21 TOP38 CTTTCTTCCTCTCTCTTTT 
IPO7 TOP39 CTTCTCTTTCCTTTC 
GARNL3 TOP40 CCTTTTTTTTTTTTCTC 
LAMB1 TOP41 CCCCTTCCT 
DDX39B TOP42 CTCTTCT 
GNAI3 TOP43 CCCCTCTCCC 
CS TOP44 CCCTTCCT 
MATR3 TOP45 CCTCCTT 
EIF2S3 TOP46 CCTTCCTCTCT 
EIF3A TOP47 CTTTCC 
KPNA3 TOP48 CTCTTT 
- sTOP CTTTCT 





2.13.5. Synthetic Proximal Promoters 
Synthetic proximal promoters were taken from literature (Brown and James, 2015; Brown et 
al., 2014a, 2017), and substituted the proximal promoters of both CMV and Ef1α, upstream of 
their cores, in the AstraZeneca in-house TU1 vector, using EcoRI/NheI and EcoRI/AflII 













































2.14. Graphing and Statistics 
• Error bars displayed on all bar and line graphs are of the standard error of the mean.  
• Box and whisker plots show the minimum and maximum values of the dataset.  
• Statistical significance was measured by paired t.test in the case of datasets with 





3. RNA-Binding Proteins 
3.1. Introduction 
3.1.1. Overcoming export deficiencies of intronless transcripts by 
tethering to mRNA binding proteins 
Whilst minimisation of DNA vectors is desirable, removal of introns is well documented to 
decease gene expression (Callis et al., 1987; Lu and Cullen, 2003; Rathus et al., 1993). The extent 
of this effect is gene-dependent, ranging from a 35-fold to 2-fold decrease in expression upon 
intron removal, but is universal across intron-containing genes (Lu and Cullen, 2003). This 
effect occurs because mRNA recruitment into processing and export machinery in 
mammalian cells is splicing dependent (Heath et al., 2016; Masuda et al., 2005). The splicing-
associated proteins in the exon junction complex (EJC), as well as DDX39B (Heath et al., 2016; 
Viphakone et al., 2019) and Prp19 (Chanarat and Sträßer, 2013) are required for the stable 
deposition of the TREX complex on nascent mRNA. Since mRNA export is an extensively 
coupled process, for instance in the passing of mRNA from TREX to NXF1 (Viphakone et al., 
2012), and from NXF1 to the nuclear pore complex (Okamura et al., 2014), lack of TREX 
recruitment via splicing has a knock on effect downstream, decreasing expression of genes 
with removed introns. 
Natural intronless genes have evolved strategies to compensate for this expression deficit. A 
study into expression of several intronless mammalian genes found that a conserved portion 
of their coding region conferred TREX and NXF1 dependent cytoplasmic accumulation and 
expression. These cytoplasmic accumulation regions (CARs) also conferred cytoplasmic 
localisation on an unrelated cDNA when inserted into its coding sequence (Lei et al., 2011). In 
further studies, these CARs were found to associate with TREX and Prp19 components. When 
a multimerised CAR was inserted downstream of an intronless β-globin reporter, it rescued 
expression. This rescue was reversed upon TREX knockdown, or mutation of the CAR 
sequence (Lei et al., 2013). These data suggest that naturally intronless genes contain sequence 
specific elements that recruit them into the TREX processing pathway, compensating for a 
lack of co-splicing recruitment. 
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Another group of intronless proteins compensating for their expression deficit with this 
strategy can be found in viruses. The Hepatitis B Virus (HBV) core protein (HBc) has been 
shown to specifically interact with NXF1 and with TREX components by 
immunoprecipitation. Furthermore, non-spliced HBV RNAs were found to decrease in 
cytoplasmic accumulation upon siRNA treatment of NXF1 (Yang et al., 2014). Taken together, 
these data suggest that HBV compensates for lack of expression in its intronless genes by 
‘hijacking’ its way into the TREX/NXF1 export pathway via the HBc protein. Further evidence 
of this strategy in HBV is found in a post-transcriptional RNA element, SEP1. The RNP that 
forms on this element in the nucleus contains TREX and other export factors. The element was 
found to bind ZC3H18, a TREX associated protein, and enhance cytoplasmic localisation in a 
manner dependent on both sequence, and ZC3H18 (Chi et al., 2014).  This strategy can be 
found in a variety of viruses, with Herpesvirus Saimiri protein ORF57 linking viral mRNA to 
the export adaptor ALYREF (Tunnicliffe et al., 2014), and with the same protein in Kaposi’s 
Sarcoma–Associated Herpesvirus, in which cytoplasmic localisation of viral mRNA is 
disrupted by ORF57 mutation and by ALYREF or NXF1 mutation (Boyne et al., 2008). Export 
of Herpes Simplex Virus 1 mRNA is dependent upon the ICP27 protein, which binds viral 
mRNAs and ALYREF (Tian et al., 2013). Finally, the Epstein-Barr virus early protein EB2 has 
been shown to contain a nuclear export signal that binds both viral mRNAs and NXF1, and is 
required for cytoplasmic localisation of viral mRNA (Juillard et al., 2009).  
Together, these results show that a generalised strategy for efficient intronless RNA export is 
by hijacking, by either protein-protein or protein-RNA interactions, into mRNP processing 
and export pathways. Therefore, if an intronless expression cassette could be similarly 
hijacked into the export pathway, it could overcome the export deficit given by its’ 
minimisation. 
3.1.2. PP7/MS2 Tethering 
PP7 and MS2 tethering are two analogous technologies for RNA-protein recruitment. Each 
system comprises of a bacteriophage coat protein, and an RNA hairpin loop, to which the coat 
protein binds in a sequence-specific manner (Chao et al., 2008). In order to bind these RNA 
hairpins, the coat proteins must first dimerise. This is usually a rate limiting process, with the 
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Kd associated with coat protein dimerisation around an order of magnitude higher for 
dimerisation than RNA binding, as shown in Table 3.1 (Wu et al., 2012). 
 
Table 3.1 – The dissociation constants 
associated with each stage of PP7/MS2 
RNA-protein tethering. 
 
In order to circumvent this rate limiting step, translationally fused PP7 and MS2 coat protein 
dimers (PP7d, MS2d) have been created (Wu et al., 2012), thus removing the rate-limiting 
dimerisation step of binding. This technology is powerful and versatile, for instance being 
used to measure cell-wide mRNA noise level and transcriptional activity of a single gene 
(Hocine et al., 2012), or, by tweaking specificity via a construct requiring both PP7 and MS2 
binding, to measure single mRNA molecules (Wu et al., 2014).  
It has also been shown that mRNA export and expression can be stimulated by tethering to 
proteins relating to this function. Tethering of RNA to a fusion protein containing an NXF1-
associated nuclear export sequence led to increased nuclear export (Juillard et al., 2009), and 
the same effect is replicated when the RNA is directly tethered to NXF1 (Tintaru et al., 2007). 
Tethering of GFP mRNA to an MS2 fusion with HuR, a 3’ UTR binding protein, led to 
increased localisation of GFP at the cell membrane (Berkovits and Mayr, 2015).  
Bringing these conclusions together, it was decided to emulate the generalised strategy for 
intronless mRNA expression described above. By association of intronless mRNAs with 
proteins involved in processing and export using a PP7 tethering system, a molecular biology 
tool could be created for efficient export of mRNA. Ideally, this tool would facilitate vector 
minimization by intron removal, whilst minimizing the export deficit associated with this 
change.  
3.2. Results 
3.2.1. Construction of PP7d-effector gene fusion Library 
In order to tether an intronless reporter mRNA to RNA-binding export proteins, a library of 
14 fusion proteins was created. These fusion proteins comprised an SV40 nuclear-localisation 
 PP7 MS2 
Dimerisation KD 20nM 410nM 
RNA Binding KD 1.6nM 5nM 
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sequence (NLS), a HA peptide tag, the PP7 dimer (PP7d) CDS, a short leucine-rich linker, and 
the gene of interest CDS, as detailed in section 2.2.1,  and were created by modification of the 
pcDNA5 FRT TO vector by Gibson assembly as in section 2.3.3. Correct construction was 
verified by Sanger sequencing, and a representative plasmid map can be found under ‘FRT 
TO – PP7d Fusion’ in Appendix A, and a schematic shown in Figure 3.2. Thus, the resulting 
protein would be detectable by HA western blot, localised in the nucleus, and able to tether 
to an mRNA bearing PP7bs.  
To examine whether the fusion proteins encoded by these plasmids were being properly 
expressed, 1*105 HEK-293T cells in a 24-well plate format were transiently transfected by PEI 
at a 1:5 DNA:PEI ratio with 250ng of each construct, and their cell lysates collected 72 hours 
post-transfection for analysis by western blot with a HA-tag antibody, as described in section 
2.7. As shown in Figure 3.1, testing of untransfected cell lysate led to detection of four off-
target bands. Therefore, any bands appearing in addition to these four could be attributed to 
the transfected fusion protein. All the remaining lanes in Figure 3.1 are marked with the 
expected position of each of their fusion proteins, based on their predicted molecular weight. 
In all lanes an additional band is visible in the expected position. For the PP7d-CIRP and PP7d-
RBM3 (cold-inducible genes associated with increased mRNA stability (Tan et al., 2008; Xia et 
al., 2012; Zhu et al., 2016)) lanes, the predicted position of each protein was very close to that 
of the second-lowest off-target bar. However, in both lanes the additional protein is 
discernible both by the increased intensity of this band, and by the visibility of two 
overlapping peaks of intensity within the band. The blot in the PP7d-NXF1 lane shows cells 
transfected with a PP7d-NXF1 fusion, with the addition of its’ co-dimer P15, separated by a 
P2A self-cleaving peptide. If expressed correctly, the P15 will be cleaved from the fusion 
protein at translation, creating a stoichiometric increase in P15, to match NXF1 overexpression 
in the cell. As expected, the band in this lane is the predicted size of the PP7d-NXF1 fusion, 
accounting for P15 cleavage. The data shown in Figure 3.1 therefore suggests that all the fusion 





Figure 3.1 – Showing the testing for correct transient expression of a library of PP7d-fusion proteins, by western 
blot against a HA peptide tag after transfection by PEI at a 1:5 DNA:PEI ratio into HEK-293T cells. The off-
target bands given by western blot of untransfected cell lysate are shown in lane 1. The expected position of each 
fusion protein is shown by a red star in each lane. Images taken at separate times were aligned in this figure, based 
on the molecular ladder present on each individual blot. Images were taken using automatically set exposure time, 
using ‘Optimal’ mode on the Chemidoc MP (Bio-Rad, California, USA) and ‘Strong Bands’ mode on the 
Chemidoc XRS (Bio-Rad, California, USA). No further brightness/contrast alterations were made to the images. 
Representative blots from two biological replicates are displayed. 
3.2.2. Characterisation of SEAP Assay and Reporters 
In order to accurately measure effects on SEAP expression, the assay to measure its’ titre was 
characterised. Firstly, a linear relationship between SEAP titre and absorbance measured in 
the assay had to be demonstrated. Different volumes of supernatant taken 72h post-
transfection from 1*105 HEK-293T cells transiently transfected by PEI at a 1:5 DNA:PEI ratio 
with 250ng TU1-SEAP in 24-well plates were assayed by the in-house SEAP assay described 
in section 2.6.1. TU1-SEAP represents the in-house AstraZeneca proprietary TU vector 
(section 2.2.2.), with the SEAP CDS inserted by restriction/ligation cloning, as in section 2.3.6., 
and a representative plasmid map can be found under ‘TU1’ in Appendix A. Schematics of 
the TU1-SEAP-PP7bs reporter and effector gene PP7d fusions constructs used in this chapter 




Figure 3.2 – A schematic of the TU1-SEAP-6xPP7bs reporter and effector gene PP7d fusion constructs which 
are used in this chapter.  
 
A constant total volume of 200µl was maintained by addition of fresh, uncultured medium. 
The results of this experiment are shown in Figure 3.3a, with a strong linear relationship 
between absorbance and the proportion of SEAP-containing supernatant present in the assay. 
Next, 1*105 HEK-293T cells in 24-well plates were transfected with increasing quantities of 
TU1-SEAP using PEI at a 1:5 DNA:PEI ratio, and their supernatants assayed for SEAP titre 72 
hours post-transfection, by the in-house method in section 2.6.1. As shown in Figure 3.3b, a 
non-linear, second order exponential relationship was observed between SEAP titre and 
quantity of TU1-SEAP transfected. To further investigate this result, a constant quantity (20ng) 
of TU1-SEAP or FRT-TO-GFP (the pcDNA5 FRT TO vector expressing a GFP CDS) was 
cotransfected into 1*105 HEK-293T cells in 24-well plates by PEI at a 1:5 DNA:PEI ratio, with  
increasing quantities of FRT-TO-GFP, and SEAP titre assayed 72 hours post-transfection, by 
the in-house method in section 2.6.1. As shown in Figure 3.3c, cells subject to cotransfection 
of increasing quantities of FRT-TO-GFP alongside TU1-SEAP displayed a linear increase in 
SEAP titre, with transfection of only GFP leading to no SEAP titre being measured. In 
combination with Figure 3.3a and Figure 3.3b, these data suggest that whilst total 
concentration of SEAP present is correlated linearly with assay absorbance, SEAP titre is 
stimulated by increased total DNA transfected, even if this DNA produces no SEAP assay 
signal when transfected alone. Therefore, all transfections should be performed with constant 
DNA quantity, with ‘filler’ DNA being used to make up the total weight if necessary. Finally, 
SEAP-containing supernatant harvested for the previous assay was measured at several 
timepoints after the start-point of the assay. Figure 3.3d shows a linear relationship between 
absorbance, and the timepoint at which it was measured. Therefore, supernatants must be 
127 
 
measured at the same timepoint post-assay start, for their fold-change in SEAP titre to be 
accurately comparable.  
 
Figure 3.3 – SEAP assay characterisation using supernatant from HEK-293T cells transfected by PEI at a 1:5 
DNA:PEI ratio with TU1-SEAP. A) Increasing quantities of SEAP-containing supernatant, made up to 200µl 
with fresh medium, were tested for SEAP titre, with a linear correlation observed between concentration of SEAP 
present and absorbance. B) Increasing quantities of TU1-SEAP were used to transfect HEK-293T cells, and 
supernatant tested 72h post-transfection showed an exponential relationship between quantity of SEAP 
transfected, and titre. C) A constant quantity of 20ng TU1-SEAP or FRT-TO-GFP were cotransfected with 
increasing quantities of FRT-TO-GFP. With TU1-SEAP present, a linear correlation between total transfected 
DNA quantity and SEAP titre was observed. With only FRT-TO-GFP present, no SEAP titre was detected. D) 
SEAP containing supernatant was assayed for SEAP titre, with absorbance taken at several timepoints. A linear 
correlation was observed between absorbance measured and time-post assay start. Results presented are of 




To tether the mRNA transcript of the SEAP reporter to the library of PP7d-fusion proteins, a 
TU1-SEAP-6xPP7bs reporter was created. Six PP7 stem-loops were inserted downstream of 
the SEAP 3’UTR, as described in section 2.13.1. and Table , by Gibson assembly, as in section 









Table 3.2 – Sequences of the 2xPP7bs and 2xMS2bs stem loops. Coat protein binding sites sequence are well 
established in literature (Chao et al., 2008, 2012). Modules, containing 3 repeats of sequences of 2 stem-loops 
(totalling 6 binding sites), were isolated by PCR from an in-house laboratory plasmid, and placed downstream of 
the 3’UTR, directly upstream of the PolyA signal in the AstraZeneca in-house TU1 expression vector. 
In order to test its’ expression, 250ng TU1-SEAP-6xPP7bs was transfected by PEI at a 1:5 
DNA:PEI ratio into 1*105 HEK-293T cells in 24-well plates, and supernatants harvested 72h 
post-transfection for SEAP assay as in section 2.6.1., alongside an unmodified TU1-SEAP 
control.  The fold change of titre from unmodified TU1-SEAP to TU1-SEAP-6xPP7bs was 
calculated, and is presented in Figure 3.4. The modified reporter retained moderately high 
SEAP expression, though titre was decreased by 24% compared to the unmodified control. 
 
Figure 3.4 - Expression testing of TU1-SEAP-6xPP7bs 
reporter. SEAP titre from the modified reporter was 0.76-
fold of the unmodified TU1-SEAP, in a statistically 
significant decrease (P=0.036). The sequence of 6xPP7bs 
can be found in section 2.13.1. and Table  of this thesis. 
Results presented of technical duplicates, from three 



































3.2.3. Screening of SEAP-6xPP7bs with Overexpression and Tethering of 
the PP7d Fusion Library 
The first round of screening intronless SEAP reporters tethered to RNA-binding proteins was 
performed using characterised proteins, known to influence RNA maturation, export, and 
translation – NXF1-P15, ALYREF, CIRP, RBM3, and HuR. In order to analyse the effect of 
tethering each of these proteins to a SEAP mRNA, 200ng of each fusion protein and 20ng of 
TU1-SEAP both without and with 6xPP7bs, measuring the effect of overexpression (e.g. P-
ALYREF O) and tethering (e.g. P-ALYREF T) of each fusion protein, were transfected by PEI 
at a 1:5 DNA:PEI ratio into 1*105 HEK-293T cells in 24-well plates. Supernatant was harvested 
72h post-transfection, and assayed for SEAP titre as in section 2.6.1., relative to cotransfection 
of TU1-SEAP+/-6xPP7bs and FRT-TO-GFP. An additional control of TU1-SEAP+/-6xPP7bs 
cotransfected with the PP7d protein alone was also included. The resultant SEAP titre fold 
changes are shown in Figure 3.5. Both tethering and overexpression of ALYREF, RBM3, and 
HuR were associated with non-significant changes in titre. Overexpression of PP7d alone 
slightly increases SEAP titre, with tethering giving a significant 1.52-fold increase. PP7d-CIRP 
overexpression is associated with a significant 1.64-fold increase in titre, although this is not 
significantly different than with PP7d overexpression. Finally, both overexpression and 
tethering of NXF1-P15 we associated with a significant decrease in SEAP titre, of 0.52 and 0.48-
fold respectively.  
Figure 3.5 – SEAP titre analysis of 
characterised PP7d-RNA binding protein 
fusions, using both overexpression (O) and 
tethering (T), transfected by PEI at a 1:5 
DNA:PEI ratio into HEK-293T cells. Fold 
change in titre is relative to TU1-SEAP 
cotransfection with FRT TO-GFP, shown 
as a red dotted line. Significant titre 
increases are observed with PP7d tethering 
and PP7d-CIRP overexpression, whereas 
significant titre decreases are given by both 
overexpression and tethering of PP7d-
NXF1-P15. Results presented are of 
technical duplicates, from three biological 















































































In the second round of screening, a panel of PP7d fusions with uncharacterised proteins 
shown to bind RNA (Castello et al., 2012) was similarly created, and tested for effect on SEAP 
titre using the same method as the first. As shown in Figure 3.6, neither overexpression nor 
tethering of PP7d-C1orf52, PP7d-C1orf131, PP7d-C11orf68, PP7d-C7orf50, PP7d-C14orf156, or 
PP7d-C14orf166 were associated with a significant change in SEAP titre, compared to the FRT-
TO-GFP control. However, both overexpression and tethering of PP7d-C1orf35 led to 
significant increases in titre, of 3.35-fold and 2.58-fold respectively. Tethering, but not 
overexpression of PP7d-C14orf93 led to a significant increase of 2.57-fold in titre. In contrast, 
overexpression, but not tethering of PP7d-KNOP1 led to a significant increase of 1.4-fold in 
titre. This increase, however, is smaller in magnitude than that given by PP7d alone, as shown 
in Figure 3.5.  
 
Figure 3.6 - SEAP titre screen of uncharacterised PP7d-RNA binding protein fusions, using both overexpression 
(O) and tethering (T), transfected by PEI at a 1:5 DNA:PEI ratio into HEK-293T cells. Fold change in titre is 
relative to TU1-SEAP cotransfection with FRT TO-GFP, shown as a red dotted line. Significant titre increases 
are given by PP7d-C1orf35 overexpression and tethering, PP7d-C14orf93 tethering, and PP7d-KNOP1 














































































































































3.2.4. Overexpression of PP7d-C1orf35 is associated with increased growth 
and transient SEAP titre 
The next aim was to replicate and expand upon identification of PP7d-C1orf35 as a potential 
overexpression target to increase transient SEAP titre. Therefore, 200ng PP7d-C1orf35 or PP7d 
were cotransfected with 20ng of both intronless and intron-containing TU1-SEAP by PEI at a 
1:5 DNA:PEI ratio, both in absence and presence of PP7 binding sites, to demonstrate the 
effects of overexpression and tethering. These transfections were performed on 1*105 HEK-
293T cells in 24 well-plates, and SEAP titres measured 72h post-transfection, as in section 2.6.1. 
As shown in Figure 3.7a, the ability of PP7d-C1orf35 overexpression to stimulate intronless 
SEAP titre was replicated, producing a 3.30-fold increase compared to an FRT-TO-GFP 
control, statistically significantly greater than the 1.37-fold increase associated with PP7d 
overexpression. The ability of PP7d-C1orf35 tethering to enhance intronless SEAP titre was 
observed, but the change non-significant, producing a 2.47-fold increase compared to the FRT-
TO-GFP control, compared to the 1.54-fold increase associated with PP7d tethering. However, 
when tethered to intron-containing SEAP, as shown in Figure 3.7b, PP7d-C1orf35 
overexpression was associated with a significant decrease in SEAP titre, of 0.52-fold relative 
to the FRT-TO-GFP control, compared to a 2.64-fold increase in titre associated with PP7d 
tethering. When overexpressed, PP7d-C1orf35 non-significantly reduces intron-containing 
SEAP titre, to 1.67-fold, compared to the 2.33-fold associated with PP7d overexpression alone. 
Taken together, these data replicate the identification of PP7d-C1orf35 overexpression as 
stimulatory to transient intronless SEAP titre, and may imply that presence of C1orf35 at an 




Figure 3.7 – Testing effect on SEAP titre of PP7d-C1orf35 after cotransfection by PEI at a 1:5 DNA:PEI ratio 
into HEK-293T cells. A) PP7d-C1orf35 tethering non-significantly increases TU1-SEAP titre compared to PP7d 
tethering, at 2.47-fold and 1.54-fold respectively (P=0.118). PP7d-C1orf35 overexpression increases intronless 
TU1-SEAP titre by 3.30-fold, relative to a control overexpressing FRT TO-GFP, significantly higher than PP7d 
alone, which increases titre by 1.37-fold (P=0.023). B) PP7d-C1orf35 tethering significantly decreases intron-
containing SEAP titre by 0.52-fold, compared to a 2.64-fold increase conferred by PP7d tethering alone (P=0.036). 
PP7d-C1orf35 overexpression non-significantly decreases intron-containing SEAP titre by 1.67-fold, compared 
to a 2.33-fold increase associated with PP7d overexpression alone (P=0.094). Results presented are of technical 




To further investigate and replicate the stimulatory properties of PP7d-C1orf35 in a more 
industrially relevant CHO cell line, 2µg TU1-SEAP was cotransfected with 10µg of either 
PP7d-C1orf35 or FRT-TO-GFP into a CHO transient host cell line by PEI at a 1:5 DNA:PEI ratio, 
using 10ml culture at 1*106cells/ml in cultiflasks. Cell growth was monitored every 24h, and 
SEAP titre measured 72h post-transfection as in section 2.6.1. Figure 3.8a shows that PP7d-
C1orf35 overexpression was associated with a 1.39-fold increase in SEAP titre compared to the 
FRT-TO-GFP control. Figure 3.8b implies cell growth as the cause of this increase, with VCD 
of PP7d-C1orf35 overexpressing cultures growing to 1.38-fold higher than control after 72h. 
Combining these data reveals that no significant change in SEAP specific productivity occurs 
between PP7d-C1orf35 overexpression and FRT-TO-GFP controls, as displayed in Figure 3.8c. 
Therefore, the stimulatory effect of PP7d-C1orf35 on transient SEAP titre may be mediated 
through improved cell culture performance.  
 
Figure 3.8 - PP7d-C1orf35 overexpression increases SEAP titre in CHO transient host cells when transfected 
with PEI at a 1:5 DNA:PEI ratio, through cell culture performance. A) Overexpression of PP7d-C1orf35 
significantly increases transient SEAP titre by 1.39-fold, compared to an FRT-TO-GFP control (P=0.041). B) 
This is accompanied by a significant increase in cell growth, fold change in viable cell density compared to the 
FRT-TO-GFP control increasing from 0.98 at 24h, 1.18 at 48h, and 1.38-fold 72h post-transfection (P=0.019).  
C) There is no significant difference in SEAP specific productivity upon PP7d-C1orf35 cotransfection. Results 




3.2.5. Overexpression of FLAG-C1orf35 in HEK-293T cells is associated 
with an increase in cell growth 
Since PP7d-C1orf35’s stimulatory effect on SEAP titre occurred without being tethered, it was 
decided to investigate whether overexpression of a non-fusion C1orf35 protein could 
reproduce this effect. Therefore, an expression vector bearing a FLAG-tagged C1orf35 was 
created, by insertion of C1orf35 into the p3X-FLAG expression vector, using Gibson assembly 
as in section 2.3.3., and correct construction checked by Sanger sequencing. A representative 
plasmid map can be found under ‘p3X-FLAG-C1orf35’ in Appendix A. 2µg of this FLAG-
C1orf35 vector was cotransfected with 200ng TU1-SEAP by PEI at a 1:5 DNA:PEI ratio into 
1*106 HEK-293T cells in 6cm dishes, and SEAP titre relative to a FLAG cotransfection control 
measured 72h post-transfection, as in section 2.6.1. Figure 3.9a displays that SEAP titre was 
increased 2.19-fold by FLAG-C1orf35 overexpression, compared to the FLAG control. Cells 
from these transfections were also analysed for SEAP mRNA abundance by RT-qPCR, as in 
section 2.9.1. No significant difference in SEAP mRNA levels were detected between FLAG-
C1orf35 and FLAG coexpression, as displayed in Figure 3.9b. Finally, the protein concentration 
in the cell lysate 72h post-transfection was measured by Bradford assay, as a proxy 
measurement for cell growth, as in section 2.4.4.1. The data from this experiment are presented 
in Figure 3.9c, exhibiting a 1.47-fold increase in protein concentration upon FLAG-C1orf35 
cotransfection, compared to a FLAG control. These data corroborate earlier findings, 
presented in Figure 3.9, that C1orf35 increases transient SEAP titre independently of tethering, 
and that this effect is mediated through cell culture performance, rather than specific 
productivity.  
 
Figure 3.9 – FLAG-C1orf35 overexpression increases SEAP titre in HEK-293T cells when transfected with PEI 
at a 1:5 DNA:PEI ratio through cell culture performance. A) Overexpression of FLAG-C1orf35 significantly 
increases SEAP titre by 2.19-fold, compared to a FLAG-bearing control (P=0.0003). B) SEAP mRNA is not 
significantly increased in abundance by FLAG-C1orf35 overexpression. C) Protein lysate concentration 72h post-
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transfection is significantly increased by 1.47-fold by FLAG-C1orf35 overexpression, compared to a FLAG-
bearing control (P=0.004). Results presented are of technical duplicates, from three biological replicates. FC: fold-
change. 
3.2.6. Overexpression of C1orf35 is associated with mixed effects on titre 
in CHO cells 
To ascertain whether C1orf35 overexpression could also stimulate the cell culture performance 
and titre of a stable producing CHO cell line, C1orf35 was codon optimised for CHO cell 
expression, and inserted into the in-house CHO expression vector (TU-C1orf35) by 
restriction/ligation cloning between the AgeI and SbfI sites as in section 2.3.6., with correct 
construction verified by Sanger sequencing. A representative plasmid map can be found 
under ‘TU1’ in Appendix A. CHO cells stably expressing an ETE mAb, were transfected with 
this vector against a TU1-GFP control. To examine whether any effect was dose-responsive, 
or whether there was an optimal dosage for titre, TU-C1orf35 was titrated against TU1-GFP at 
five strengths (0%, 25%, 50%, 75%, 100%). A constant total load of 10µg DNA was transfected 
using PEI at a 1:5 DNA:PEI ratio, into 10ml CHO cell culture at 1*106 cells/ml in cultiflasks. 
Growth was monitored at 24h, 48h, and 72h by ViCell as in section 2.4., and IgG titre was 
measured 72h post-transfection as in section 2.10.1. As shown in Figure 3.10a, some significant 
effects on growth were observed, with 50% and 75% dosage resulting in a temporary 
reduction in VCD at 24h (0.90 and 0.85-fold respectively), and 25% dosage leading to a 1.14-
fold increase in VCD at 72h. However, no significant effects were measured across all 
titrations on viability 24h, 48h, or 72h post-transfection, or on titre 72h post-transfection, as 
displayed in Figure 3.10b and Figure 3.10c.  
To investigate whether C1orf35 was being correctly expressed by this cell line and vector, a 
FLAG-tag was added to the 5’ terminus of the C1orf35 CDS by site-directed mutagenesis as in 
section 2.3.2., creating the TU1-FLAG-C1orf35 vector, with correct construction verified by 
Sanger sequencing. 10µg of this vector was transiently transfected by PEI at a 1:5 DNA:PEI 
ratio into stable IgG-expressing CHO cells in 10ml culture at 1*106 cells/ml in cultiflasks, and 
cell lysates analysed 72h post-transfection by western blot using an anti-FLAG primary 
antibody. This western blot is displayed in Figure 3.11. A band is clearly visible in lane 2, 
representing cells transiently transfected with TU1-FLAG-C1orf35 at the predicted molecular 
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weight of the FLAG-C1orf35 protein, 32kDa. No such band is found in the corresponding lane 
representing untransfected cells.  
Collectively, Figure 3.10 and Figure 3.11 imply that whilst C1orf35 is properly expressed in a 
stable IgG-producing CHO cell line, it is unable to significantly affect cell culture performance, 
or IgG titre.  
 
Figure 3.10 - TU-C1orf35 overexpression titration by PEI at a 1:5 DNA:PEI ratio has no significant effect on 
titre of a stable IgG expressing CHO cell line.  A) 50% and 75% titration of TU-C1orf35 led to a temporary 
reduction of VCD 24h post-transfection of 0.90-fold (P=0.0009) and 0.85-fold (P=0.0005), respectively. 25% 
titration led to a slight increase in VCD 72h post-transfection of 1.14-fold (P=0.0018).  B) No significant changes 
in cell viability at 24, 48, or 72 hours post expression were measured. C) No significant changes in IgG titres 
were measured 72h post-transfection. Results presented are of technical duplicates, from three biological 






Figure 3.11 - FLAG-C1of35 is correctly expressed by the CHO 
transient host when transfected by PEI at a 1:5 DNA:PEI ratio. A 
western blot using an anti-FLAG primary antibody shows a band 
corresponding to the expected molecular weight of FLAG-C1orf35 
(32kDa) for cells transfected with TU1-FLAG-C1orf35, and no 
band for untransfected cells. A representative blot from two 




Next, it was examined whether the lack of significant effects imparted by TU-C1orf35 seen in 
Figure 3.10 were due to the product being a non-fusion, as opposed to a PP7d-fusion protein. 
Similarly to the experiment presented in Figure 3.10, PP7d-C1orf35 transient transfection was 
titrated against FRT-TO-GFP with PEI at a 1:5 DNA:PEI ratio into the stable IgG-producing 
CHO cell line, 10ml culture at 1*106 cells/ml in cultiflasks. Growth was measured at 24h, 48h, 
and 72h post-transfection by ViCell as in section 2.4., and IgG titre measured 72h post-
transfection by ELISA as in 2.10.1. The results of this experiment are displayed in Figure 3.12. 
Similarly to TU-C1orf35 in Figure 3.10, PP7d-C1orf35 overexpression titration led to some 
temporary effects on cell growth, with a 25% dosage leading to a 1.19-fold increase in VCD at 
24h post-transfection. Also similarly, no significant changes in viability or titre were observed 
across the titration. These results suggest that neither C1orf35 or PP7d-C1orf35 confer a 
significant effect on cell culture performance or titre in a stable IgG-expressing CHO cell line.  
 
Figure 3.12 - PP7d-C1orf35 overexpression titration by PEI transfection at a 1:5 DNA:PEI ratio has no 
significant effect on titre of a stable IgG expressing cell-line. A) 25% dosage of PP7d-C1orf35 led to a temporary 
increase of VCD at 24h by 1.17-fold (P=0.0043). B) No significant changes in cell viability at 24, 48, or 72 hours 
post expression were measured. C) No significant changes in IgG titres were measured 72h post-transfection. 




To investigate whether C1orf35 overexpression could stimulate cell culture performance and 
titre of a more industrially relevant transiently-expressed product, a constant load of a DTE 
mAb expression vector was cotransfected by PEI at a 1:5 DNA:PEI ratio into a transient CHO 
cell line alongside TU-C1orf35, titrated against TU1-GFP. As in previous experiments, 10ml 
cell culture at 1*106 cell/ml in cultiflasks was used, growth measured at 24h, 48h, and 72h post-
transfection by ViCell as in section 2.4., and IgG titre measured 72h post-transfection by ELISA 
as in section 2.10.1. As shown in Figure 3.13a and Figure 3.13b, no significant effect on cell 
growth or viability was seen with any titration of C1orf35. However, as displayed in Figure 
3.13c, titration of TU-C1orf35 was associated with a decline in IgG titre, from 1.00mg/l at 0% 
to 0.35mg/l at 100%.   
 
 
Figure 3.13 – TU-C1orf35 overexpression titration by PEI transfection at a 1:5 DNA:PEI ratio decreases 
transient titre of a DTE mAb. A) No overexpression titrations of TU-C1orf35 led to a significant change in VCD 
24, 48, or 72h post-transfection. B) No overexpression titrations of TU1-C1orf35 led to a significant change in 
cell viability 24, 48, or 72h post-transfection. C) IgG titre of the DTE mAb decreases across the overexpression 
titration, with a significant difference of 1.00mg/l at 0% to 0.35mg/l at 100% (P=0.011). Results presented are of 




The results presented in this section indicate that the effect of C1orf35 overexpression on cell 
culture recombinant protein production may be unpredictable, changing from positive to 
negative to non-significant, in a manner dependent on cell line, expression method, and 
protein product.  
3.2.7. Overexpression of PP7d-HuR in CHO cells is associated with 
increased specific productivity 
To assess the replicability of the assays described in section 3.2.3. between HEK-293T and 
CHO cells, the transient overexpression of four PP7d-fusion proteins (PP7d-
ALYREF/CIRP/HuR/C1orf35) alongside TU1-SEAP was repeated in a CHO transient host cell 
line. To this end, 10ml of cells in cultiflask shaking culture were transfected by electroporation 
with 10µg PP7d-fusion protein and 2µg TU1-SEAP, and seeded at 0.2*106 cells/ml. SEAP titre 
fold change was measured relative a control cotransfected with FRT-TO-GFP, 72h post-
transfection, as in section 2.6.1. Figure 3.14 shows the SEAP titre fold-change associated with 
the overexpression of each fusion protein, with results from each cell line plotted against one 
another, taking the HEK-293T data from Figure  and Figure 3.6. No significant correlation can 
be observed between titre fold changes in the two cell lines. PP7d-C1orf35 retains a positive 
effect on SEAP expression in both cell lines, but this effect decreases from 3.35-fold in HEK-
293T to 1.65-fold in CHO, whereas PP7d-HuR overexpression decreases titre to 0.75-fold in 
HEK-293T cells, but increases it by 4.85-fold in CHO cells.  
 
Figure 3.14 - Comparison of SEAP 
titre fold changes upon PP7d fusion 
protein coexpression following PEI 
transfection at a 1:5 DNA:PEI ratio 
between HEK-293T and CHO 
transient host cell lines. No 
significant correlation is observed in 
SEAP titre between the two cell 
lines. Results presented are of 
technical duplicates, from three 


































In order to validate and characterise the ability of PP7d-HuR overexpression to increase 
transient SEAP titre in CHO cells, the CHO transient host was transiently transfected using 
PEI at a 1:5 DNA:PEI ratio in 10ml shaking cultiflask culture at 1*106 cells/ml with 10µg PP7d-
HuR and 2µg TU1-SEAP. Growth was measured 24h, 48h, and 72h post-transfection by ViCell 
as in section 2.4., and SEAP titre measured 72h post-transfection, relative to a control 
cotransfected with FRT-TO-GFP, as in section 2.6.1. As shown in Figure 3.15a, cotransfection 
of PP7d-HuR was associated with a significant 2.95-fold increase in SEAP titre. This was 
achieved despite decreasing cell growth, as shown in Figure 3.15b, with viable cell density 
decreasing from 1.12-fold after 24h, to 0.67-fold after 48h, to a significant 0.58-fold decrease in 
VCD 72h-post transfection. Together, these results show that PP7d-HuR overexpression 
imparts a 4.78-fold increase in SEAP cell-specific productivity, as shown in Figure 3.15c.  
 
Figure 3.15 – PP7d-HuR overexpression by PEI transfection at a 1:5 DNA:PEI ratio increases transient SEAP 
titre in the CHO transient host through specific productivity. A) Overexpression of PP7d-HuR significantly 
increases transient SEAP titre by 2.95-fold, compared to an FRT-TO-GFP control (P=0.033). B) Cell division 
significantly decreases upon PP7d-HuR overexpression, fold change in VCD decreasing from 1.12 at 24h, 0.64 at 
48h, and 0.58-fold 72h post-transfection (P=0.018). C) These data imply a significant 4.78-fold increase in SEAP 
specific productivity(P=0.0063). Results presented are  of technical duplicates, from three biological replicates. 
FC: fold-change. 
To further investigate the cause of the difference in SEAP titre brought about by PP7d-HuR 
overexpression in HEK-293T and CHO cells, 1*105 HEK-293T cells in 24-well plates were 
transfected with 200ng PP7d-HuR and 20ng TU1-SEAP by PEI at a 1:5 DNA:PEI ratio, and 
their cell lysates analysed 72h post-transfection by RT-qPCR for relative abundance of SEAP 
mRNA, compared to a control cotransfected with FRT-TO-GFP, as in section 2.9.1. As shown 
in Figure 3.16, SEAP mRNA is significantly 2.73-fold more abundant in cells cotransfected 




Figure 3.16 – PP7d-HuR overexpression by PEI 
transfection at a 1:5 DNA:PEI ratio increases 
mRNA abundance of transiently expressed 
SEAP in HEK-293T cells. Abundance of SEAP 
mRNA significantly increases by 2.73-fold, 
relative to an FRT-TO-GFP control (P<0.0001). 
Results presented are of technical triplicates, 
from three biological replicates. FC: fold-change. 
 
 
Taken together, the results from Figure 3.15 and Figure 3.16 imply that overexpression of 
PP7d-HuR can affect the cell-specific productivity of SEAP, through an effect granting a 
greater abundance of SEAP mRNA, but which also significantly decreases cell growth. The 
overall change in titre may therefore be derived from the difference in strength between each 





















3.2.8. Overexpression of PP7d-HuR is associated with an increase in 
transient SEAP specific productivity 
Next, it was investigated whether this response to PP7d-HuR overexpression was dose-
responsive, whether an optimal balance between cellular growth and specific productivity 
could be reached, and whether PP7d-HuR tethering could amplify this effect. To do this, the 
CHO transient host was transfected by PEI at a 1:5 DNA:PEI ratio with 2µg TU1-SEAP, both 
with and without 6xPP7bs in the 3’UTR, alongside a titration of PP7d-HuR against FRT-TO-
GFP, from 0-10µg. These transfections were performed in 10ml cultiflask culture, at 1*106 
cells/ml. VCD of these transfections was measured 24h, 48h, and 72h post-transfection by 
ViCell as in section 2.4., and SEAP titre measured 72h post-transfection as in section 2.6.2. The 
overexpression results from SEAP without 6xPP7bs are displayed in Figure 3.17, and the 
tethering results from SEAP-6xPP7bs (SEAP-BS) are shown in Figure 3.18. In both cases, 
greater quantities of PP7d-HuR were associated with decreases in cell growth and viability, in 
a dose-responsive pattern. With SEAP lacking binding sites, the 100% titration led to a 
significant 0.72-fold decrease in viable cell density and a 0.81-fold decrease in cell viability 72h 
post-transfection, similar to SEAP-BS, where it conferred a 0.73-fold decrease in VCD and a 
0.76-fold decrease in viability. In the case of SEAP, all titrations of HuR were associated with 
slight increases in SEAP titre, with 100% titration giving a significant 1.16-fold increase, as 
shown in Figure 3.17c. Figure 3.18c shows that no significant effect on titre was observed with 
SEAP-BS upon PP7d-HuR tethering titration. Small changes in titre despite decreases in cell 
growth imply a significant increase in specific productivity, and this is borne out by Figure 
3.17d, where a dose-responsive increase in specific productivity of SEAP lacking binding sites 
is shown, up to a significant 1.63-fold increase at 100% titration. As shown in Figure 3.18d, 
this effect is more modest and less clearly dose-responsive when PP7d-HuR is tethered to 
SEAP-BS, with 75% and 100% titrations both significantly increasing specific productivity by 
1.28-fold.  
The data presented in Figure 3.17 and Figure 3.18 corroborate the hypothesis stated above, 
that PP7d-HuR overexpression affects transient SEAP titre by decreasing cell growth and 
increasing cell-specific productivity. Both of these effects were shown to be responsive to the 
total quantity of PP7d-HuR transfected, growth and specific productivity decreasing and 
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increasing respectively as PP7d-HuR was titrated into the transfections. For both SEAP and 
SEAP-BS, it showed that the optimal titration of PP7d-HuR in this case is 100%, giving both 
their highest SEAP titres and specific productivity. Finally, it showed that increases in titre 
occurred independently of mRNA-PP7d tethering. Moreover, tethering may actually inhibit 
the stimulation of specific productivity, whilst not mitigating the losses of cell growth 
associated with PP7d-HuR titration.  
 
Figure 3.17 – PP7d-HuR overexpression titration by PEI transfection at a 1:5 DNA:PEI ratio decreases cell 
growth and viability, and increases transient SEAP specific productivity in the CHO transient host. A) 
Overexpression titration of PP7-HuR decreases VCD, to a fold change of 0.71 from 0% to 100% at 72h 
(P=0.0044). B) Viability also decreases significantly, to 0.81-fold from 0% to 100% at 72h (P=0.014). C) SEAP 
titre increases significantly, to 1.17-fold between 0% to 100%. D) SEAP specific productivity increases 
significantly, to 1.63-fold at 72h (P<0.0001).  Results presented are of technical duplicates, from three biological 




Figure 3.18 - PP7d-HuR tethering titration by PEI transfection at a 1:5 DNA:PEI ratio decreases cell growth 
and viability, and increases transient SEAP specific productivity in the CHO transient host. A) Overexpression 
titration of PP7-HuR decreases VCD, to a fold change of 0.73 from 0% to 100% at 72h (P=0.0072). B) Viability 
also decreases significantly, to 0.76-fold from 0% to 100% at 72h (P=0.046). C) No significant effect is measured 
on SEAP titre. D) SEAP specific productivity increases significantly, to 1.28-fold at 72h (P=0.0055).  Results 
presented are of technical duplicates, from three biological replicates. VCD: viable cell density; FC: fold-change; 




3.2.9. Overexpression of HuR is associated with mixed effects on transient 
and stable mAb titre  
To test whether HuR overexpression could replicate its stimulatory effect on SEAP specific 
productivity with a more industrially relevant protein, another cotransfection titration 
experiment was performed. As tethering was shown to have a negative impact on specific 
productivity compared to overexpression, a plasmid was constructed, by restriction/ligation 
cloning of CHO codon optimised HuR into the TU1 vector between the AgeI and SbfI sites as 
in section 2.3.6., and verification by Sanger sequencing, creating the TU1-HuR vector. A 
representative plasmid map can be found under ‘TU1’ in Appendix A. This construct was 
titrated up to 10µg against TU1-GFP, as in previous titration experiments. These titrations 
were cotransfected with 2µg of a plasmid bearing both the light and heavy chain of a DTE 
mAb using PEI at a 1:5 DNA:PEI ratio, into the transient CHO host, in 10ml cultiflask culture 
at 1*106 cells/ml. Growth and viability were measured at 24h, 48h, 72h by ViCell as in section 
2.4., and the titre of mAb measured 72h post-transfection by ELISA as in section 2.10.1. The 
dose-dependent decrease in VCD upon HuR titration is replicated in Figure 3.19a, with a 
significant decrease of 0.73-fold in VCD at 100% titration, 72h-post transfection. The effect on 
viability was not replicated, however. Figure 3.19b shows that viabilities across all TU1-HuR 
titrations were slightly, but not significantly decreased, and with no clear response to TU1-
HuR dosage. In further contrast to results measured with SEAP, Figure 3.19c shows that 
titration of TU1-HuR was associated with a drastic decrease in mAb titre, in a dose-responsive 
pattern, and with a 10-fold reduction of 0.20mg/l at 0% to 0.021mg/l at 100% titration. Given 
the slightly decreased growth upon TU1-HuR titration, the effect on specific productivity was 
slightly less marked, but still clearly dose responsive, resulting in a reduction to 0.16-fold 
change between 0% and 100%. These data suggest that HuR overexpression may have a 





Figure 3.19 - TU1-HuR overexpression titration by PEI transfection at a 1:5 DNA:PEI ratio decreases cell 
growth, and transient expression of a DTE mAb in the CHO transient host. A) TU1-HuR overexpression 
titration decreases VCD, to 0.73-fold from 0% to 100% at 72h post-transfection (P=0.0019). B) No significant 
effect is measured on cell viability at 24h, 48h, or 72h post-transfection. C) IgG titre is significantly decreased 
across the overexpression titration, from 0.202mg/l at 0%, to 0.021mg/l at 100% (P=0.0042). D) IgG specific 
productivity is significantly decreased across the overexpression titration, to 0.16-fold from 0% to 100% 
(P<0.0001). Results presented are of technical duplicates, from three biological replicates. VCD: viable cell density; 




To investigate whether TU1-HuR overexpression could positively affect the production 
characteristics of a stable cell line, a similar titration of TU1-HuR was performed, into the CHO 
cell line stably expressing an ETE mAb. 10µg TU1-HuR was titrated against TU1-GFP, in 10ml 
cultiflask culture at 1*106 cells/ml using PEI at a 1:5 DNA:PEI ratio. Growth was measured 
after 24h, 48h, 72h by ViCell as in section 2.4., and mAb titre measured 72h post-transfection 
by ELISA as in section 2.10.1. As shown in Figure 3.20a, titration of TU1-HuR initially led to a 
dose-responsive decrease in VCD, to a significant decrease of o.81-fold at 100% after 24h. 
However, the VCD of all titrations subsequently recovered compared to controls, and no 
significant differences are measured at either 48h or 72h. Figure 3.20b shows that no 
significant effects on cell viability were detected across the titrations, at any timepoint. 
Similarly, as shown in Figure 3.20c, no significant differences were measured in mAb titres 
across all of the transfections. These data suggest that TU1-HuR overexpression may not 
significantly affect the production characteristics of CHO cell lines stably expressing a 
recombinant protein.  
Taken collectively, the data presented in this section suggest that in some circumstances, HuR 
overexpression can increase recombinant protein titres, by decreasing cell growth, and 
increasing cell-specific productivity. However, both the presence and strength of these effects 




Figure 3.20 – TU1-HuR overexpression titration by PEI transfection at a 1:5 DNA:PEI ratio has no significant 
effect on a stable IgG expressing CHO cell line.  A) Overexpression titration of TU1-HuR briefly decreases cell 
growth, with a significant 0.81-fold change between 0% and 100% at 24h (P<0.0001). Following this, no 
significant changes in VCD at 48h or 72h post-transfection were measured. B) No significant changes in cell 
viability at 24, 48, or 72 hours post transfection were measured. C) No significant changes in IgG titres were 
measured 72h post-transfection. Results presented are of technical duplicates, from three biological replicates. 






The investigations published in this chapter are mostly predicated on transient SEAP 
expression as a model for biopharmaceutical production. Whilst this is a commonly used 
model in literature (Brown et al., 2019; Johari et al., 2015; Peng et al., 2011; Tastanova et al., 
2016), a set of rules for its’ transfection and assay first had to be established. These rules were 
established by the results in Figure 3.3. Figure 3.3a demonstrates that, unlike in other assays 
such as ELISA, 405nm absorbance measured at the end of the assay is linearly correlated with 
concentration of SEAP present. This line of best fit does not intersect with the graph’s point of 
origin, as a signal is still produced in blank samples lacking any SEAP. Therefore, after 
substituting the absorbance value of a blank sample, fold change in titre across an experiment 
can be inferred directly from the fold change in absorbance at 405nm, taken at the same time 
point. Figure 3.3b seems to contradict this finding, however, displaying an exponential 
increase in absorbance as quantity of SEAP transfected increases. This is explained by Figure 
3.3c, in which it is shown that increased total DNA load, with a constant quantity of SEAP 
DNA, is stimulatory to SEAP titre. This is likely as a consequence of the increased transfection 
efficiency observed with HEK-293T cells and PEI, when overall DNA load is increased 
(Ehrhardt et al., 2006). Therefore, the exponential relationship described in Figure 3.3b can be 
ascribed to the product of two linear factors: increased transfection efficiency due to DNA 
load, and increased SEAP titre due to increasing quantities of SEAP DNA. All directly-
comparable transfections in future studies should therefore be performed with an equal total 
DNA load, and were in this research. The slight reduction in SEAP expression upon 
introduction of 6xPP7bs displayed in Figure 3.4 is not unexpected, as past studies have shown 
that inclusion of PP7/MS2 stem loops in mRNA can led to improper 3’UTR formation, and 
aberrant localisation in p-bodies, though this only becomes severe upon glucose starvation 
(Heinrich et al., 2017). 
Screening of PP7d fusion proteins with SEAP +/- PP7 binding sites gave the unexpected result 
that PP7d overexpression alone enhanced SEAP titre, compared to the GFP cotransfection 
control. This effect may be mediated by PP7d binding to mRNA having beneficial effects, for 
example in mRNA stability. However, this is unlikely, as the effect is replicated in the absence 
of PP7 binding sites, and it has been shown that the PP7 coat protein binding is very specific, 
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having decreased affinity by several orders of magnitude even for similar, but non-cognate 
RNA stem loops (Chao et al., 2008; Lim et al., 2001). All of the constructs used in this 
experiment utilise CMV promoters, which can interfere with one another through competition 
for transcription factors, in a manner dependent on transcript length (Huliák et al., 2012). 
However, PP7d and GFP have very similar transcript lengths (828bp vs 720bp), making this 
explanation of the difference observed unlikely. Under conditions of ER stress, it has been 
shown that transiently expressed GFP can be secreted from the cell (Lee et al., 2016a; Tanudji 
et al., 2002). Therefore, cytoplasmic GFP could compete with SEAP for secretion, limiting 
expression in a mechanism neutralised by the NLS present in the PP7d construct. 
Another surprising result from this screen was that overexpression of PP7d-NXF1-P2A-P15 
led to a significant decrease in SEAP titre, as shown in Figure 3.5. Numerous intronless 
mRNAs have been shown to enhance their export by sequestering NXF1 (Braun et al., 2001; 
Tian et al., 2013; Yang et al., 2014). Moreover, inclusion of an NXF1-sequestering motif has been 
shown to increase titre across SEAP, EPO, and Luciferase reporters, an increase which is 
further stimulated by co-expression of NXF1 (Aihara et al., 2011). An explanation for this may 
be that the PP7d fusion interferes with NXF1’s export capacity. An export-noncompetent 
NXF1 that still bound to mRNPs would compete with WT NXF1 present in the cell, 
diminishing exported mRNA and resultant titre. Alternatively, if the PP7d fusion rendered 
the SV40 NLS inert, the PP7d-NXF1 construct could have sequestered competent mRNA in 
the cytoplasm, preventing its translation. However, this explanation would be contradictory 
to previous evidence suggesting that NXF1-P15 only binds mRNA after handover from TREX 
components (Viphakone et al., 2012). This hypothesis of fusion proteins failing to re-enter the 
nucleus could nevertheless explain the general non-significant effect of overexpression and 
tethering of the effector gene fusion proteins. SV40 NLS’s have been successfully utilized in 
combination with PP7d-fusion vectors in previous literature. However, in this case, an in 
frame polylinker was used to separate the two features, which may have prevented them from 
interfering with one another (Gesnel et al., 2009). 
C1orf35 was identified from the initial screen presented in Figure 3.6 as stimulating transient 
SEAP titre. Further experiments confirmed this stimulatory effect, and protein lysate 
concentration measurements from HEK-293T cells, combined with VCD measurements from 
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transient host CHO cells implied that this effect was mediated through enhanced cell growth. 
This effect, however, was not replicated when co-expressing a DTE mAb, as shown in Figure 
3.13. In this case, where expression of the DTE mAb may cause UPR induction and apoptosis 
(Chromikova et al., 2015; Reinhart et al., 2014), the stimulatory effect of C1orf35 on growth may 
be negated. Whilst it is an uncharacterised protein, some work has been performed with 
C1orf35, with one study showing it’s overexpression can increase cell growth and proliferation 
in NIH3T3 cells, by accelerating the transition from G1 to S phase in the cell cycle (Hu et al., 
2015). In Figure 3.7b, tethering of PP7d-C1orf35 to an intron-containing SEAP vector 
unexpectedly reduced SEAP titre, and in Figure 3.13, titration of TU-C1orf35 reduced titre of 
an intron-containing DTE mAb, implying a role for the protein in splicing. This observation 
is corroborated by a protein:protein interaction which has been detected between C1orf35 and 
Prp19 (Li et al., 2015). A potential mechanism to link these two phenotypes could surface from 
C1orf35 influencing alternative splicing, which has been shown to affect cell proliferation and 
survival (Prinos et al., 2011). The picture is further complicated, however, by the detection of 
a nucleolar localisation sequence in C1orf35 (Scott et al., 2010), potentially implying a role in 
ribosome biogenesis. With all this considered, C1orf35 may be an interesting gene for future 
research. However, its’ failure to significantly reproduce this stimulation of cell culture 
performance in more industrially-relevant systems (a stable mAb-producing cell line, and 
transient expression of a DTE mAb), disqualify it as a predictable molecular biology tool, for 
positively controlling biopharmaceutical titre.  
In contrast to C1orf35, neither PP7d-HuR overexpression nor tethering to SEAP in HEK-293T 
cells led to a significant change in titre, compared to GFP controls, as shown in Figure 3.5. 
However, when the experiment was replicated in transient-host CHO cells, to assess whether 
one cell line could be used as a model for the other, its overexpression produced a significant 
increase in SEAP titre, despite a negative effect on growth, as shown in Figure . Combined 
with  Figure 3.16, in which it is shown at PP7d-HuR overexpression almost triples SEAP 
mRNA abundance, this discrepancy can be explained. Overexpression of HuR simultaneously 
increases specific productivity of recombinant proteins, and decreases cell growth. Since titre 
is a product of these two factors, the strength and significance of each antagonistic effect 
(dependent on the cell line, culture conditions, expression mode, etc.) relative to one another 
will dictate the overall change in titre. 
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HuR is well documented to increase the stability and translation efficiency of the mRNAs to 
which it binds. Binding of the nuclear-cytoplasmic shuttling protein HuR to β-globin mRNA 
via binding regions known as AREs enhanced the mRNAs stability (Fan and Steitz, 1998). 
Overexpression of the DNA damage response p53 protein upon UV irradiation has been 
shown to be partially due to HuR binding to the 3’ UTR of p53 mRNA, leading to stabilisation 
and translational enhancement (Mazan-Mamczarz et al., 2003). Knockdown of HuR led to 
reduced expression of genes containing 3’ UTRs able to bind to HuR, as identified by RNA-
protein crosslinking (Lebedeva et al., 2011). Finally, it has been demonstrated that tethering of 
HuR to GFP mRNA by an MS2 system leads to greater cytoplasmic membrane localisation of 
GFP (Berkovits and Mayr, 2015). As shown in Figure 3.17 and Figure 3.18, this effect appears 
to be independent of, and perhaps even diminished by, tethering. This mechanism of increase 
in specific productivity through enhanced mRNA stability and translation is also compatible 
with the results presented Figure 3.19. Stimulating translation and lengthening mRNA half-
life will effectively increase specific productivity in systems where the cell can fold, modify, 
and secrete the extra protein load it receives. This is the case with SEAP, where studies have 
shown that vector features can increase its’ expression ~4-fold, before cell engineering must 
be performed to relieve bottlenecks downstream (Brown et al., 2019). However, DTE mAbs 
most often form bottlenecks downstream, at the stages of post-translational modification and 
secretion, forming aggregates and inducing the UPR (Chromikova et al., 2015; Reinhart et al., 
2014). Increasing the protein load in these systems would only further aggravate this UPR 
response, promoting ER-associated degradation, arresting growth, and inducing apoptosis. 
Like all synthetic expression tools, HuR cannot alleviate a bottleneck downstream of its point 
of action. 
Regardless of their mechanism of action, neither of the candidate proteins investigated in this 
chapter were able to impart any permanent, significant impact on either the culture 
performance or specific productivity of the clonal stable mAb-producing CHO cell line. These 
experiments are shown in Figure 3.12 and Figure 3.20. Some titrations of TU-C1orf35 or PP7d-
C1orf35 briefly increased VCD, and TU1-HuR briefly decreased VCD, before both reverted 
back to control levels. Neither construct at any titration had a significant effect on mAb titre 
compared to controls. This may be due to the problem with using effector genes for cell 
engineering explored in Chapter 1 of this thesis. CHO cells exhibit extremely high genetic 
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instability, meaning that non-clonal pools of cells – such as the CHO transient host – carry 
high genetic heterogeneity. This makes them a good generic background for the generalised 
testing of effector genes. However, solutions identified against this general background may 
not be effective in cells lines – such as the stable mAb producer – which have been exposed to 
rigorous clonal selection and expansion. Such cell lines have used the genetic heterogeneity 
of their ancestral pools as a resource, to find an optimal, single, genetic solution for the 
problem of the selection they underwent. For these reasons, the strategy of cellular 
engineering by effector genes investigated in this chapter does not represent a predictable 
synthetic biology tool in a model predicated on testing in heterogenous transient systems, 
before transfer to clonal, stable expression systems.  
Complicating the dissection of these results is that fact that multiple variables were changed 
across experiments, for example, between Figure 3.17 and Figure 3.19, both the reporter (from 
SEAP to mAb) and effector gene (from unoptimized PP7d-HuR to codon-optimized TU1-
HuR) were changed. This makes it difficult to disentangle which factor is responsible for the 
reversal of the effect on product titre observed. In this example, a positive control, 
cotransfecting optimized TU1-HuR with the SEAP reporter, could be performed to elucidate 
this question. However, in light of the limited time and resources of a PhD project, and the 
observation that as the experimental systems more closely resembled industrial conditions, 
interventions became more detrimental or ineffective toward reporter expression, it was 
decided to change methodology, toward direct manipulation of biopharmaceutical vectors, as 
will be shown in chapters 4, 5, and 6 of this thesis.  
3.4. Conclusion 
In this chapter, I have presented the screening of multiple candidate genes, using RNA:protein 
tethering technology, and an optimised in-house SEAP assay to measure their ability to 
stimulate and control biopharmaceutical expression. I identified two novel candidate proteins 
for cell engineering. C1orf35 showed a putative ability to enhance cell culture performance, as 
PP7d-C1orf35 overexpression was associated with a 1.38-fold increase in VCD 72 hours post-
transfection. HuR showed putative and novel increases in specific productivity, with its’ 
overexpression associated with an increase in SEAP mRNA of 2.73-fold in HEK-293T cells, 
and a 1.63-fold increase in SEAP specific productivity 72 hours post-transfection. 
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If effective, predictable, and titratable, these could have been powerful tools for 
biopharmaceutical expression. For instance, a reliable stimulator of cell growth and 
proliferation could have ameliorated the often-time-consuming step of culture scale-up, 
whilst an enhancer of cell-specific productivity could have aided the production of complex, 
next generation molecules, such as bispecifics. However, both tools were limited, unable to 
consistently replicate their effects across different reporters due to their mechanism of action. 
C1orf35 failed to significantly alter cell growth when overexpressed in a stable IgG-expressing 
cell line and was associated with a 0.35-fold decrease in transient titre of a DET mAb. Likewise, 
HuR overexpression produced no significant change in a stable IgG-expressing cell line, and 
was associated with a 0.16-fold decrease in transient DTE mAb specific productivity. Due to 
these undesirable outcomes, combined with the seemingly intractable incompatibility of 
effector-gene based cell engineering between transient and stable production systems, neither 
of these candidate genes can be judged to be effective, predictable, synthetic molecular biology 
tools for biopharmaceutical expression. In future work, presented in the following chapters of 
this thesis, an alternative approach will be taken, utilising the direct modification of 
biopharmaceutical vector sequences.  
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4. The 3’UTR and mRNA Stability 
4.1. Introduction 
Suboptimal mRNA stability can drastically affect production of recombinant protein, in both 
stable and transient systems (Hung et al., 2010; Mason et al., 2012). Traditionally, the most 
relevant remedy for mRNA stability in biopharmaceutical production has been maximising 
codon optimality (Hung et al., 2010; Presnyak et al., 2015). However this approach is limited, 
for instance in cases where overly-efficient translation elongation may result in sub-optimal 
protein folding, or where mRNA instability is insensitive to codon optimisation, such as with 
poly-proline tracts causing ribosome stalling (Rodnina, 2016). 
Multiple mechanisms exist to control mRNA stability, which could be developed as molecular 
biology tools. Many RNA-binding proteins effect mRNA stability, in particular those that bind 
to the 3’UTR. AU-rich elements (AREs) in the 3’UTR for instance regulate binding of a proteins 
such as TTP, which encourages rapid degradation of mRNA through binding of CNOT1, a 
scaffolding protein for the CCR4/NOT1 complex (Fukao and Fujiwara, 2017). On the other 
hand, binding of AREs by HuR (overexpression of which was explored earlier in this thesis) 
has been shown to extend mRNA half-life and translation (Berkovits and Mayr, 2015; Fan and 
Steitz, 1998; Wu et al., 2015). In the 5’UTR, binding of 5’ terminal oligo-pyrimidine motifs 
(5’TOP) by LARP1 can extend half-life of mRNA by sequestering the 40S ribosome subunit 
(Gentilella et al., 2017). Related to this is the hypothesis that efficiency of translation initiation, 
as opposed to elongation, is primarily responsible for the stability of most mRNAs, as 
competition for binding provided by the PIC inhibits decapping and deadenylation 
machinery, and that slowing of elongation can in some cases increase mRNA half-life (Chan 
et al., 2018). Presence of miRNA binding sites in the 3’UTR can also influence mRNA stability 
and protein output (Radhakrishnan and Green, 2016). Proliferating cells have been shown to 
transcribe shortened 3’UTRs, in order to avoid this regulation (Sandberg et al., 2008b), and 
design of synthetic 3’UTRs to avoid miRNA recognition sites could be a powerful tool. The 
sequence and structural features of the 3’UTR also significantly affect mRNA stability, for 
instance observed in the positive correlation between 3’UTR length and mRNA stability in 
Zebrafish (Mishima and Tomari, 2016). 3’UTR secondary structural features can influence 
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mRNA half-life through factors such as optimising the distance from the PolyA signal to 
cleavage site by formation of stem-loops (Wu and Bartel, 2017), or by specific stem-loop 
binding by proteins such as HRNPA2B1 (Goodarzi et al., 2012).  
4.1.1. 3’UTR Vector Elements for Modulating mRNA Stability 
In light of the results presented in Chapter 3 of this thesis, and the concluded difficulty of 
translating cellular engineering strategies from transient to stable expression systems, it was 
decided to pursue a strategy of vector engineering for control of mRNA stability. As the 3’UTR 
primarily coordinates mRNA stability at the vector level, it was selected for engineering. In 
this chapter, two potential vector tools will be tested for control of biopharmaceutical titre 
through mRNA stability: 3’triple helices, and stability elements.  
3’ Triple Helices  
Triple helices denote a wide family of RNA secondary structures, with a diverse series of 
functions. For instance, the SAM-II triple helix functions as a riboswitch, coordinating gene 
expression in response to specific S-adenosylmethionine binding, and the TER triple helix acts 
as an essential cofactor for telomerase activity (Conrad, 2014). The category of triple helices 
which may be candidates for this molecular biology tool are Elements for Nuclear Expression 
(ENEs). They have been discovered in many organisms, localised near the 3’ terminus of 
multiple transcripts, such as in noncoding RNA from DNA and RNA viruses (Tycowski et al., 
2012), mammalian lncRNAs (Brown et al., 2012), and in transposable element RNAs across 
plants and fungi (Tycowski et al., 2016). Their generalised function is to protect RNA from 
deadenylation and decay, and their enrichment in intronless RNAs suggest that they may 
have evolved to overcome expression deficits associated with a lack of splicing (Conrad, 2014; 
Tycowski et al., 2016). Structural studies have shown that both viral and mammalian ENEs 
wrap around and ‘lock down’ a PolyA sequence or A-rich tract, sterically inhibiting 
deadenylation to achieve this effect (Brown et al., 2014b; Mitton-Fry et al., 2010). The best 
studied viral ENE, found in the Kaposi’s sarcoma–associated herpesvirus PAN RNA, has been 
shown to extend the half-life of both the PAN RNA (Mitton-Fry et al., 2010), and an intronless 
β-globin transcript (Brown et al., 2014b; Tycowski et al., 2012). The two best characterised 
mammalian ENEs, found in the MALAT1 and MENβ lncRNAs, have been shown not only to 
replicate this effect, but to increase translational efficiency when inserted into mRNA, and to 
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produce comparable expression levels to a PolyA control, whilst lacking a PolyA downstream 
(Brown et al., 2012, 2014b; Wilusz et al., 2012).  
Stability Elements 
As opposed to the prescriptive method of target identification taken above, assigning a 
characterised family of features to a function, a descriptive method can be taken, by deploying 
an MPRA platform, as described in section 1.2.3.7. of this thesis. The stability elements tested 
in this chapter were identified in this manner, in Oikonomou et al., 2014. The 3’UTRs of 
multiple vertebrate genomes were analysed for conserved 34nt sequences, producing a library 
of 16,332 sequences. These sequences were synthesized on a microarray, amplified, inserted 
downstream of a fluorescent reporter, and transfected together into a pool of Flp-293T cells. 
Cells were sorted by fluorescent intensity by FACS, and the bins subjected to deep sequencing. 
34nt sequences enriched in the highest-expressing bins were denoted activators of expression, 
and when inserted downstream of an mCherry reporter, demonstrated increased protein 
expression and mCherry transcript abundance, as measured by flow cytometry and RT-qPCR 
respectively (Oikonomou et al., 2014).  
4.2. Results 
4.2.1. Generating the SEAP-3’ Triple Helices library 
In order to test the hypothesis that 3’ triple helices (3’TH) could control mRNA dynamics, and 
thereby titre of a recombinant protein, a library of SEAP-3’ triple helix reporters was created, 
utilising the MALAT1 and MENβ sequences (Brown et al., 2012), and PAN ENE (Brown et al., 
2014b). To identify endogenous CHO sequences for MALAT1 and MENβ, published 
consensus sequences (Wilusz et al., 2012) were aligned against the CHO-K1 genome assembly 
(2014), and the sequence covering the length of the alignment used. For the non-endogenous 
PAN ENE, the sequence was taken directly from literature (Mitton-Fry et al., 2010). These 
sequences were then inserted downstream of the 3’UTR, in the TU1-SEAP reporter vector. As 
they have been tested both with (Brown et al., 2012) and without (Wilusz et al., 2012) PolyA 
tails, both variants of the MALAT1 and MENβ constructs were created, using the SV40 PolyA 
sequence found in unmodified TU1-SEAP. The PolyA tails forms an essential part of the PAN 
ENE structure (Mitton-Fry et al., 2010), so no PolyA-lacking variant was created. Molecular 
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cloning was performed by restriction/ligation with SbfI/NotI and Not1/KpnI as in section 
2.3.6., correct construction verified by Sanger sequencing, the sequences used can be found in 
section 2.13.2 and Table , and a representative plasmid map found  under ‘TU1-SEAP-Triple 
Helices’ in Appendix A. Schematics of the TU1-SEAP-Triple Helices reporters used in this 
chapter are shown in Figure 4.1. 
 













Table 4.1 – The sequences of the MALAT1, MENβ, and PAN triple helices used in this study. CHO MALAT1 
and MENβ triple helices sequences were identified by aligning established human triple helices sequences (Brown 
et al., 2012, 2014b), with the CHO-K1 genome, taking the region of homology as the CHO triple helices. The 
PAN triple helix sequence was taken from literature (Mitton-Fry et al., 2010; Tycowski et al., 2012). Triple helices 
were placed directly downstream of the 3’UTR, in the AstraZeneca in-house TU1 vector, inserted between the 
SbfI/NotI restriction sites, both with and without a PolyA sequence downstream, between the NotI/ KpnI 
restriction sites, by restriction/ligation cloning. 
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4.2.2. The addition of 3’ Triple Helices is not associated with an increase 
in transient SEAP titre 
To analyse this library, transient host CHO cells at a density of 1*106 cells/ml in 96 deep-well 
plates were transfected with each TU1-SEAP-3’TH reporter using PEI at a 1:5 DNA:PEI ratio. 
At 72 hours post-transfection, fold change in cell growth was measured by Prestoblue assay 
as in section 2.4.4.2., and fold change in SEAP titre by Sensolyte assay as in section 2.6.2., 
compared to a control transfected with unmodified TU1-SEAP. As seen in the results of this 
screen presented in Figure 4.2,  transfection of both constructs containing an endogenous 
triple helix, in the absence of PolyA, drastically reduced SEAP titre compared to TU1-SEAP, 
to 0.10-fold for SEAP-MALAT1, and o.11-fold for SEAP-MENβ, albeit with slightly reduced 
growth resulting in a marginally higher fold-change in SEAP specific productivity for each. 
Addition of a PolyA downstream increased titre of both to an extent, up to 0.30-fold for SEAP-
MALAT1-pA and 0.27-fold for SEAP-MENβ-pA, once again with reduced growth slightly 
increasing the specific productivity relative to TU1-SEAP. In contrast, SEAP-PAN-pA 
displayed a 1.24-fold and 1.37-fold increase in SEAP titre and specific productivity, 
respectively. These fold changes, however, were non-significant. These results show that the 
endogenous MALAT1 and MENβ triple helices are not adequate replacements or 
supplements for PolyA sequences in recombinant protein expression. They also imply that 
the PAN ENE may be capable of increasing SEAP titre, though statistical significance could 




Figure 4.2 – Comparative analysis of TU1-SEAP-3’ Triple Helix library by PEI transfection at a 1:5 DNA:PEI 
ratio in the CHO transient host in 96 deep-well plates. Four of the constructs led to a significant (P<0.05) decrease 
in growth: SEAP-MALAT1-pA (0.92-fold), SEAP-MENβ (0.92-fold), SEAP-MENβ-pA (0.91-fold), and SEAP-
PAN-pA (0.92-fold). SEAP-MALAT1 and SEAP-MENβ led to a significant (P<0.0001) decrease in SEAP titre 
and qP, of 0.11-fold and 0.12-fold, respectively. SEAP-MALAT1-pA and SEAP-MENβ-pA led to a significant 
(P<0.0005) decrease in SEAP titre and qP, of 0.32-fold and 0.29-fold, respectively. SEAP-PAN-pA gives a non-
significant1.24-fold increase in SEAP titre, and 1.37-fold increase in SEAP qP. All triple helix sequences 
referenced can be found in section 2.13.2. and Table  of this thesis. Results presented are of technical duplicates, 














































































To confirm whether the PAN ENE increases SEAP titre in a lower-throughput, less variable 
system, TU1-SEAP-PAN-pA and the TU1-SEAP control were transfected into transient host 
CHO cells by PEI at a 1:5 DNA:PEI ratio, in 10ml culture at 1*106 cells/ml in cultiflasks. Cell 
density and viability were measured 72h and 120h post-transfection by ViCell as in section 
2.4., and these values used to calculate the IVCD of each culture. Fold change in SEAP titre 
was measured 72h and 120h post-transfection by Sensolyte assay, as in section 2.6.2. The 
results from this experiment are shown in Figure 4.3. No significant changes were measured 
in either cell culture performance, shown by IVCD in Figure 4.3a and by cell viability in Figure 
4.3b, or in SEAP titre, shown 72h post-transfection in Figure 4.3c, and 120h post-transfection 
in Figure 4.3d. These data, combined with those presented in Figure 4.3, suggest that the PAN-
ENE triple helix does not significantly affect transient production of SEAP, and that any non-
significant increases in titre and specific productivity originally detected were products of the 
high variability associated with high throughput screening systems.   
 
Figure 4.3 – The PAN ENE has no significant effect on transient SEAP titre, or cell culture performance when 
transfected by PEI at a 1:5 DNA:PEI ratio into the CHO transient host in cultiflasks. A) No significant difference 
is found between the IVCD of cultures transfected with TU1-SEAP and TU1-SEAP-PAN-pA, with values of 
20.5*106 and 21.5*106 cell days respectively. B) No significant difference in viability is found, with values of 
98.5% and 98.0% respectively at day 3, and 96.4% and 96.2% respectively at day 5. C) Titre of SEAP-PAN-pA 
is non-significantly reduced by 0.86-fold compared to SEAP, 72h post-transfection. D) Titre of SEAP-PAN-pA 
is non-significantly reduced by 0.94-fold compared to SEAP, 120h post-transfection. The PAN triple helix 
sequences referenced can be found in section 2.13.2. and Table  of this thesis. Results presented are of technical 
duplicates, from four biological replicates. IVCD: integral of viable cell density; FC: fold-change.  
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4.2.3. Generating the SEAP-3’ Stability Element Library 
To build a library of short stability elements, to test for their ability as part of a recombinant 
mRNA to control mRNA half-life, and thereby protein expression, the 34nt conserved 
sequences identified in Oikonomou et al., 2014 were utilised. The total library of elements 
discovered in this study were ranked according to three metrics: their q-value, describing the 
significance of their enrichment in high-abundance compared to low-abundance mRNA bins, 
the ratio of their enrichment in the highest, compared to the lowest abundance mRNA bins, 
and their total enrichment in the highest abundance mRNA bin. The seven highest of each 
category were chosen. In addition, a randomly shuffled element, and the element most 
significantly enriched in low-expressing mRNA bins were included, making a total library of 
24 constructs, including a non-modified control. All of these 34nt elements were inserted 
directly downstream of the SEAP CDS in the TU1-SEAP vector by site-directed mutagenesis 
as in section 2.3.2., and correct insertion verified by Sanger sequencing. Stability element 
sequences can be found in section 2.13.3. and Table 1, and a plasmid map showing their 
location in Appendix A. A schematic of the TU1-SEAP-stability element constructs can be 
found in Figure 4.4. 
 





Name Oikonomou et al., 2014 
SequenceID 
Sequence 
SE1 C3U-seq15901 TTTGTTTTAGATGGAATAGCACAAGGAGAAAAAT 
SE2 C3U-seq10578 GTTTTTTGAGGAATCTCAAGATGTGATATATTGG 
SE3 C3U-seq4185 ATGTCTCCAGTTACAACTCCGCAGTGGATGTGAA 
SE4 C3U-seq8401 GCAATTTAGCATGTTGGAACGTCTAGGGAGAAGG 
SE5 C3U-seq12424 TCTCATTCCAGTAAGGCAGTTAGACACTTGAGTT 
SE6 C3U-seq5465 CAGTTGAGATGAAGCACGTCGTTAGAACGTTGTT 
SE7 C3U-seq212 AAAATGTAAAAATGTAACTATAGCATATGAATTG 
SE8 C3U-seq1204 AAGTGGAGGTCTGGTTTGTAACTTTCCTTGTACT 
SE9 C3U-seq8665 GCCTTAGGAGACTGGAAGTTTAAAAATGTACAAG 
SE10 C3U-seq3598 ATAGCTGTACAAATATAAGAATAAAATGTTGAAA 
SE11 C3U-seq9065 GGAGAAAGCTTCTCTATTTTGGATGCATTTCAGA 
SE12 C3U-seq477 AAAGTTGCAAGATAAACAGCTGTAATTCGGACAA 
SE13 C3U-seq10512 GTTTTAAGTAACTTTTTATAGCAAGATGATACAA 
SE14 C3U-seq16091 TTTTGACTATTTTTATATATAAAGAAGAACTCAA 
SE15 C3U-seq14491 TTATTGTGGATAACAAAGATATCTTTTCTTTAGA 
SE16 C3U-seq13367 TGGCAGGTATTCCCATGATTCACAGAGTTACATT 
SE17 C3U-seq248 AAACAAAAGCCTGGCTGAGTTGATGTTTTACATT 
SE18 C3U-seq5093 CACAGTATTCGTGAATAAGTTGATTCTGTCCCCC 
SE19 C3U-seq5184 CACTGAAGAGGTGGAAAAATAATCGTGTCAATCT 
SE20 C3U-seq2244 ACTATAAATGCTTTGCAAAAATGGTTTCACGTTT 
SE21 C3U-seq13645 TGTAGATCATAGGATAGCTGACTTTGACAGTCAC 
SE22 C3U-seq1502 AATGGAACACAGACAGTGTAGAAGAATTCCTGAG 
SE23 N/A AGTAAACTGACGTTGTCCAACGTGCATATGGATT 
Table 1.2 – The stability element sequences used in this study. 34nt stability elements were extracted from the 
data of Oikonomou et al., 2014, and placed directly downstream of the reporter CDS-bordering SbfI restriction 





4.2.4. Screening of the SEAP-3’ Stability Element library 
This library was transfected into transient host CHO cells at a density of 1*106 cells/ml using 
PEI at a 1:5 DNA:PEI ratio, in 96 deep-well plates. Fold-change in cell growth was measured 
by Prestoblue assay as in section 2.4., and SEAP titre by Sensolyte assay as in section 2.6.2., 
72h post-transfection. As shown by the results presented in Figure 4.5a, a number of stability 
elements were associated with a slight increase in SEAP titre, three of which did so 
significantly: SE8, 10, and 20, to a maximum increase of 1.74-fold with SE8. Figure 4.5b shows 
that expression of 14 stability elements was associated with a slight decrease in cell growth 
after 72h. However, these decreases in cell growth display a regular pattern of periodicity 
every 12 samples, which will be discussed later in this chapter. Finally, in Figure 4.5c these 
data show a significant increase in SEAP specific productivity associated with 6 stability 





Figure 4.5 – Transient screening of the TU1-SEAP stability element library, by transfection with PEI at a 1:5 
DNA:PEI ratio into the CHO transient host in 96 deep-well plates. A) Three stability elements were associated 
with a significant (P<0.05) increase in SEAP titre: SE8, 10, and 20 imparting 1.74-fold, 1.42-fold, and 1.59-fold 
increases in titre respectively. B) Expression of 14 stability elements (SE1-10,13-15,17) was associated with a 
slight, but significant (P<0.05) decrease in cell growth, to an average of 0.92-fold. C) Expression of 6 stability 
elements gave rise to a significant (P<0.05) increase in SEAP specific productivity: SE2 by 1.24-fol, SE3 by 1.57-
fold, SE7 by 1.41-fold, SE8 by 1.90-fold, SE10 by 1.48-fold, and SE20 by 1.82-fold. The sequence of all stability 
elements referenced can be found in section 2.13.3. and Table 1 of this thesis. Results presented are of technical 
duplicates, from three biological replicates. FC: fold-change; qP: specific productivity. 
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To validate the ability of candidate stability elements to increase SEAP titre, the four stability 
elements associated with the largest significant increases in specific productivity in Figure  
were selected. TU1-SEAP plasmids bearing these stability elements were transfected with PEI 
at a 1:5 DNA:PEI ratio into the CHO transient host at 1*106 cells/ml in 10ml culture in 
cultiflasks. VCD, cell viability, and SEAP titre of each culture was measured 72h and 120h 
post-transfection, by ViCell as in section 2.4. and Sensolyte assay as in section 2.6.2., 
respectively. As displayed in Figure 4.6a and Figure 4.6b, no significant changes in cell culture 
performance, reflected in either culture’s IVCD or viability, were measured between cells 
transfected with different stability elements. As shown in Figure 4.6c and Figure d, cells 
transfected with SEAP-SE20 exhibited 1.62-fold higher titre than the SEAP control 72h post-
transfection, and a 1.28-fold increase 120h post-transfection. SEAP-SE10 was also associated 
with a significant 0.72-fold decrease in SEAP titre 120h post-transfection. Figure e shows that 
cells transfected with SEAP-SE20 exhibited a 1.45-fold increase in SEAP specific productivity 
compared to the SEAP control, across the 120h culture length. SEAP-SE3 and SEAP-SE10 in 
contrast, were associated with a reduction in SEAP specific productivity across their cultures 
by 0.81-fold and 0.74-fold, respectively. Finally, as shown in Figure f, the titre fold change 
associated with each stability element, compared to the unmodified SEAP control, decreased 
from 72h to 120h in a consistent fashion: SE20 by 21%, SE8 by 23%, SE3 by 18%, and SE10 by 
17%. These data validate the ability of SE20 to increase transient titre of SEAP, whilst raising 
questions about the mechanistic effect which could reduce the titre fold change of each 




Figure 4.6 – Transient analysis of candidate SEAP-SE constructs by transfection with PEI at a 1:5 DNA:PEI 
ratio into the CHO transient host in cultiflasks. A) No significant difference was measured in IVCD across the 
candidate library, with values ranging from 20.1*106-23.1*106 cell days, across 120h culture. B) No significant 
difference was measured in viability across the candidate library, with values ranging from 97.9-98.1% 72h post-
transfection, and 93.5-95.2% 120h post-transfection. C) Expression of SE20 is associated with a significant 
(P=0.012) 1.62-fold increase in titre 72h post transfection, with SE8 associated with a non-significant (P=0.095) 
1.40-fold increase. D) Expression of SE20 is associated with a significant (P=0.0004) 1.28-fold increase in SEAP 
titre 120h post-transfection, whereas SE10 significantly (P=0.0076) decreases titre by 0.72-fold. E) Expression of 
SE20 is associated with a significant (P=0.014) 1.45-fold increase in SEAP specific productivity, whereas SE3 is 
associated with a 0.81-fold decrease (P=0.0043), and SE10 a 0.74-fold decrease (P=0.029). F) The titre fold change 
of every SEAP-SE construct decreases relative to unmodified SEAP titre from 72h to 120h post-transfection. The 
sequence of all stability elements referenced can be found in section 2.13.3. and Table 1 of this thesis. Results 




VCD measurements during this experiment taken on culture days 0, 3, and 5, are shown in 
Figure . These data indicate that cells were in log phase from day 0 to 3, roughly doubling in 
density every day, before transitioning to stationary phase between day 3 and day 5, with 
density increasing little, and even decreasing in the case of cells transfected with SEAP-SE8.  
Figure 4.7 - Viable cell densities of SEAP-3'SE 
cultiflask screen. Cell cultures appear to 
transition from growth to stationary phase 
around day 3 post-transfection. Results 
presented are of technical duplicates from three 
biological replicates. VCD: viable cell density. 
  




























4.2.5. The addition of SE20 is associated with an increase in SEAP mRNA 
half-life  
To investigate the mechanistic basis of the stimulation of SEAP titre by SE20, transient host 
CHO cells at 1*106 cells/ml in 10ml culture in cultiflasks were transfected with TU1-SEAP and 
TU1-SEAP-SE20 using PEI at a 1:5 DNA:PEI ratio. 48h post transfection, pellets were spun 
down of each transfection for analysis by RT-qPCR as in section 2.9.2., with the relative 
abundance of SEAP mRNA measured compared to fkbp1a, as recommended in Brown et al., 
2018. The results of this experiment are shown in Figure a. No significant difference in 
abundance is measured between SEAP and SEAP-SE20. Immediately following the extraction 
of these samples, cell cultures were treated with 20µM Actinomycin D, in order to inhibit their 
transcription, as in section 2.12. Following this treatment, cell pellets were similarly sampled, 
at timepoints of 1h, 2h, 4h, 8h, and 24h post-treatment. These samples were analysed by RT-
qPCR for relative abundance of SEAP mRNA, compared to fkbp1a. The results of this 
experiment are displayed in Figure b, plotting the relative abundance of each SEAP mRNA 
against the timepoint at which it was measured. Each set of points is fitted with a one-phase 
exponential decay curve, of which the curve for SEAP exhibits a noticeably faster drop-off in 
abundance. The half-life of each mRNA, as derived from this fitted curve, is shown in Figure 





Figure 4.8 – The addition of SE20 is associated with extended half-life of SEAP mRNA when transfected by PEI 
at a 1:5 DNA:PEI ratio into the CHO transient host in cultiflasks. A) No significant difference is measured in 
the abundance of SEAP and SEAP-SE20 mRNA pre-ActD treatment, with relative abundances of 2.96 and 3.38, 
respectively. βB) Abundance of each SEAP transcript was measured 1h, 2h, 4h, 8h, and 24h post-ActD treatment, 
and fitted by a one-phase exponential decay curve. C) SEAP-SE20 mRNA exhibits a significantly (P=0.032) 
longer half-life than SEAP, at 4.04h compared to 0.68h. The sequence of SE20 can be found in section 2.13.3. and 






Comparative analysis of mammalian 3’ triple helices for their effect on SEAP expression 
resulted in a severe, though not total, reduction in titre. Whether or not this result is 
unexpected is difficult to disentangle. Significant upregulation of mRNA levels upon addition 
of MALAT1/MENβ before the PolyA signal of intronless β-globin has been demonstrated 
(Brown et al., 2012), but this data may be misleading, as β-globin is almost uniquely extremely 
affected by intron removal, reducing expression ~35-fold (Lu and Cullen, 2003). This effect has 
not been shown with a WT β-globin transcript and may not be replicated in a transcript less 
sensitive to intronless expression, such as SEAP.  
The lack of annotated CHO triple helices may also have led to incomplete or improper 
sequence being used, as alignment of the H.sapiens triple helices against the CHO genome may 
miss non-conserved regions essential for CHO function. Triple helices do show a measure of 
sequence variation between species (Tycowski et al., 2016), which is slightly diminished 
between mammalian genomes (Wilusz et al., 2012), but may be exacerbated by the genetic 
instability of immortalised CHO cell lines. Evidence for their correct assembly may be seen in 
the only partial rescue of expression by downstream insertion of the SV40 PolyA in both cases. 
It can be inferred from expression levels of SEAP-PAN-pA, and by the stability element 
screen, that insertion of sequence upstream of the PolyA in the 3’UTR is not deleterious to 
expression unless the sequence in question carries an actively deleterious effect. Therefore, 
the MALAT1 and MENβ sequences used in this study are unlikely to be entirely non-
functional, though a partial inhibition of function remains possible.  
Analysis of SEAP-PAN-pA gave an initially promising result, delivering a higher, though 
non-significantly so, titre and specific productivity than SEAP controls, when screened in 96 
deep-well plates. However, the hypothesis that PAN-pA increases SEAP titre was 
conclusively proven incorrect by screening in scaled-up cultiflask culture, where no 
significant changes in cell culture performance or SEAP titre were observed compared to 
controls. This false positive can therefore be attributed to the higher error associated with 
high-throughput experimental platforms, where small pipetting errors in cell culture and 
transfection mixes become proportionally more influential, and consistent conditions may not 
be upheld across a multi-well plate (to be discussed further below). Therefore, any ambiguous 
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results and conclusions gained from high-throughput testing, should be verified in alternative 
culture platforms. Collectively, these data suggest that 3’ triple helices are not an appropriate 
tool for predictably enhancing biopharmaceutical expression by improving mRNA stability. 
Screening of 3’ stability elements in 96 deep-well plates led to a significant increase in SEAP 
titre with three constructs. Furthermore, some slight, but significant reductions in cell growth 
imply 6 constructs granted a significant increase in SEAP specific productivity. However, 
these reductions in cell growth appear to follow a regular periodicity every 12 constructs. This 
is likely the result of different conditions at the edge of plates, arising either from the cell 
culture platform (edge wells exhibiting higher cell growth), or the growth assay (edge wells 
giving a higher Prestoblue signal). If the effect can be attributed to the former mechanism, the 
implied increases in specific productivity would be accurate, but if it is the latter, they may be 
misleading. As stated above, in such ambiguous cases, results should be verified in an 
alternative culture platform.  
When verified in a scaled-up culture platform, one stability element (SE20) granted a 
significant increase in day 3 titre, day 5 titre, and specific productivity across the culture 
length, validating its’ ability to increase SEAP expression. No significant changes in IVCD or 
viability were measured, corroborating the hypothesis that differences in growth measured 
in the 96 deep-well plate screen were artefacts of an edge effect. Another observation from 
this screen was that the titre of all SEAP constructs bearing a stability element decreased 
compared to the SEAP control from day 3 to day 5. As the elements used in this study were 
identified in a descriptive, rather than prescriptive manner, identifying sequences enriched in 
highly-expressed mRNA without describing their mechanism or synthetically designing their 
function, it is difficult to infer a mechanistic explanation for this decrease. However, the data 
presented in Figure , showing that this decrease in titre is accompanied by a halt in cell growth 
may imply that these stability elements are more effective when cell cultures are in their 
growth, as opposed to stationary phase. 
 Whilst a mechanistic basis of SE20’s stimulation of SEAP titre cannot be directly drawn from 
literature; some inferences can be made from the results presented in Figure 4.7. These data 
show that addition of SE20 to the 3’UTR of a SEAP is associated with a significant increase in 
mRNA half-life. This result is plausibly consistent with literature, wherein it is shown that 
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3’UTR sequences have a significant influence over mRNA half-life, via mechanisms such as 
occlusion of RNA-binding protein landing sites and miRNA target sites, and creation of 
optimal distances between the stop codon at PolyA signal (Berkovits and Mayr, 2015; Mishima 
and Tomari, 2016; Oikonomou et al., 2014; Sandberg et al., 2008a; Wu and Bartel, 2017).  
Despite these feasible explanations, there are no readily detectable sequence features which 
explain why SE20 performs this function, as opposed to any other stability element. The 
stability elements used in this thesis tend to be A/T-rich, (64.7%  A/T over the entire library 
with a standard deviation of 8.7%), but SE20 is not remarkable in this metric, with 70.6% A/T 
content. Moreover, no significant correlation is found between stability element A/T content 
and effect on SEAP titre or specific productivity, as measured in Figure . A/T-rich tracts in the 
3’UTR conferring effects on mRNA stability may imply a role for ARE-binding proteins. 
However, SE20 does not contain any of the motifs used to detect ARE-protein binding 
(Fallmann et al., 2016). No significant C.griseus miRNA sites of complementarity are found in 
SE20 by search in miRBase (Griffiths-Jones et al., 2008). Formation of secondary structures is 
another possible explanation; however, no significant secondary structure is found in SE20, 
with a minimum free energy of -2.70 kcal/mol predicted by the RNAfold web server, 
compared with -3.40 kcal/mol for the shuffled stability element control. Taking another 
descriptive approach, all stability elements which sufficiently activated SEAP expression to 
be taken forward to the validation screen (SE3, 8, 10, 20) were analysed for conserved motifs 
using the DMINDA 2.0 web server (Yang et al., 2017), and a conserved TTGNAA motif was 
found in all four sequences. However, this motif is also found in SE4 (TTGGAA) and SE12 
(TTGCAA), both of which failed to significantly increase SEAP titre. Finally, no regions of 
alignment are found between SE20 and the TU1-SEAP vector from which it was being 
expressed.  
Despite an increase in mRNA half-life, no significant difference in relative abundance was 
measured in SEAP-SE20, compared to the SEAP control. As the rate of cytoplasmic turnover 
of SEAP-SE20 is lower than SEAP alone, its rate of generation must therefore be diminished 
as well. Whilst it is unlikely that transcription would be significantly affected by an addition 
of 34bp to a transcript, the processing and export of mRNA can be affected by 3’UTR 
structures (Heinrich et al., 2017), in which case the titre stimulation granted by SE20 could be 
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attributed to higher translation efficiency; and a higher rate of translation could itself provide 
an explanation for the extension of half-life (Bicknell and Ricci, 2017). Alternatively, a long-
lived pool of recombinant mRNA could trigger a feedback mechanism to reduce transcription, 
in which case increases in titre could be attributed toward a more energetically efficient 
solution for the cell: investing less in transcription, and more in translation.  
More work to understand these mechanisms would need to be performed in order to design 
a stability element fully synthetically, render its’ effect titratable, or even answer questions 
such as whether different elements may be needed for different vectors or recombinant 
proteins. Nonetheless, the evidence presented suggests that stability elements, specifically 
SE20, could represent a predictable molecular biology tool for the stimulation of recombinant 
protein production. Increasing the attractiveness of this novel tool is the validated mechanism 
of extension of mRNA half-life, and the ease of incorporated a short vector sequence (34bp) 
into a vector. More generally, these data suggest the potential power in the application of 
sequences discovered via MPRA platforms to biopharmaceutical expression. 
4.4. Conclusion 
In this chapter, I have presented two different proposed solutions to increase mRNA stability 
in recombinant protein production, both based on insertion of sequence elements into the 
3’UTR of recombinant transcripts. The first proposal of 3’ triple helices failed to meet the 
standards of such a molecular biology tool; the mammalian structures having a detrimental 
effect on titre, and no effect being measured from the viral element. The second solution, short 
mRNA stability elements, present a novel method to increase recombinant protein 
production.  SE20 was shown to increase the specific productivity of transiently expressed 
SEAP by 1.45-fold over a 120h culture, and it’s mechanism validated, as it was associated with 
an extension of SEAP mRNA half-life from 0.68-4.04h. Whilst further investigation and design 
will be required to render this tool truly synthetic, user-defined, and titratable, the data 
presented in this chapter show it as a predictable enhancer of recombinant protein titre. 
Furthermore, the relative simplicity of incorporating a 34bp element into a vector render it an 
attractive solution for multiple rounds of testing, when transiently optimising a vector for 
stable production. Combined with results of a multi-element screen to be presented in Chapter 
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6 of this thesis, stability elements, specifically SE20, appear to represent an effective tool for 
the control of mRNA stability, and thereby protein titre, in biopharmaceutical production.  
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5. 5’TOP Motifs and Translation Initiation 
5.1. Introduction 
5.1.1. 5’TOP Motifs for the Modulation of Titre by Translation Initiation 
Control 
Besides the ubiquitous Kozak sequence, no synthetic, predictable and titratable molecular 
biology tools exist for controlling initiation, which is most often the rate-limiting step in 
translation (Aitken and Lorsch, 2012),  and at which stage bottlenecks in expression are often 
observed (Rajendra et al., 2015a). In this chapter, the use of 5’ Terminal Oligo Pyrimidine 
(5’TOP) motifs - short RNA sequences exhibiting translational control - as a molecular biology 
tool for controlling biopharmaceutical titre through translation initiation will be investigated 
and developed.  
5’TOP motifs are found in mRNA, with each part of this name describing an obligatory feature 
of the motif. 5’ Terminal refers to the fact that TOP motifs must be placed precisely at the 
transcription start site, and therefore at the 5’ terminus of an mRNA (Eliseeva et al., 2013; 
Philippe et al., 2018), typically by the TC+1T core promoter motif, of which the C+1 is the 
obligatory start of the TOP motif (Parry et al., 2010; Vo ngoc et al., 2017). Following this C+1 is 
the Oligo Pyrimidine sequence, typically comprising 5-15 bases, Cs and Ts in DNA, Cs and 
Us in the resultant mRNA (Meyuhas and Kahan, 2015). Endogenous 5’TOP motifs are found 
in mRNA transcripts coding for proteins required for growth and proliferation, enabling 
regulation of their expression, and therefore cell growth and proliferation, in response to a 
number of factors, such as nutrient availability (Miloslavski et al., 2014; Roux and Topisirovic, 
2018; Yao et al., 2017), growth factors (Markou et al., 2010; Tuxworth et al., 2008), and even viral 
infection (Hopkins et al., 2015). 5’TOP motifs can be found in transcripts for various proteins, 
such as elongation factors, but are mostly found in ribosomal mRNAs (Fonseca et al., 2018; 
Yamashita et al., 2008). 
5.1.2. MTORC1 Regulation 
5’TOP motifs are subject to a subset of the more global translational regulation performed by 
mTOR (mammalian target of rapamycin), more specifically within MTORC1 (mTOR complex 
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1), with the protein factors Raptor and mLST8 (Aylett et al., 2016). MTORC1 is a central 
regulatory node, which integrates various growth signals, and coordinates cellular response, 
by phosphorylation of factors to upregulate anabolic processes, such as nucleotide and lipid 
synthesis, and downregulate catabolic processes such as lysosome biogenesis and autophagy 
(Ben-Sahra and Manning, 2017).  
The sensing of these various stimuli by MTORC1 is primarily coordinated through a logical 
‘AND-gate’, wherein full activation of the complex is achieved by recruitment to the 
lysosomal membrane by both growth factor-sensing Rheb, and the amino-acid sensing Rag 
factors (Buel and Blenis, 2016; Saxton and Sabatini, 2017). Rheb is a GTPase, which can only 
bind and activate MTORC1 in its Rheb-GTP form. The GTPase activating protein (GAP) TSC2 
(part of the TSC complex) promotes conversion of this form to Rheb-GDP, thus inhibiting 
MTORC1. The TSC complex is in turn inhibited via phosphorylation by factors such as AKT, 
ERK, and RSK, all of which are activated by kinase cascades started by binding of growth 
factors, oxygen and energy supply, and presence of glucose (Ben-Sahra and Manning, 2017; 
Nandagopal and Roux, 2015; Roux and Topisirovic, 2018). The four Rag proteins (RagA/B/C/D) 
form the obligate heterodimers RagA/B and RagC/D, which bind GTP and GDP respectively, 
and it is in these forms that they recruit and activate MTORC1. GATOR1 is a GAP which acts 
on the Rags to inhibit MTORC1 activation, and is in turn inhibited by the presence of cytosolic 
Arginine and Leucine, acting through CASTOR1 and Sestrin1/2 respectively (Yao et al., 2017). 
Rag-MTORC1 association is upregulated by Ragulator, a guanine exchange factor (GEF) for 
the Rags, which is in turn upregulated by cytosolic glutamine and lysosomal arginine, through 
vATPase and the arginine-sensing SLC38A9 (Ben-Sahra and Manning, 2017; Buel and Blenis, 
2016). This nutrient-sensing ability is more critical than growth factor-sensing, meaning that 
whilst both are required for full MTORC1 activation, nutrients alone are sufficient for a basal 
activation level, whereas growth factors alone fail to activate the complex (Valvezan and 
Manning, 2019).  
Once activated, mTOR primarily controls global translation by activation of the S6Ks, and 
inhibition of the 4E-BPs, both by phosphorylation. The S6Ks (S6K1 and S6K2 in mammals) 
regulate the phosphorylation state of multiple translation-associated proteins, such as Rps6 
and eEF2-kinase (eEF2K), to generally upregulate translation (Iadevaia et al., 2014; Meyuhas, 
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2015). When unphosphorylated, 4E-BPs bind and sequester eIF4E, partially inhibiting 
translation initiation, through disruption of PIC formation (Musa et al., 2016). As discussed in 
section 1.4.3. of this thesis, not every factor is strictly obligatory for translation initiation, 
rather, initiation factors form a web of interconnected redundancies, from which particular 
transcripts may be more or less dependent on particular factors (Mayberry et al., 2009). Thus, 
transcripts that contain 5’UTRs dependent on the presence of eIF4E are considered ‘mTOR-
sensitive’. Identification of mTOR-sensitive transcripts is difficult, with issues of assay 
sensitivity and transcript abundance initially leading to the belief that only 5’TOP motifs were 
mTOR-sensitive (Masvidal et al., 2017; Thoreen et al., 2012), and a spurious supposed 
correlation between 5’UTR length and mTOR sensitivity (Leppek et al., 2018; Thoreen et al., 
2012). Current analysis places mTOR-sensitive transcripts into two general categories: short 
transcripts, enriched in mitochondrial function, sensitive to eIF4E, but insensitive to eIF4A, 
and long transcripts, enriched in growth factors, sensitive to both eIF4E and eIF4A (Gandin et 
al., 2016; Masvidal et al., 2017).  
5.1.3. 5’TOP Motifs and LARP1 
In addition to these global mechanisms of translational control, transcripts containing 5’TOP 
motifs are subject to specific control by another MTORC1-regulated protein, LARP1, 
rendering them MTORC1-hypersensitive (Ben-Sahra and Manning, 2017; Hong et al., 2017).  
Proteomic studies initially discovered that LARP1 associates with 5’TOP transcripts in an 
MTORC1-dependent manner, and controls their translation (Tcherkezian et al., 2014). 
Subsequently,  X-ray crystallography has shown LARP1 specifically binding polypyrimidine 
sequences via a repurposed and unique HEAT domain (Lahr et al., 2015), and specifically 
binding both 5’cap analogues and 5’caps followed by a cytidine (Lahr et al., 2017), explaining 
the need for 5’TOP motifs to be 5’ terminal. This binding domain was shown to be sufficient 
to specifically regulate 5’TOP transcripts (Philippe et al., 2018), and this binding is relieved 
upon LARP1 phosphorylation by MTORC1 and S6K. Based on these observations, a model 
was developed in which LARP1 inhibits translation initiation by outcompeting eIF4F for 5’cap 
binding, until MTORC1 activation, when LARP1 is phosphorylated, the binding is released, 
and the inhibition relieved (Hong et al., 2017). LARP1 has also been shown to bind to the 
3’UTR, via an association with PABP (Aoki et al., 2013). When mTOR is inactive, and therefore 
LARP1 is bound to 5’TOP sequences, this facilitates a circularisation of the mRNA, which is 
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then recruited to 40S ribosomes. This protects 5’TOP mRNA from degradation, in order to 
maintain a constantly available pool of growth-associated mRNAs, ready to be translated 
upon MTORC1 activation (Gentilella et al., 2017). When MTORC1 is activated, LARP1 
dissociates from the 5’TOP motif, but remains bound to PABP, where it recruits active 
MTORC1 to the mRNA, further promoting translation (Hong et al., 2017; Philippe et al., 2018).  
5.1.4. MTORC1 in CHO Cells 
A number of studies have investigated the potential use of MTORC1 manipulation in CHO 
cells for recombinant protein expression. Dreesen and Fussenegger found that transient 
overexpression of mTOR increased the yield of both SEAP and an FC-fusion protein, both 
expressed transiently and stably. Stable mTOR overexpression was then added to a stable 
mAb-producing cell line, showing increased cell growth, viability, and specific productivity 
(Dreesen and Fussenegger, 2011). Studies by Dadehbeigi et al. and Courtes et al. both 
investigated the treatment of cell cultures with a low concentration of Rapamycin (an inhibitor 
of mTOR), using 20ng/ml and 100nM, respectively. Both studies found that by slightly 
compromising maximal growth by this method, culture could be extended, and overall titre 
of recombinant proteins improved by 50% and 16%, respectively. Conversely, both studies 
found that the more significant increase in maximum cell count, culture length and titre 
associated with the common practice of regularly feeding a batch culture (a fed-batch), may 
be partially creditable to the additional MTORC1 activation given by this nutrient supply 
(Courtes et al., 2014; Dadehbeigi and Dickson, 2015). Josse et al. investigated MTORC1’s effects 
on mAb yield from a number of differentially-expressing cell lines, by looking at relative 
abundance and phosphorylation of eIF4E and 4E-BP. Though they were unable to produce 
any changes in titre by manipulating 4E-BP phosphorylation, a correlation was observed 
between mAb titre and eIF4E/4E-BP stoichiometry (Josse et al., 2016).  Whilst some approaches 
to modulate global cell-line performance by manipulation of MTORC1 have been examined, 





5.2.1. Constructing the 5’TOP library 
In order to test their effect on biopharmaceutical expression when placed inside a recombinant 
mRNA transcript, a library of 5’TOP motifs was constructed. To rationally select motifs 
exhibiting high expression levels, an Omics dataset was utilised, firstly containing 
transcriptomic data gathered by RNA-seq from a CHO cell line stably expressing an ETE mAb 
(Geoghegan et al., 2018). Secondly, an MS-based proteomic dataset gathered inhouse by 
AstraZeneca, utilising pulsed SILAC, as in Schwanhäusser et al. 2011, from the same stably-
expressing CHO cell line. For this dataset, cells were pulse-labelled with ‘heavy’ SILAC 
media, containing 13C and 15N-labelled L-arginine and L-lysine. Proteins were extracted, 
separated by SDS-polyacrylamide gel electrophoresis, and analysed by LC-MS/MS. The sum 
of peptide peak intensities were divided by the number of theoretically observable tryptic 
peptides to determine absolute protein amounts. The mean of three technical replicates was 
used. As a CHO transcription start site (TSS) database was not available, genes were extracted 
from this dataset, by cross-reference against a study identifying 5’TOP transcripts from 
H.sapiens and M.musculus TSS datasets, taking only genes positively identified in both 
organisms (Yamashita et al., 2008). These putative CHO 5’TOP genes were then ranked by the 
following criteria in the Omics dataset: 
• mRNA abundance, measured in FPKM.  
• Specific translational activity, measured by the number of amino acids incorporated 
into each respective protein, per cell, per hour.  
• Specific translation efficiency, given by controlling the specific translational activity of 
each gene by its’ mRNA abundance.  
Once 5’TOP genes were ranked in this way, the following iterative process was performed to 
compile the library of motifs: 
1. Find the highest-ranked gene of each list in the CHO-K1 genome (2014).  
2. Identify a sequence that satisfies the following criteria: 
a. Upstream of the start codon. 
b. Nearest to the start of the annotated gene. 
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c. Begins with a Cytidine.  
d. Comprises an exclusive tract of 5+ pyrimidines. 
3. If no such sequence can be identified, restart this process with the highest ranked gene 
of the next list.  
Using this process, a library of 46 5’TOP sequences was compiled (TOP3-48), the gene of origin 
and sequence of which are shown in Table 2. An expression plasmid was constructed for these 
sequences, removing the CMV promoter and 5’UTR from the inhouse TU1-SEAP vector, and 
replacing them with an Ef1α promoter and 5’UTR, to create the TU1-Ef1α vector. This 
molecular cloning was performed by restriction/ligation between EcoRI/PpuMI sites as in 
section 2.3.6, and correct construction verified by Sanger sequencing. The Ef1α promoter 
contains a TCT motif at its transcription start site, followed by a 5’TOP sequence, which 
functions as the first control for this library (TOP1). Alternative 5’TOP sequences were 
therefore integrated by direct switching of TOP1 by the sequence in question. The second 
control was established by removal of the 5’TOP sequence from the vector (TOP2). Every 
5’TOP motif used in this thesis can be found in section 2.13.4. and Table 5.1, and a 
representative map of the ‘TU1-Ef1α’ plasmid found in Appendix A. A schematic of the TU1-
TOP-SEAP library used in this section are shown in Figure . 
 




Source Name Sequence  Source Name Sequence 
EF1a TOP1 CTTTTTC  HSPD1 TOP26 CCCTCCC 
NON-TOP TOP2    IPO5 TOP27 CTCCCTCCTCCTTCTCTCTCTC 
ACTB TOP3 CTCTTTCTTC  RPL7 TOP28 CTTCCTCTCTCT 
RPLP2 TOP4 CTTCCTTTC  RPL10 TOP29 CTTTTCCTCC 
RPL11 TOP5 CCTCCT  EIF2S3 TOP30 CCTTCCTCTCT 
RPS14 TOP6 CCTCCCCT  HNRNPF TOP31 CCTCTTCCTCCTC 
GAPDH TOP7 CTCTCT  RPL3 TOP32 CCTCT 
RPL13A TOP8 CCTCCTCCTTTCCC  RPL30 TOP33 CTTCCTTTCT 
RPL14 TOP9 CCTTCTTCCTTCTC  RPS2 TOP34 CCTTCCCC 
RPS10 TOP10 CTTCTC  RPL23A TOP35 CCTTTT 
RPS25 TOP11 CTCCTCCC  EEF2 TOP36 CTCTTCTCC 
RPS23 TOP12 CCTTCCT  ENO2 TOP37 CTTTCTCCTTCCTCC 
RPS24 TOP13 CCTTCC  DDX21 TOP38 CTTTCTTCCTCTCTCTTTT 
RPS7 TOP14 CCTCTTTCT  IPO7 TOP39 CTTCTCTTTCCTTTC 
RPL31 TOP15 CTTCCCTTCCC  GARNL3 TOP40 CCTTTTTTTTTTTTCTC 
RPL18A TOP16 CTTCCTTTT  LAMB1 TOP41 CCCCTTCCT 
RPS3A TOP17 CTCCCC  DDX39B TOP42 CTCTTCT 
RPS3A#2 TOP18 CCCTTTT  GNAI3 TOP43 CCCCTCTCCC 
HSP90AB1 TOP19 CTTCTC  CS TOP44 CCCTTCCT 
TUBB TOP20 CCTTCCCTCCT  MATR3 TOP45 CCTCCTT 
RPS27A TOP21 CCTCTCTTCTC  EIF2S3 TOP46 CCTTCCTCTCT 
VIM TOP22 CCTCT  EIF3A TOP47 CTTTCC 
RPS8 TOP23 CCTTCCC  KPNA3 TOP48 CTCTTT 
EEF1G TOP24 CCTTTT  - synTOP CTTTCT 
EEF2 TOP25 CTCTTCTCCT  - TOP36-
1 
CTCTTCTC 
Table 2.1 –The 5’TOP motif sequences used in this study. 5’TOP motifs were substituted with the natural 
sequence from the Ef1α transcription start site in both the Ef1α and modified CMV-TCT promoters, by site-




5.2.2. Transient screening of the 5’TOP-SEAP library 
The library of 5’TOP sequences described above in the TU1-Ef1α promoter were placed 
upstream of the SEAP CDS, creating the 5’TOP-SEAP library. This molecular cloning was 
performed by site-directed mutagenesis as in section 2.3.2., and sequence verified by Sanger 
sequencing. This library was transfected by electroporation into transient host CHO cells in 
96 deep-well plate shaking culture, seeding at 0.2*106 cells/ml. At 72 hours post-transfection, 
fold-change in growth and SEAP titre were measured by Prestoblue and Sensolyte assays, 
respectively, as in sections 2.4.4.2 and 2.6.2. Figure a shows that cells transfected with three 
5’TOP sequences exhibited significantly increased titre compared to NON-TOP controls, with 
five significantly reduced. Surprisingly, removal of the natural Ef1α TOP (TOP1) was 
associated with a significant increase in titre. This picture is complicated by the data presented 
in Figure b, with significant variability observed in growth across the library. Ten 5’TOP 
sequences were associated with significantly lower growth than NON-TOP controls. 
However, significant deviation was observed across the screen, with an average SEM of 0.18 
fold-change, greater than 0.30 fold-change in ten cases. As shown in Figure c, these data show 
a significant increase in SEAP specific productivity associated with 10 5’TOP sequences, 
compared to NON-TOP controls, up to a maximum of 2.32-fold with TOP42. These data are 
influenced by the highly variable results in Figure b, for example TOP26 moving from a non-
significant 0.87-fold change in titre to a significant 2.04-fold increase in specific productivity, 
and TOP37 moving from a significant 0.68-fold reduction in titre to a significant 1.62-fold 





Figure 5.2 – Screening by electroporation of the 5’TOP-SEAP library in the CHO transient host, in 96 deep-well 
plates. A) Three sequences gave a significantly (P<0.05) higher SEAP titre than NON-TOP controls, TOP42 
(1.57-fold), TOP45 (1.46-fold), and TOP46 (1.10-fold), whereas five sequences led to a significantly lower titre: 
TOP1, 13, 22, 24, and 37, to a minimum of 0.68-fold with TOP37. B) Ten sequences were associated with 
significantly (P<0.05) lower growth than NON-TOP controls: TOP14, 21, 22, 24, 26, 35, 37, 38, 44, and 46, to 
a minimum of 0.42-fold with TOP37. C) Ten sequences gave a significantly higher SEAP specific productivity 
than NON-TOP controls: TOP25, 26, 33, 35, 37, 38, 39, 40, 41, and 42, to a maximum of 2.33-fold with TOP42.  
All 5’TOP sequences referenced can be found in section 2.13.4. and Table 5.1 of this thesis. Results presented are 





To investigate whether these disparities between titre and specific productivity were the 
genuine impact of 5’TOP motifs, or an artefact of a highly-variable transfection method, the 
5’TOP-SEAP library was screened again with an alternative transfection method. The library 
was transfected by PEI at a 1:5 DNA:PEI ratio into transient host CHO cells at 1*106 cells/ml in 
96 deep-well plate shaking culture. Again, 72 hours post-transfection, fold change in growth 
was measured by Prestoblue assay and fold change in SEAP titre was measured by Sensolyte 
assay, as in sections 2.4.4.2., and 2.6.2. A wide range of SEAP titre can be observed in Figure 
a, from a 0.49-fold reduction associated with TOP8, to a 3.34-fold increase with TOP36. In a 
more expected result, cells transfected with the natural Ef1α TOP outperformed NON-TOP 
controls in titre, by 1.87-fold. The fold changes in growth presented in Figure b show 
substantially lower variation than those presented in Figure b, displaying a greater than 10-
fold reduction in their average standard error of 0.014 fold-change, and ranging only between 
a 0.87-1.04 fold-change in growth. Similarly to data presented in Figure 4.5, the growth data 
displays a pattern of periodicity every 12 samples, in a manner concluded to be an edge effect 
of a multiwell plate, on either cell growth or Prestoblue assay. However, these variations make 
little difference, rendering only three fold-changes in specific productivity (Figure c) 
significant when they were not so in titre. Fold changes in specific productivity correlate 
significantly better with titre in Figure  (R2=0.87) compared to Figure 5.2 (R2=0.09). As with 
titre, a significant range in specific productivity is observed, ranging from 0.50-fold in cells 




Figure 5.3 – Transfection by PEI at a 1:5 DNA:PEI ratio of the 5’TOP-SEAP library in the CHO transient host, 
in 96 deep-well plates. A) 21 sequences led to a significant (P<0.05) increase in SEAP titre, up to a maximum of 
3.34-fold with TOP36, whereas two sequences gave a significant reduction in titre, TOP8 to 0.49-fold, and TOP9 
to 0.71-fold. B) 16 sequences were associated with small, but significant (P<0.05) changes in cell growth, ranging 
from a 0.87-fold reduction with TOP16 to a 1.04-fold increase with TOP1. C) 23 sequences gave a significant 
(P<0.05) increase in SEAP specific productivity, to a maximum of 3.96-fold with TOP36, whereas only TOP8 at 
0.50-fold gave a significant reduction. All 5’TOP sequences referenced can be found in section 2.13.4. and Table 





To compare the expression activation of 5’TOP motifs between electroporation and PEI 
transfection techniques, the fold change imparted by the total library upon addition of a 5’TOP 
motif are displayed in Figure 5.4, with titre in Figure 5.4a and specific productivity in Figure 
5.4b. As a group, 5’TOP-SEAP reporters were associated with significantly (P<0.0001) higher 
titre fold change compared to NON-TOP controls when transfected by PEI than by 
electroporation, with average fold-changes of 1.59-fold and 1.15-fold, respectively. A similar 
result is found for specific productivity, with a significant difference between the average 1.75-
fold increase with PEI and 1.39-fold increase with electroporation. Collectively from this data, 
it can be concluded that 5’TOP motifs are capable of facilitating significant changes in 
recombinant protein expression characteristics, and that the PEI, as opposed to 
electroporation, transfection method gives both data with less variability, and significantly 
activates the expression of the 5’TOP sequences.  
 
 
Figure 5.4 – Transfection by PEI activates expression of the 5’TOP library significantly more than 
electroporation. A) Fold change in titre of the library is significantly (P<0.0001) higher with PEI (1.59) than 
electroporation (1.15). B) Fold change in specific productivity is significantly (P=0.0030) higher with PEI (1.75) 
than electroporation (1.39). Results presented are of technical duplicates from four biological replicates. FC: fold 




Taking the data from Figure 5.3, a negative correlation was observed, between length of the 
5’TOP motif in nucleotides and the expression characteristics of SEAP. This correlation with 
titre is displayed in Figure 5.5a, and with specific productivity in Figure 5.5b. The correlations 
may suggest that shorter 5’TOP sequences give greater expression activation than their longer 
counterparts.  
 
Figure 5.5 – Fold change in 5’TOP-SEAP expression compared to TOP2-SEAP upon PEI transfection into the 
CHO transient host in 96 deep-well plates is negatively correlated with 5’TOP length, reflected in both A) Titre, 
and B) Specific productivity. Results presented are of technical duplicates from four biological replicates. FC: fold 
change; qP: specific productivity.  
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5.2.3. Expression of 5’TOP-SEAP is not specifically enhanced by addition 
of cell culture feed or amino acids 
To test whether expression of 5’TOP motifs could be specifically activated or repressed, TOP1-
SEAP and TOP2-SEAP were transfected by PEI at a 1:5 DNA:PEI ratio, into the transient host 
CHO cell line at 1*106 cells/ml, into 96 deep-well plates in shaking culture. At 24 hours post-
transfection, these cells were treated with one of three titrated supplements: an amino acid 
mix of Leucine, Glutamine, and Arginine (the three amino acids most associated with 
MTORC1 activation (Yao et al., 2017)) from 0-20mM, a commercial feed mix ranging from 0-
20%, or rapamycin, ranging from 0-200ng/ml, as in section 2.11. At 72h post-transfection, fold 
change in cell growth was measured by Prestoblue assay as in section 2.4.4.2., and SEAP titre 
measured by Sensolyte assay as in section 2.6.2. To assess the activation of 5’TOP expression, 
and the effect this has on growth, the ratio of TOP1-SEAP/TOP2-SEAP titre and growth were 
calculated for each treatment and are shown in Figure 5.6. Local maxima and minima on these 
plots would indicate specific activation or repression of 5’TOP expression, through their acute 
MTORC1-mediated regulation. Figures 5.6a and 5.6b show no local maxima in TOP1/TOP2 
ratio across either cell growth or SEAP titre. A slight downward trend is in fact observed, with 
a titre ratio of 1.50 with 0mM amino acids, compared with a ratio of 1.18 upon treatment with 
20mM. A similar pattern is seen with feed supplementation, Figures 5.6c and 5.6d, where no 
significant local maxima are observed, and a negative correlation appears between feed 
titration and titre ratio, ranging from 1.51-fold at 0% to 1.14-fold at 20%. In contrast, a local 
minimum in TOP1/TOP2 titre ratio is seen in Figure 5.6e, moving from 1.29 at 12.5ng/ml 
rapamycin, to 0.58 at 25ng/ml, and back up to 1.06 at 50ng/ml, both of which are statistically 
significant changes. No such local minima are observed in growth ratio, presented in Figure 
5.6f. These data imply that expression of 5’TOP-SEAP cannot be specifically activated by 
treatment with amino acids or feed solution, but may be specifically repressed by treatment 
with the correct concentration of rapamycin, at concentrations lower than is necessary for the 




Figure 5.6 - Activation/repression of 5’TOP-SEAP expression in the CHO transient host by treatment with 
chemical supplements. No significant local maxima are observed in the TOP1-SEAP/TOP2-SEAP ratio upon 
amino acid titration in A) SEAP titre, or B) cell growth. No significant local maxima are observed in the TOP1-
SEAP/TOP2-SEAP ratio upon feed titration in C) SEAP titre, or D) cell growth. E) A local minima in 
TOP1/TOP2 SEAP titre is observed upon treatment with 25ng/ml rapamycin, in a statistically significant 
decrease compared to 12.5ng/ml (P=0.047) and 50ng/ml (P=0.030) treatment. F) No significant local minima are 
observed in the TOP1/TOP2 growth ratio upon rapamycin titration. All 5’TOP sequences referenced can be found 
in section 2.13.4. and Table 5.1 of this thesis. Results presented are of technical duplicates from three biological 










































































































































To validate that changes in expression characteristics of SEAP imparted by 5’TOP motifs were 
as a result of the expected mechanism of acute LARP1/MTORC1 inhibition, and therefore 
sensitive to rapamycin treatment, the transient CHO host was transfected with the 5’TOP-
SEAP library by PEI at a 1:5 DNA:PEI ratio, at 1*106 cells/ml, in 96 deep-well plate shaking 
culture. 24h post-transfection, all transfected cells were treated with 25ng/ml rapamycin, as in 
section 2.11. SEAP titre and growth fold change were measured 72h post-transfection, by 
Sensolyte and Prestoblue assay, as in sections 2.6.2. and 2.4.4.2. The fold changes in SEAP titre 
and specific productivity associated with transfection of the total TOP-SEAP library, 
compared to the NON-TOP control, are shown in Figure 5.7. A non-significant reduction in 
average titre is  observed upon rapamycin treatment, from  1.60-fold to 1.43-fold. A significant 
reduction in average specific productivity is observed, from 1.76-fold to 1.42-fold. These 
results suggest that stimulation of SEAP expression by 5’TOP motifs is at least partially 
sensitive to rapamycin treatment. 
 
Figure 5.7 – Fold change of TOP-SEAP library expression relative to TOP2-SEAP upon treatment with 25ng/ml 
Rapamycin 24h post-transfection. A) A non-significant reduction in SEAP titre from 1.60 to 1.43-fold is 
observed. B) A significant (P=0.0079) reduction in specific productivity from 1.76 to 1.42-fold is observed. Results 
presented are of technical duplicates from four biological replicates. FC: fold-change; qP: specific productivity.  
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5.2.4. A library of synthetic promoters do not function as designed in 
expression of 5’TOP-SEAP 
To begin expanding upon and developing the use of 5’TOP motifs to control recombinant 
protein expression, it was first decided to investigate whether they could be integrated with 
synthetic promoters, designed in Brown et al., 2014, for both maximising, and predictably 
titrating expression. A total of seven proximal promoters were inserted upstream of the Ef1α 
core in the TU1-Ef1α-SEAP vector, in place of the Ef1α proximal promoter. Four had a user-
defined strength of transcription (5RPU, 10RPU, 80RPU, 100RPU), two were based on tandem  
repeats of a TFRE (10X ERSE, 10X NFκB ), and finally the CMV proximal promoter was used. 
This molecular cloning was performed by restriction/ligation between the EcoRI/AflII sites as 
in section 2.3.6., the synthetic promoters used found in section 2.13.5. and Table , and a 
representative plasmid map found under ‘TU1-Ef1α’ in Appendix A. A schematic of the 
Proximal Promoter-TOP-SEAP library used in this section is shown in Figure 5.8. 
 

















































Table 5.2 – The synthetic proximal promoters used in this study. Synthetic proximal promoters were taken from 
literature (Brown and James, 2015; Brown et al., 2014a, 2017), and substituted with the proximal promoters of 
both CMV and Ef1α, upstream of their cores, in the AstraZeneca in-house TU1 vector, using EcoRI/NheI and 




The 5’TOP motif was then removed from each construct, creating TOP1/NON-TOP variants 
of each proximal promoter construct. The level of transcription performed by the synthetic 
promoters could therefore be measured by comparing expression against cells transfected 
with unmodified Ef1α-SEAP, and correct transcription of 5’TOP motifs in these promoter 
assemblies by a difference in expression between TOP1/NON-TOP variants. These 14 
constructs were then transfected into the CHO transient host at 1*106 cells/ml using PEI at a 
1:5 DNA:PEI ratio, in 24 shallow-well plate shaking culture, against a TU1-Ef1α-SEAP control. 
VCD was measured by Iprasense 72h and 120h post-transfection, as in section 2.4.4.3. SEAP 
titres were measured 120h post-transfection by Sensolyte assay as in section 2.6.2., shown as 
fold-change compared to TU1-Ef1α-SEAP, Figure 5.9a, and fold-change in specific 
productivity, Figure b. The CMV proximal promoter was associated with a significant 
decrease in SEAP titre of 0.45-fold, and no difference between TOP variants. The synthetic 
proximal promoters did not boost expression compared to unmodified Ef1α, did not perform 
relative to one another as designed, with cells transfected with 10RPU associated with the 
highest titre, and 80RPU outperforming 100RPU, which was not significantly different to 
5RPU, and did not produce any significant difference between TOP variants. The 10x ERSE 
proximal promoter produced no significant change in titre compared to Ef1α-SEAP, and no 
difference between TOP variants. In contrast, a significant difference was observed between 
the TOP variants of the 10x NFκB  proximal promoter, with its’ TOP1 variant increasing SEAP 
titre by 1.58-fold and specific productivity by 1.76-fold. Cells were also pelleted 120h post-
transfection, for measurement of relative SEAP mRNA abundance by RT-qPCR as in section 
2.9.2., results shown in Figure c. The calculated fold-changes in translation efficiency, taken 
by controlling specific productivity by mRNA abundance, are displayed in Figure d. The 
relative abundance of SEAP mRNA correlates strongly with its’ titre, the only difference being 
that a significant change in abundance is observed between the TOP variants under the 10x 
ERSE proximal promoter. The 10x NFκB  TOP variants retain their significant difference in 
abundance, from 1.25 to 0.66-fold. Finally, the translational efficiency of every NON-TOP 
variant, apart from with the CMV proximal, is slightly, though not significantly, higher than 
their respective TOP1 variant. These results suggest that the synthetic promoters designed in 
Brown et al., 2014 do not function as intended in the production of SEAP when paired with an 
Ef1α core promoter. A proximal promoter comprising of 10x NFκB  TFREs may be compatible 
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with the Ef1α core, increasing SEAP expression, and maintaining proper terminal 
transcription of the 5’TOP sequence. Interestingly, the increase in SEAP titre given by the 
TOP1 variant appears mainly due to mRNA abundance, as opposed to translation efficiency. 
 
Figure 5.9 – Testing of synthetic proximal promoters with the TU1-Ef1α-SEAP vector, fold changes measured 
against unmodified Ef1α-SEAP. 10x NFκB  shows a significant difference between its’ TOP1/NON-TOP 
variants in A) SEAP titre (P=0.0003) B) SEAP specific productivity (P=0.0015) and C) SEAP mRNA abundance 
(P=0.0025). 10x ERSE also shows a significant difference in SEAP mRNA abundance between TOP1/NON-
TOP (P=0.0064). All 5’TOP sequences referenced can be found in section 2.13.4. and Table 5.1, and synthetic 
promoter sequences found in section 2.13.5. and Table 5.2 of this thesis. Results shown are of technical duplicates, 








5.2.5. The TCT core can integrate TOP motif functionality into the CMV 
promoter 
To determine whether 5’TOP motifs could be integrated into alternative promoters that do 
not possess a TCT core and retain their function, a library of CMV-TCT-TOP vectors was 
created, using the TU1-SEAP vector, containing a CMV promoter. The Initiator sequence in 
the CMV core (GTCA+1GA) was replaced by the TCT motif (TC+1TTTTT) from the Ef1α. Four 
spacing variants were created, adding one base pair from the Ef1α core promoter upstream of 
the TCT motif each time, to vary the distance between the TATA box and transcription start 
site between 29bp (the distance from TATA box to Inr motif in WT CMV) and 32bp (the 
distance between the TATA box to transcription start site in WT CMV). Taking the C+1 of the 
TCT motif as the start of a TOP motif, four TOP variants for each spacing variant were created: 
NONTOP (-), TOP1, TOP8, and TOP36. This molecular cloning was performed by site-
directed mutagenesis as in section 2.3.2., and sequence verified by Sanger sequencing. 5’TOP 
motif sequences can be found in section 2.13.4. and Table 5.1, and a representative plasmid 
map under ‘TU1-TCT-SEAP’ in Appendix A. A schematic of the TU1-TCT -TOP-SEAP library 
is shown in Figure . 
 
Figure 5.10 – A schematic of the TU1-TCT-TOP-SEAP library used in this thesis. 
This total library of 16 constructs, alongside an unmodified TU1-SEAP control, was 
transfected by PEI at a 1:5 DNA:PEI ratio into transient host CHO cells at 1*106 cells/ml, in 24 
shallow-well plate shaking culture. VCD was measured by Iprasense 72h and 120h post-
transfection as in section 2.4.4.3., and SEAP titre measured 120h post-transfection by Sensolyte 
assay as in section 2.6.2. Fold change in SEAP titre and specific productivity, compared to 
TU1-SEAP, are shown in Figure 5.11a and Figure 5.11b.  In all spacing variants, titre and 
specific productivity fold change increase sequentially from cells transfected with TOP1, to 
NON-TOP, to TOP8, to TOP36. For example, TCT-SEAP is associated with 0.117, 0.112, 0.747, 
and 1.04-fold changes in titre respectively, compared to TU1-SEAP. Little difference is 
observed in specific productivity between the TCT, TCT+2, and TCT+3 spacing variants. 
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However, transfection of the TCT+1 variant results in a significantly lower titre (0.64-fold) 
specific productivity (0.58-fold) with TOP36, compared to TCT-TOP36 (titre P=0.0084, specific 
productivity P=0.027) and TCT+2 (titre P=0.024, specific productivity P=0.035). These data 
suggest that TOP motifs are capable of imparting changes in recombinant protein titre in the 
context of a modified CMV promoter, up to levels comparable with unmodified CMV, and 
that whilst the system is partially permissive, some spacing variants are less effective in this 
than others.   
 
 
Figure 5.11 – Comparative analysis of the CMV-TCT-TOP-SEAP library, transfected by PEI at a 1:5 DNA:PEI 
ratio into the CHO transient host in 24-well plates. Fold change expression is measured relative to the TU1-SEAP 
control. Significance is measured relative to the NONTOP variant of each spacing variant. A) In all spacing 
variants, a sequential increase in titre is observed from TOP1 to NONTOP, to TOP8, to TOP36. TCT+1-TOP36 
displays significantly reduced fold-change in titre compared to its’ surrounding spacing variants. A maximal fold 
change 0f 1.04 is reached by TCT-TOP36. B) Specific productivity follows the same pattern as titre, with fold 
changes up to 1.08 with TCT+3-TOP36. All 5’TOP sequences referenced can be found in section 2.13.4. and  
Table 5.1 of this thesis. Results presented are of technical duplicates from 5 biological replicates. FC: fold-change, 
qP: specific productivity.  
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5.2.6. 5’TOP motifs can modulate the titre of codon optimized and 
deoptimized EPO 
To validate the ability of 5’TOP motifs to control the expression characteristics of a 
recombinant protein other than SEAP, and to investigate whether translation initiation 
activation by 5’TOP motifs can work synergistically with translation elongation activation, 
two EPO CDSs were inserted into the TU1-Ef1α vector: the codon deoptimised EPO68, and 
optimised EPO71. A selection of 8 5’TOPs which had a strong and significant effect on titre 
and specific productivity in the 5’TOP-SEAP library were then added to this vector. Two 
strategies were used to attempt the design of synthetic, optimised 5’TOP motifs. Firstly, the 
highest 10 performing 5’TOP motifs in terms of specific productivity from library 1 were 
analysed for conserved motifs, and the most significant result used as the new TOP sequence: 
synthetic TOP (synTOP). Next, the observation from Figure 5.5 that increases in expression 
are negatively correlated with TOP length was utilised to remove one base from the end of 
the strongest performing sequence from library 1, TOP36, creating TOP36-1. With the TOP1 
and NON-TOP controls, a total library of 24 plasmids was created. These cloning steps were 
performed by restriction/ligation between the AgeI/SbfI sites as in section 2.3.6., and site-
directed mutagenesis as in section 2.3.2., respectively, and verified by Sanger sequencing. All 
5’TOP motif sequences can be found in section 2.13.4. and Table 5.1, and a representative 
plasmid map found under ‘TU1-Ef1α’ in Appendix A. A schematic of the TU1-TOP-EPO 
constructs used in this section is shown in Figure 5.12. 
 




This library was transfected into transient host CHO cells at 1*106 cells/ml by PEI at a 1:5 
DNA:PEI ratio, in 24 shallow-well plate shaking culture. VCD was measured at 72h and 120h 
post-transfection by Iprasense as in section 2.4.4.3., and supernatant assayed for EPO 
concentration by ELISA 120h post-transfection, as in section 2.10.2. The measured EPO titres 
are displayed in Figure 5.13a. Cells transfected with 19 constructs exhibited a significantly 
higher titre than with NONTOP-EPO68 with 381.5U/ml, up to a maximum of 903.3U/ml with 
TOP37-EPO71. EPO specific productivity, displayed in Figure 5.13b, follows a very similar 
pattern, with transfection of 21 constructs associated with significantly higher specific 
productivity than with NONTOP-EPO68, and range from 24.2U/ml/cell day*106, up to 
59.3U/ml/cell day*106. Whilst the titre and specific productivity associated with NONTOP 
constructs increase in EPO71 compared to EPO68, only TOP37 significantly increases titre in 
both EPO variants, with its’ titre increasing from 606.9-903.3U/ml (P=0.0079), and specific 
productivity increasing from 40.5-59.3U/mL/cell day*106 (P=0.022). These data imply that 
while both 5’TOP motifs and codon optimisation are capable of increasing recombinant 
protein expression, they may not be predictably synergistic in combination. 
Cells from these experiments were also pelleted 120h post-transfection for analysis of relative 
EPO mRNA abundance by RT-qPCR as in section 2.9.2., Figure 5.13c. It should be noted that, 
since EPO68 and EPO71 are different CDSs, their relative abundance was detected by different 
primers. Their relative abundance is therefore only comparable to themselves, and not across 
the data sets. Relative to NONTOP-EPO68, transfection of two TOP-EPO68 constructs gave a 
significant increase in EPO68 mRNA: TOP24 and TOP36 with 3.11-fold and 2.51-fold changes 
respectively, whereas TOP47-EPO68 and TOP48-EPO68 were associated with significant 
decreases of 0.46-fold and o.41-fold respectively. In contrast, all TOP-EPO71 constructs 
increased EPO71 mRNA levels compared to the NONTOP-EPO71 control, 8 of which were 
significant, to a maximum significant increase of 2.90-fold with TOP37-EPO71. Analysing 
these data collectively by EPO variant in Figure 5.13d, it can be seen that addition of 5’TOP 
motifs to EPO71 has a significantly (P<0.0001) different effect than their introduction to 
EPO68, increasing mRNA abundance by an average of 2.49-fold, as opposed to an average of 
1.37-fold with EPO68. These results suggest that 5’TOP motifs may be capable of influencing 
recombinant protein expression by more than one mechanism, and that this mechanism may 





Figure 5.13 – Screening and analysis of TOP-EPO library, transfected by PEI at a 1:5 DNA:PEI ratio into the 
CHO transient host in 24-well plates. A) 19 constructs exhibit a significant (P<0.05) increase in EPO titre, 
compared to NONTOP-EPO68 with 381.5U/ml, up to 903.3U/ml with TOP37-EPO71. B) Specific productivites 
of the TOP-EPO library are significantly correlated with titres (R2=0.934). 21 constructs significantly (P<0.05) 
increase specific productivity compared to NONTOP-EPO68, from 24.2U/ml/cell day*106, up to 59.3U/ml/cell 
day*106 with TOP37-EPO71. C) With EPO68, a variety of significant (P<0.05) fold-changes in mRNA upon 
addition of TOPs was observed, from 0.41-fold with TOP48, and 3.11-fold with TOP24. All TOP motifs increased 
the relative abundance of EPO71 mRNA, 8/11 doing so significantly (P<0.05), to a maximum of 2.90-fold with 
TOP37. D) TOP motifs generally increase EPO71 mRNA abundance, but have no significant effect on EPO68. 
A significant (P<0.0001) difference is observed in the effect on mRNA abundance upon addition of TOP motifs 
to EPO71, compared to EPO68, an average of 2.49-fold increase compared to 1.37-fold. All 5’TOP sequences 
referenced can be found in section 2.13.4. and Table 5.1 of this thesis. Results presented are of technical duplicates 
from four biological replicates. qP: specific productivity; FC: fold-change. 
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RT-qPCR analysis of this screen offers further insight, in the finding that addition of 5’TOP 
sequences to EPO68 has mixed effects on mRNA abundance, generally implying an increase 
in translational efficiency, whereas addition to EPO71 led to an increase in mRNA in every 
case, surprisingly implying a decrease in translational efficiency. These fold-changes in 
translation efficiency, calculated by dividing specific productivity by mRNA abundance, 
compared to each NONTOP-EPO control are show in Figure 5.14. Addition of a 5’TOP motif 
to EPO71 universally led to a decrease in translational efficiency, significantly so with four 
sequences: TOP1 (P=0.001), TOP8 (P=0.001), TOP12 (P=0.08), and TOP46 (P=0.006). 
Meanwhile, addition of 5’TOP motifs to EPO68 led to more mixed effects, with four significant 
increases given by TOP12 (P=0.022), TOP46 (P=0.008), TOP48 (P=0.016), up to a 5.28-fold 












Figure 5.14 – Addition of 5’TOP motifs to codon de/optimized EPO has a variety of effects on translation 
efficiency. With deoptimized EPO68, effects vary between a significant 5.28-fold increase with TOP47 (P=0.037) 
and a significant decrease of 0.54-fold with TOP24 (P=0.034). With optimized EPO71, translation efficiency is 
universally decreased, four 5’TOP motifs doing so significantly, down to a 0.34-fold change with TOP46 
(P=0.006). All 5’TOP sequences referenced can be found in section 2.13.4. and  Table 5.1 of this thesis. Results 
presented are of technical duplicates from four biological replicates. FC: fold-change. 
 
  











































5.2.7. 5’TOP motifs increase the titre of SEAP and a fusion protein in an 
industrial-standard transient expression laboratory 
To validate that control of recombinant titre by 5’TOP motifs could be replicated in 
industrially-relevant culture and transfection platforms, and with fully industrially relevant 
products, two libraries were created. Firstly, a selection of 6 TOP motifs were inserted into the 
TU1-Ef1α-SEAP vector, alongside TOP1 and NONTOP controls. All 8 of these transcription 
units were subsequently inserted into an MGVT vector, containing an OriP for stimulation of 
transient production (Daramola et al., 2014). These molecular cloning steps were performed 
by site-directed mutagenesis, as in section 2.3.2., and golden-gate cloning as in section 2.3.5. 
respectively, and verified by Sanger sequencing. All 5’TOP sequences used can be found in 
section 2.13.4. and Table 5.1, and a plasmid map of MGVT found in Appendix A. A schematic 
of the MGVT-TOP-CDS constructs used in this thesis is shown in Figure 5.15. 
 
Figure 5.15 – A schematic of the MGVT-TOP-CDS constructs used in this thesis.  
In an AstraZeneca transient production laboratory, this library was transfected by PEI into the 
CHO transient host by a proprietary method, and subject to conditions for an AstraZeneca-
optimised 7-day transient production process. To assess whether TOP expression could be 
further activated, two feed schemes were used, one feeding only on day 0 (D0 feed), the other 
feeding on day 0 and day 4 (D0+4 feed), both with a proprietary feed. Supernatants were 
collected 7 days post-transfection, and analysed for SEAP titre by Sensolyte assay, as in section 
2.6.2. The results of this analysis are shown in Figure 5.16. Figure 5.16a shows the titre fold 
changes resulting from the D0 feed. Transfection of all seven TOP sequences increased SEAP 
titre compared to the NONTOP control, six of which were significant, with a maximum  1.88-
fold change with TOP36. With the alternative feeding regime, D0+4 feed, displayed in Figure 
b, transfection of all seven TOP sequences were again associated with increased titre, six 
significantly, with a maximum of 2.56-fold with TOP37. Comparing the fold change in titre 
associated with the same TOP sequences between the two feeds in Figure c, the expression of 
four TOP sequences (TOP8, 12, 36, 37) is significantly activated by the D0+4 feed. Grouping 
all constructs with a TOP sequence together in Figure d, it can be seen that their expression is 
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significantly activated by the D0+4 feed compared to the D0 feed, with average titre fold-
changes of 1.98 and 1.49, respectively. To assess whether control of titre with the same 
recombinant protein was replicable across different culture platforms, the titres measured 
from this experiment were plotted against those given by the same TOPs, in the 96 deep-well 
plate transfection described earlier in Figure 5.3. When plotted against titres from the D0 feed 
in Figure e, a significant correlation is noted, with an R2 value of 0.71. In contrast, plotting of 
D0+4 feed titres in Figure f yields no significant correlation, with an R2 value of 0.09. These 
data show that TOP motifs can be used to control titre in an industry-relevant transient culture 
platform, increasing titre beyond the natural Ef1α 5’TOP, that these titres may be further 
activated by different feed schemes, and that whilst the same TOP-CDS constructs can show 




Figure 5.16 – 5’TOP motifs can control SEAP titre in an industry transient expression process. A) 6/7 TOP 
motifs impart a significant (P<0.05) increase in SEAP titre compared to NONTOP controls on a D0 feed, up to 
a 1.88-fold change with TOP36. B) 6/7 TOP motifs impart a significant (P<0.05) increase in SEAP titre compared 
to NONTOP controls on a D0+4 feed, up to a 2.56-fold change with TOP37. C) 4/7 TOP motifs are significantly 
(P<0.05) activated by the D0+4 feed compared to the D0 scheme. D) TOP-SEAP titres are significantly 
(P=0.0009) activated by the D0+4 feed compared to the D0 feed. E) TOP-SEAP titres from the D0 feed display a 
significant correlation (P=0.045, R2=0.71) with their corresponding titres from a 96 deep-well plate transfection, 
whereas F) D0+4 fed cultures do not (P=0.56, R2=0.09). All 5’TOP sequences referenced can be found in section 
2.13.4. and Table 5.1 of this thesis. The results shown are of two technical replicates, from three biological 
replicates. FC: fold-change; D: day. 
To validate that 5’TOP motifs could be used to control titre of an industrially relevant protein, 
a single-chain fusion protein (scFP)was inserted into the TU1-Ef1α vector, the same 8 TOP 
variants introduced as in the previous experiment, and inserted into the MGVT vector 
containing OriP. These molecular cloning steps were performed by restriction/ligation 
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between AgeI/SbfI sites as in section 2.3.6., site-directed mutagenesis as in section 2.3.2., and 
golden-gate cloning as in section 2.3.5. respectively, and verified by Sanger sequencing. All 
5’TOP sequences used can be found in section 2.13.4. and  Table 5.1, and the MGVT plasmid 
map found in Appendix A.  
These 8 constructs were similarly transfected with PEI into the CHO transient host by a 
proprietary method, and subject to the AstraZeneca 7-day transient production process, with 
the D0 and D0+4 feed schemes. Titres of the protein were measured 7 days post-transfection 
by Octet assay, as in section 2.10.3. Titres measured from the D0 feed are shown in Figure 
5.17a. All TOP sequences were associated with increased titre compared to the NONTOP 
control at 61.4mg/l, TOP1 and TOP8 showing significant increases with 111.1mg/l and 
109.5mg/l, respectively. Data from the D0+4 feed, Figure 5.17b, showed that cells transfected 
with all TOP sequences again exhibited increased scFP titre compared to the NONTOP control 
at 72.4mg/l, TOP37 and TOP36 showing significant increases with 153.6mg/l, and 127.2mg/l, 
respectively. Comparing titres derived from the two feeding regimes in Figure 5.17c, titre of 
scFP is increased by the D0+4 feed with all constructs, including the NONTOP control, but 
this increase is only significant with TOP37, increasing from 83.8mg/l to 153.6mg/l. Finally, 
the total TOP-scFP library shows significant expression activation by the D0+4 feed compared 
to the D0 feed, increasing from an average of 88.9mg/l to 124.2mg/ml, as shown in Figure 
5.17d. These results show that TOP sequences can be used to control the titre of an industrially 
relevant biotherapeutic protein, and that in one case, further additive increases in titre may be 




Figure 5.17 – 5’TOP motifs can control titre of an industrially relevant DTE molecule in an industrial transient 
expression process. A) All TOP motifs increase the titre of scFP compared to a NONTOP control with a D0 feed, 
two doing so significantly: TOP1 (P=0.025) and TOP8 (P=0.0051). B) All TOP motifs increase the titre of scFP 
compared to a NONTOP control with a D0+4 feed, two doing so significantly: TOP36 (P=0.033) and TOP37 
(P=0.027). C) Expression of TOP37-scFP is significantly (P=0.023) activated by the D0+4 feed. D) As a group, 
expression of the TOP-scFP library is significantly (P=0.0015) increased by the D0+4 feed. All 5’TOP sequences 
referenced can be found in section 2.13.4. and Table 5.1 of this thesis. Results presented are of technical duplicates 





Throughout the results presented in this chapter, it is evident that the effect of 5’TOP motifs 
on recombinant protein expression is setting-dependent. The first such discrepancy came 
when screening the 5’TOP-SEAP library. Although PEI transfection was first utilised to target 
more consistent cell growth across the plate, it also leads to significant activation of the 5’TOP 
motifs’ effect on titre. Although correlation was noted between their effect on specific 
productivity (R2=0.64), electroporation and PEI led to identification of different 5’TOP motifs 
as significantly increasing expression, for instance 23 5’TOP motifs increased specific 
productivity with PEI, and 10 with electroporation, of which only 5 were in common. 
Therefore, one method had to be chosen as the model from which successful sequences could 
be identified. The 96 deep-well plate electroporation method has been shown to produce high 
transfection efficiencies of greater than 90% (Cartwright et al., in print). However, its’ variable 
effect on cell growth renders it a difficult system for reliably measuring specific productivity. 
Transfection by PEI led to far more consistent growth, considerably activated 5’TOP 
expression compared to electroporation, and is the most commonly used method for high-
yielding transient biopharmaceutical production (Daramola et al., 2014; Hacker et al., 2013; 
Rajendra et al., 2015a). Therefore, it was chosen as the more appropriate model system for 
selection of 5’TOP motifs to take forward into future studies.  
Activation of MTORC1, and therefore of acute activation of 5’TOPs, is mediated through both 
growth factors and nutrients, particularly glucose, leucine, arginine, and glutamine (Ben-
Sahra and Manning, 2017; Saxton and Sabatini, 2017; Yao et al., 2017), with both required for 
its’ full activation (Valvezan and Manning, 2019), and inhibited by rapamycin (Roux and 
Topisirovic, 2018). However, supplementation titration of culture in Figure 5.6 with both a 
commercially available feed, and with specifically targeted amino acid mix failed to 
specifically activate 5’TOP-SEAP expression. The same figure shows the successful 
implementation of the effect in reverse: specific, acute repression of 5’TOP expression by 
25ng/ml rapamycin. One explanation may be that 5’TOP motifs are already active in basal 
CHO cell culture, with nutrient-rich media and ideal conditions for cell growth. Figure 5.3 
shows 5’TOP motifs are sufficiently activated in basal CHO cell culture to give a 3.34-fold 
increase in SEAP titre with the right 5’TOP sequence.  However, this explanation is 
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contradicted by analysis of the Omics dataset from which the 5’TOP library was derived, 
comparing the Log10 of various expression characteristics of TOP and NON-TOP genes, 
presented in Figure 5.18. Figure 5.18a, b, and c show that TOP genes have on average a higher 
protein abundance, mRNA abundance, and total translational activity that their NON-TOP 
counterparts. However, the translational efficiency (how many amino acids are added to the 
respective gene’s protein, per hour, per mRNA) of TOP genes is slightly lower than NON-
TOP. This is consistent with current models of 5’TOP repression, wherein mRNA abundance 
is kept high by the stabilising effect of LARP1 binding and 40s ribosome sequestering 
(Gentilella et al., 2017). Moreover, Omics datasets from other cell lines show that 5’TOP genes 
can exist in a translationally-enhanced state, as shown in Figure 5.19, where an Omics dataset 
derived from NIH3T3 cells (Schwanhausser et al., 2011) shows that translation efficiency of 
TOP genes (and a ribosomal protein subset) are significantly increased compared to the total 
gene dataset, in contrast to the CHO Omics dataset, where no such activation is observed.  
Furthermore, significant activation of TOP expression was achieved in Figure 5.16 and Figure 
5.17 by differences in proprietary feed, with both SEAP and scFP. Collectively, the data in this 
thesis imply that whilst TOP motif expression is sufficiently activated to produce significant 
increases in titre, it may not be fully activated in basal CHO cell culture. TOP motif expression 
can be further stimulated by chemical manipulation via a proprietary feed. This effect was not 
replicated by simple nutrient supplementation, but the root cause of the activation cannot be 






Figure 5.18 – Translation efficiency of TOP genes is not activated in basal CHO cell culture. TOP genes exhibited 
higher A) protein abundance (P<0.0001), B) mRNA abundance (P<0.0001), and C) translational activity 
(P<0.0001) that NON-TOP genes. However, as shown in D) translation efficiency is significantly (P=0.049) 




Figure 5.19 – Translation efficiency of TOP genes is 
activated in NIH3T3 culture. TOP genes, as well as a 
ribosomal protein subset, both exhibited significantly 
(P<0.0001) higher translational efficiency than the total 


































In an attempt to integrate the translational control imparted by 5’TOP motifs with the 
transcriptional control granted by synthetic promoters, a selection of user-defined synthetic 
proximal promoters taken from Brown et al., 2014 were inserted upstream of the Ef1α core 
promoter. Figure  5.9 shows that this approach was unsuccessful: the promoter strengths did 
not align to user definition. This can be explained by the promoter architecture of Ef1α. The 
transcription start-site element of Ef1α is a TCT motif, in contrast to CMV, which uses an Inr 
motif. TCT motifs, and the resultant 5’TOP motifs they transcribe, are a rare core element, 
occurring in ~1% of mammalian promoters (Ngoc et al., 2017). Importantly, TCT core 
promoters are not bound by the TFIID/TBP complex which is necessary for Inr transcription, 
and indeed are insensitive to TBP knockdown (Wang et al., 2014). Instead, TCT core promoters 
are bound by TRF2, facilitating TATA-independent transcription (Duttke et al., 2014). It has 
been postulated that this functional difference allows for specialised control of transcription 
(Lenhard et al., 2012), which may have facilitated evolution of the Bilateria (Duttke et al., 
2014). The RNA Polymerase II core promoter is described as punctilious (Vo ngoc et al., 2017): 
sequence elements are essential and specific for function, and it has been shown that enhancer 
regions for TCT promoters do not necessarily stimulate Inr core promotors, and vice-versa 
(Zabidi et al., 2015). Therefore, the synthetic promoters used in this study did not act as 
designed because they were designed against the Inr CMV core (Brown et al., 2014a). The 
success of the 10xNFκB  promoter demonstrates, however, that synthetic promoters could be 
designed against the Ef1α core, and even that it may have responsive TFREs in common with 
CMV. Taking the opposite approach, by integrating a TCT core into the CMV promoter 
yielded promising results, as seen in Figure 5.11, in contrast to similar attempts made in 
literature with endogenous genes (Parry et al., 2010). Relatively strong expression from an Inr-
less promoter, and differential yields between TOP variants suggest TCT-based, TRF2-
dependent transcription. Whether or not this TCT core is rendered receptive to Inr-based 
proximal control by placement in an Inr promoter will be explored in Chapter 6 of this thesis.   
The results presented in this chapter show that 5’TOP motifs are a viable and powerful tool 
for control of biopharmaceutical expression, especially in the light of Figure 5.16 and Figure 
5.17, showing their efficacy both in an optimised transient biopharmaceutical production 
setting, and with a directly industrially relevant biotherapeutic protein. Their effect on 
expression, however, appears not to be predictable. This is demonstrated in Table , where the 
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average titre fold-changes imparted by four 5’TOP motifs across different protein products 
and culture conditions are shown. 
Having established by results presented in Figure 5.3 that 5’TOP motifs can grant significant 
increases in SEAP titre and specific productivity, a more nuanced result was gained from 
screening of the 5’TOP-EPO library, in Figure 5.13. Addition of TOP sequences to the 
deoptimised EPO68 universally increased titre and specific productivity. Similarly, the 
optimised EPO71 carried a significantly higher titre without a TOP sequence, compared to 
NONTOP-EPO68. However, only TOP37 significantly increased the titre of EPO71, compared 
to the NONTOP control. Moreover, TOP37 and NONTOP were the only variants which saw 
a significant increase in titre between EPO68 and EPO71. Whilst TOP37 may share a sequence-
specific affinity with EPO71 (an effect which will be discussed below), these findings generally 
imply that although codon optimisation or addition of TOP motifs individually benefit 
expression, their effects may not combine in a synergistic, modular fashion. When translation 
efficiency is sufficiently optimised, by initiation or elongation, these data suggest that a 
bottleneck is formed downstream, for instance in folding or secretion, rendering expression 
insensitive to further increases in translation efficiency. Further investigation using codon 
optimised and deoptimised proteins known to be easy (e.g. SEAP, GFP) and difficult to 
express (e.g. an aggregating mAb) may elucidate this question.  
Another explanation for this bottleneck could be the saturation of translational machinery, for 
instance initiation factors or ribosomes, by sufficiently high levels of EPO expression (Jackson 
et al., 2010). This hypothesis could be investigated by additional stimulation of expression by 
cellular engineering by translational, and non-translational, components. If overexpression of 
non-translational components, for example XBP1, fails to relieve this expression bottleneck, 
and translational components succeed, it would support this hypothesis.  
Two mechanisms of stimulation of EPO titre can be inferred from Figure 5.14, where codon-
optimized EPO68 is increased in terms of translation efficiency, whereas the optimized EPO71 
is increased in terms of mRNA abundance. Both of these mechanisms of expression 
manipulation are consistent with models of TOP expression. In the case of EPO71, MTORC1 
may not be fully activated, meaning TOP mRNA is sequestered, increasing half-life and 
decreasing translation efficiency (Gentilella et al., 2017). With EPO68, MTORC1 may be 
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activated or deactivated, replicating the effect observed with EPO71, or increasing translation 
efficiency (Hong et al., 2017). These observations are consistent with the hypothesis of 
downstream expression bottlenecks: if EPO translation, engineered through 5’TOP motifs or 
codon optimisation, is elevated enough to cause bottlenecks in folding and induce the UPR, 
autophagy may be induced to counterbalance this effect (Bernales et al., 2006; Hussain et al., 
2014), requiring the deactivation of MTORC1 (Saxton and Sabatini, 2017). As with all 
molecular biology tools, 5’TOP motifs are not capable of alleviating bottlenecks downstream 
of their point of action, and these data demonstrate that control of translation may be rendered 


























TOP8  0.49 1.22 1.89  1.49 0.92  1.78 1.68 
TOP12  2.51 1.43 2.04  1.5 1.04  1.44 1.49 
TOP36  3.34 1.88 2.44  1.43 1.07  1.47 1.76 
TOP37  1.86 1.62 2.56  1.59 1.4  1.36 2.12 
 
Table 5.3 – 5’TOP motifs produce highly variable fold-changes in titre across different product proteins and 
conditions. Heatmaps showing strength of titre fold-change are calibrated separately for each product protein.   
The effect exerted by 5’TOP motifs on titre appears firstly dependent on the protein being 
expressed. TOP8, for instance, appears ineffective at enhancing SEAP titre, giving the lowest 
titre in all three conditions tested, down to a 0.49-fold decrease in 96 deep-well plates. 
However, it performs reasonably well producing scFP, producing the highest titre with the 
D0 feed. TOP36, in contrast, excels at SEAP production, scoring the highest titre fold changes 
in two conditions, and second-highest in the third, up to an impressive 3.34-fold increase in 
96 deep-well plates, but is only moderately effective at producing EPO and scFP, scoring three 
second places and one last place. TOP12 is a moderate-to-low performer for SEAP and EPO, 
scoring two second and three third places, but is drastically worse at producing scFP, being 
associated with the lowest titre in both conditions.  
Secondly, effects on titre appear dependent on cell culture conditions. TOP37 is generally one 
of the highest-performing presented in this study, producing the highest titre in 4 out of the 7 
conditions presented in Table , including a 2.12-fold increase in scFP titre with the D0+4 feed. 
However, with the same protein and the D0 feed, it is associated with the lowest titre.  
In an ideal case, a TOP sequence could be synthetically designed to possess a user-defined 
effect on expression, titratable across a range of titres. Whilst this may be possible, the data 
presented in this chapter suggest that modelling of the TOP’s surrounding plasmid, coding 
sequence, expression system, and culture conditions may be required to reliably predict its’ 
effect on expression. 
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Whilst the use of 5’TOP motifs for controlling translation presented in this thesis are 
predictable nor titratable in its effect, it may still be a useful target in a transient screening 
system. Desirable traits of the tools develop in this chapter include dramatic changes include 
the ability to dramatically increase transient titre, for example of a biopharmaceutical scFP by 
>2-fold, integration with multiple promoter assemblies, and relatively simple insertion of such 
short sequences into expression plasmids. Combined, these characteristics make them an 
attractive tool for high-throughput transient testing. 
5.4. Conclusion 
In this chapter, I have investigated and developed the novel use of 5’TOP motifs as a tool for 
controlling biopharmaceutical expression. Their power to affect recombinant protein 
expression was repeated across multiple culture conditions and proteins, including the 
increase in productivity of a biotherapeutic protein in an industry optimised 7-day 
transfection platform, where TOP37 was associated with an increase in titre from 72.4mg/l, to 
153.6mg/l, compared to a NONTOP control. Promoter architecture requirements for their 
proper expression may limit their use beyond the Ef1α promoter, though this may be 
circumvented by the modification of Inr to TCT promoter cores, novel within the context of 
an industrial Ef1α promoter. With currently available data, a predictive model of 5’TOP 
motif’s effect on titre cannot be constructed. However, due to their effect on recombinant 
protein expression, and ease of implementation, they represent a viable and attractive tool for 
controlling biopharmaceutical expression.  
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6. Multielement Screen and Concluding 
Remarks 
6.1. Introduction 
Besides being predictable and titratable, an additional desirable trait of synthetic molecular 
biology tools is to be modular, meaning it can work in concert with other tools being deployed 
elsewhere in the system. The generalised behaviour of two wholly modular tools are shown 
in Figure 6.1.  The effects of the two modular tools combine synergistically, and their product 







Figure 6.1 – The behaviour of wholly modular synthetic biology tools. The 
effects of Tool A (1.5-fold) and Tool B (2-fold) combine synergistically, to 
provide a total 3-fold effect when used in combination. 
 
 
In practice, almost no synthetic biology tools will be entirely modular in this way. Overlaps 
and redundancies in mechanism, bottlenecks in expression downstream, and dozens of 
unpredictable example-specific interactions all prevent tools from cooperating in this strictly 
synergistic fashion. Nonetheless, it is important to know to what extent and in what 
circumstances tools behave modularly, as the most powerful expression and process 
engineering occurs when such tools are deployed together. For example, in Johari et al., 2015, 
both cellular engineering by protein overexpression, and chemical treatment of cultures are 
tested as methods of enhancing production of a DTE Fc-fusion protein. From this screen, CypB 
is identified as a target gene to enhance transient production, increasing titre by ~1.4-fold 
when cotransfected at 20% of the gene load of the Fc-fusion, mediated through increased 
IVCD. Two chemical compounds were also identified: PBA and Glycerol, which increased 




























respectively, both affecting titre through increasing specific productivity. These three tools 
were combined into a 12-day biphasic transient production process, which overall gave a 6-
fold increase in protein titre, displaying the power of synergistically combining synthetic 
biology tools. Further demonstration of the power of modular tools, and demonstration of 
limitations in their modularity, are found in Brown et al., 2019. In this study, various vector 
elements are first tested individually for their ability to increase SEAP titre, relative to a 
construct bearing industry-standard parts. A synthetic promoter is identified that increases 
titre by 2.05-fold, a signal peptide that does to by 1.48-fold, and a method of codon 
optimisation that does so by 1.38-fold. In combination, all three elements achieved only a 3.02-
fold increase in titre, in a non-synergistic combination that failed to outperform a similar 
construct made from less optimal variants of all three synthetic parts. However, when this 
bottleneck was relieved by integration with an adapted cell-line for secretion, and 
identification of ATF6 as an effector gene at an optimal dosage, the components acted in a 
more synergistic pattern, up to an impressive 9.24-fold increase in SEAP titre with the original 
transient screening system, increasing up to 12.37-fold in a six day fed-batch transient process, 




Table 6.1 – The synergistic effect of 
molecular biology tools identified by 
Brown et al., 2019. The predicted effect 
upon perfect synergy of each component 
(14.83-fold) is closely matched by the 
observed effect (12.37-fold), indicating 
a high degree of modularity.  
 
Finally, modular tools can also be used for more creative purposes than the synergistic 
maximisation of protein titre. For example in Yeo et al., 2017, different synthetic antibiotic 
selection markers are attenuated using mutated IRESs in alternative cell lines. Using 
Zeomycin as a selection agent, as opposed to Hygromycin increased product titres from 
9.80mg/l to 29.1mg/l, and selection marker attenuation of this IRES-Zeomycin brought titres 
as high as 353.5mg/l. 
Synthetic Tool SEAP Titre Fold Change 
Promoter 2.05 
Signal Peptide 1.48 
Codon Optimisation 1.38 
Cell Line 2.20 
Effector Gene 1.61 
Predicted Synergistic Effect 14.83 




6.2.1. Construction of the multielement SEAP library 
In order to test the modularity of the synthetic biology tools identified in this thesis, and to 
measure the range of expression they enabled in combination, a multi-element library was 
constructed. This library varied the core promoters (Ef1α, CMV-TCT), proximal promoters 
(100RPU, 20RPU, 10xNFκB ), TOP motif (TOP2, 8, 36, 37), and stability element (SE20), in the 
TU1-SEAP vector. Restriction/ligation and site-directed mutagenesis molecular cloning were 
both used to create this library, as in sections 2.3.6. and 2.3.2., which was verified by Sanger 
sequencing. Since the EF1α core has previously been shown not to perform as expected with 
the Brown et al., 2014 synthetic promoters, this combination was not used. The 100RPU and 
20RPU promoters were instead combined with the CMV-TCT core promoter, and the 
10xNFκB proximal promoter combined with the Ef1α core. Apart from these exceptions, every 
component was used in combination with every other, ensuring a thorough test of their 
modularity. This made for a total library of 40 constructs, in addition to the 2 controls of TU1-
SEAP, and TU1-Ef1a-SEAP, summarised in Figure 6.2. 
 
Figure 6.2 - A schematic of the multielement SEAP library. Four elements were varied in this library: proximal 
promoter, core promoter, TOP motif, and stability element. Each core promoter was only tested with its’ cognate 
proximal promoters: Ef1α with Ef1α-proximal and 10xNFκB , and CMV-TCT with CMV-proximal, 100RPU, 
and 20RPU. TOP: terminal oligo-pyrimidine; SEAP: secreted alkaline phosphatase; SE: stability element; UTR: 




6.2.2. Synthetic expression elements in combination are associated with a 
large range of transient SEAP titres 
This total library of 42 constructs was transfected by PEI at a 1:5 DNA:PEI ratio into the CHO 
transient host at 1*106 cells/ml, in 96 deep-well plate shaking culture. 72h post-transfection, 
VCD was measured by Iprasense as in section 2.4.4.3., and SEAP titre measured by Sensolyte 
assay, as in section 2.6.2. The measured SEAP titre, and calculated specific productivity, 
relative to TU1-SEAP, are displayed from highest to lowest in Figure 6.3. Figure 6.3a shows 
that transfection of 19 constructs was associated with significant increases in SEAP titre 
compared to TU1-SEAP, with a densely-populated range from 1.11-fold with 100RPU-TCT-
TOP36-SEAP, up to 5.23-fold with 10xNFκB-TOP36-SEAP-SE20. Five constructs were 
associated with significantly decreased titre, down to 0.82-fold with TCT-TOP2-SEAP. 
Similarly in Figure 6.3b, cells transfected with 19 constructs exhibit significantly increased 
specific productivity, from 1.08-fold with TCT-TOP2-SEAP-SE20, up to 5.98-fold with 
10xNFκB-TOP36-SEAP-SE20. Five constructs were associated with decreases in specific 
productivity, down to 0.81-fold with TCT-TOP2-SEAP. SEAP titre and specific productivities 
measured in this experiment are significantly correlated (P<0.0001, R2=0.99). These data 
suggest that an expansive range of expression strengths are made attainable by the combined 





Figure 6.3 – Multielement SEAP library screening. A) SEAP titres of 0.82-fold to 5.23-fold relative to TU1-
SEAP are observed across the library, with 19 constructs signficantlty (P<0.05) increasing titre, and 5 
significantly decreasing it. B) SEAP specific productivities of o.81-fold to 5.98-fold are observed across the library, 
with 19 constructs signficantlty (P<0.05) increasing specific productivity, and 5 significantly decreasing it. All 
synthetic promoter sequences referenced can be found in section 2.13.5. and Table  of this thesis, 5’TOP sequences 
in section 2.13.4. and  Table 5.1, and stability elements in section 2.13.3 and Table 4.2. Results presented are of 




To examine whether SE20 performs the function of titre stimulation consistently across 
different constructs, the SEAP titre observed with each construct from the previous 
experiment, with and without SE20 are shown in Figure 6.4. The addition of SE20 was 
associated with a significant increase in titre with 14 out of 20 constructs, and a non-significant 
increase in titre from TCT-TOP2-SEAP, from 0.82-fold to 0.94-fold. Interestingly, the addition 
of SE20 decreases the titre of every construct containing TOP37, with 2 out of 5 being 
significant. These data suggest that SE20 generally stimulates the expression of multiple 
SEAP-containing constructs, but can be rendered suppressive by sequence-specific effects.  
 
Figure 6.4 – SE20 enhances the titre of all SEAP constructs, apart from those bearing TOP37. 14/20 constructs’ 
SEAP titre is significantly (P<0.05) activated by addition of SE20, and 2 significantly decreased, both of which 
contain TOP37. All synthetic promoter sequences referenced can be found in section 2.13.5. and Table  of this 
thesis, 5’TOP sequences in section 2.13.4. and Table 5.1, and stability elements in section 2.13.3 and Table 4.2. 
























































































































































































































To identify whether the 10xNFκB  proximal promoter consistently increases titre when placed 
upstream of the Ef1α core promoter, the titre fold change imparted by all constructs 
containing the Ef1α proximal promoter compared to 10xNFκB , from the experiment 
described above, are shown in Figure 6.5. In all 8 such constructs, 10xNFκB  was associated 
with a higher titre than the Ef1α proximal promoter, 5 doing so significantly. A consistent 
ratio is seen between 10xNFκB /Ef1α constructs, with an average of 1.20 and standard 
deviation of 0.096. These data show that the 10xNFκB  proximal promoter is consistently 
capable of  increasing SEAP titre, compared to the unmodified Ef1α promoter, within the 
context of an Ef1α core. 
 
Figure 6.5 – The 10xNFκB  proximal promoter consistently increases SEAP titre from the Ef1α core promoter. 
5/8 constructs give significantly (P<0.05) higher titre with the 10xNFκB  proximal promoter than modified Ef1α. 
All synthetic promoter sequences referenced can be found in section 2.13.5. and Table  of this thesis, 5’TOP 
sequences in section 2.13.4. and  Table 5.1, and stability elements in section 2.13.3. and Table 4.2. Results 














































































It was assessed whether the CMV-TCT promoter core developed in Chapter 5 of this thesis is 
receptive to predictable control of transcription by the synthetic proximal promoters 
developed in Brown et al., 2014. All constructs with this core from the previously-described 
experiment are presented together in Figure 6.6, showing the difference in SEAP titre 
associated with the CMV, 20RPU, and 100RPU proximal promoters. No significant change is 
measured between the CMV and 20RPU proximal promoter in any construct. However, the 
100RPU promoter is associated with a significant increase in titre compared to CMV in 6 of 
the 8 constructs. These data suggest that whilst the CMV-TCT core does not produce the pre-
defined strengths of transcription granted by proximal promoters designed for the 
unmodified CMV core, expression from it may still be stimulated by the stronger proximal 
promoters.  
 
Figure 6.6 – The 100RPU proximal promoter can stimulate expression from CMV-TCT cores. The SEAP titre 
from 6/8 constructs is significantly (P<0.05) higher with the 100RPU than the CMV proximal promoter. No 
significant changes are observed between the CMV and 20RPU proximal promoters. All synthetic promoter 
sequences referenced can be found in section 2.13.5. and Table  of this thesis, 5’TOP sequences in section 2.13.4. 
and Table 5.1, and stability elements in section 2.13.3. and Table 4.2. Data presented are of technical duplicates 




























































































To assess the modularity of the tools used in this assay, Table  shows the fold changes in titre 
associated with the constituent parts of the highest-expression constructs for each promoter 
core variant. The expected fold-change imparted by a modular combination of these elements 
and the observed fold change in titre imparted by the construct containing all three are both 
shown. In both contexts, the observed effect outperforms the fold-change predicted by the 
multiplied product of each individual element. This indicates firstly that a bottleneck in SEAP 
expression has not yet been reached, which would otherwise compromise the modularity of 
the tools. Secondly, it shows that there is little to no functional redundancy between the tools. 
Indeed, their ability to collectively outperform the expected product of their effects may 
suggest co-activation of one another. For instance, an increase in mRNA stability imparted by 
SE20 may further facilitate the activation of translation given by a 5’TOP sequence.  
Ef1a Core CMV-TCT Core 
10xNFκB  1.25 100RPU 1.67 
TOP36 1.20 TOP36 1.11 
SE20 2.47 SE20 1.15 
Predicted Modular Fold Change 3.72 Predicted Modular Fold Change 2.13 
Observed Fold Change 5.51 Observed Fold Change 2.50 
Table 6.2 – Comparing the individual effect on SEAP titre of the most efficacious single tools, within both an Ef1α 
and CMV-TCT core context, with their predicted combined effect in a modular system, calculated by the product 
of all their individual effects, and their observed effect when combined together. 
6.3. Discussion 
Over the course of this thesis, two tools have been developed for use in controlling titre of 
biopharmaceutical recombinant proteins: the stability element, and 5’TOP motifs, with the 
addition of a modified CMV core promoter to accommodate the latter. In combination with 
the previously designed tool of synthetic promoters, a vector library was constructed that 
achieved a densely-populated range of SEAP titre from 0.81-fold to 5.23-fold change relative 
to the industry-standard TU1-SEAP vector. This is firstly notable because it outperforms the 
fold-change in SEAP expression achieved in Brown et al., 2019 by vector elements alone, before 
a bottleneck was encountered that had to be relieved by cellular engineering, at around a 3-
fold increase in titre (Brown et al., 2019).  This may be due to differences in transfection 
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platform, as the lipofectamine used in Brown et al., 2019 is well documented to carry a higher 
transfection efficiency than the more industrially-relevant PEI used in this study (Hacker et 
al., 2013; Wang et al., 2018), which could lead to differences in expression dynamics. This 
difference could also be explained by alterations in the process targeted by the respective 
studies. In Brown et al., 2019, transcription is targeted by synthetic promoters, translation 
elongation by codon optimisation, and folding/secretion by signal peptides. This study shares 
the transcriptional targeting, but also targets translation initiation with 5’TOP motifs, and 
mRNA half-life with the stability element. These two processes could form a more restrictive 
bottleneck in SEAP expression that those targeted in Brown et al., 2019. However, the effector 
protein which best relieves this bottleneck in Brown et al., 2019 is ATF6Ac, a transcription 
factor that stimulates production of foldases and chaperones, implicating a bottleneck further 
downstream. More insight could be gained from this by further integration of synthetic 
elements from this study with previously developed tools, for example measuring the effects 
of 5’TOPs and signal peptides together. 
The 5’TOP sequences used in this screen display some consistency, and therefore 
predictability, in their effect on expression, but are also clearly affected by other sequence 
features. TOP37, for instance is the highest-performing 5’TOP motif in terms of titre in all 
constructs lacking SE20. In all constructs containing SE20, it produces the lowest titre of all 
the TOP variants. TOP8, meanwhile, produces no significant difference in titre compared to 
TOP2 in all constructs lacking SE20, but produces a higher titre in all construct variants 
containing SE20, significantly (P<0.05) so in 3 out of 5 cases. Figure 6.4 shows that addition of 
SE20 consistently increases SEAP titre, with the exception of constructs containing TOP37. As 
the stability elements were identified by a descriptive study, and no mechanistic basis of their  
action is known, it is difficult to infer the cause of this sequence-specific interaction. No 
complementarity is found between TOP37 and SE20 sequence. In the absence of a mechanistic 
explanation, the best conclusion to draw is that the ability of 5’TOP motifs to influence 
recombinant protein titre may be sensitive to 3’UTR sequence elements. Excluding TOP37, the 
addition of SE20, whilst consistently increasing titre, has a stronger effect on constructs with 
an Ef1a, as opposed to a CMV-TCT promoter core. As shown in Figure 6.7, the average titre 
increase given by addition of SE20 to a vector containing an Ef1α core promoter is 3.34-fold, 
244 
 
significantly higher than the 1.81-fold increase with CMV-TCT, implying that transcripts 
expressed from an Ef1α core benefit to a greater extent from extension of their half-life. 
 
 
Figure 6.7 – Addition of SE20 has a greater positive effect 
on Ef1α than CMV-TCT core constructs. The mean titre 
fold change given by addition of SE20 to Ef1α core 
constructs is 3.34-fold, significantly (P=0.0001) higher 
than those with a CMV-TCT core. Due to its’ specific 
negative interaction with SE20, TOP37 constructs are 
excluded from this dataset. The SE20 sequence can be 
found in section 2.13.3. and Table 1. Results displayed are 
of technical duplicates, from four biological replicates. FC: 
fold-change; SE: stability element. 
 
 
Figure 6.5 shows that the 10xNFκB  proximal promoter retained a consistent ability to slightly 
increase expression from the Ef1α core promoter in all SEAP constructs, these data suggesting 
it as a  predictable tool for leveraging this effect. More mixed results were gained from the 
CMV-TCT core promoter, shown in Figure 6.6. The 100RPU proximal promoter did show a 
relatively consistent ability to upregulate expression compared to the CMV proximal. Given 
that its design includes a number of highly-responsive TFREs, its ability to increase 
transcription is not surprising. However, the 20RPU proximal did not align to its’ defined 
function, to produce significantly less transcriptional activity than CMV (Brown et al., 2017). 
Together, these data suggest that whilst the synthetically engineered CMV-TCT core is more 
responsive to synthetic promoters developed for the CMV core than Ef1α, it does not possess 
the ability to entirely reconcile the precise synthetic control of transcription given by these 
synthetic promoters with control of translation by 5’TOP motifs.  
Whilst each tool presented here displays different extents of predictability, notwithstanding 
the question of whether the stability element will similarly stimulate the expression of 
alternative proteins, it can be are argued that they, as a collective, render expression strength 



























accessible, through the diverse mechanisms of controlling transcription, translation initiation, 
and mRNA stability. 
6.3.1. Future Work 
Whilst the synthetic molecular biology tools presented in this thesis are powerful, modular, 
and titratable when considered together, more work would be required to develop them into 
truly predictable tools. In this section, I will present several questions that need to be answered 
for each element to be developed in this way, and propose tests to each end.  
The most pertinent question in relation to the stability element is whether SE20 represents a 
one-size fits all solution for extension of mRNA half-life. Whilst it retained its positive 
influence on titre, the extend of this stimulation was significantly different between the Ef1α 
and CMV-TCT core promoter, suggesting a measure of dependency on its’ context. Secondly, 
the other tool developed in this thesis, 5’TOP motifs, have different optimum sequences 
depending on the protein being expressed. SE20 has only been shown to stimulate SEAP titre, 
and it is unknown whether a different stability element may be required for alternative 
recombinant proteins. These questions can be addressed by wider screening of stability 
elements, under different promoters (e.g. SV40), with different 5’UTRs and 3’UTRs, and with 
different recombinant proteins (e.g. EPO, GFP, an scFP).  
The specific titre-inhibitory interaction between TOP37 and SE20 is of note, due to its 
implication of specific 5’TOP motifs and stability elements’ potential to interfere with one 
another. To understand and predict this, the expression characteristics of this interaction 
should first be understood. Expression cassettes both with and without TOP37 and SE20 could 
be analysed by RT-qPCR, to understand their combinatorial effect on mRNA processing. 
Further investigation might involve measurement of their mRNA stability by inhibition of 
transcription, or more direct inference of their translation efficiency by polysome profiling. 
Alternatively, to determine the sequence elements necessary for the interaction, a series of 
mutational studies could be undertaken, investigating which sequence elements abolish the 
effect when altered.  
The primary questions to be answered concerning 5’TOP motifs as a tool relate to the nuanced 
results from the EPO screen presented in Chapter 5. Firstly, is the bottleneck in expression 
which prevented most 5’TOP motifs from increasing the titre of codon-optimised EPO 
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conserved across difficult to express molecules? Secondly, is the observed effect on mRNA, 
with 5’TOP motifs increasing the abundance of an optimised transcript, and having no effect 
on the non-optimised mRNA, conserved across difficult to express molecules? Thirdly, is this 
effect accompanied by induction of the UPR with optimised, high-production transcripts, as 
hypothesised in Chapter 5? These questions could be addressed by testing the effect on 5’TOP 
motifs on the expression of optimised and deoptimised transcripts of proteins known to be 
easy to express (e.g. GFP, SEAP) and difficult to express (e.g. an aggregation-prone scFP), 
coupled with RT-qPCR analysis of their transcript abundance. To assess the UPR hypothesis, 
accumulation of UPR-associated proteins such as XBP1S could be measured in parallel, by 
western blot (Johari et al., 2015). 
Studies from thesis show that the effect on expression of particular 5’TOP sequences is highly-
context dependent. Changes in effect have been noted in different vector contexts, with 
different recombinant proteins, in different culture conditions, and with different 3’UTR 
sequences downstream. If control of recombinant protein expression by 5’TOP motifs is to be 
rendered predictable, a model must be constructed which incorporates all of these conditions. 
This is difficult to achieve, and there is currently no published literature or datasets addressing 
the effect of 5’TOP motifs on recombinant protein expression. To begin approaching this 
problem, a database could be built, noting the conditions of transient expression processes, 
e.g. the cell type, vector construct, recombinant protein, feed scheme, growth profile, etc. This 
database could be analysed by a dimensionality reduction algorithm, such as principal 
component analysis, to identify trends in the data. For instance, TOP-X may tend to be a high-
producer of easy to express, non-glycosylated proteins in a 7 day process under a day 0 feed 
scheme, whilst TOP-Y may tend to stimulate production of difficult to express proteins, in a 
14-day fed-batch culture where the cells are kept in stationary phase. If such patterns do 
emerge, they could be used to make predictions of appropriate 5’TOP motifs to use for future 
expression of biotherapeutic proteins. In support of this proposal, replicability of the effect of 
5’TOP motifs with some similar conditions has been demonstrated in this thesis, by the 
correlation of titre fold changes given by TOP sequences to SEAP using a 7-day industrial 




6.3.2. How to Use This Toolkit 
In Chapter 1 of this thesis, a workflow was proposed for the rationalisation of CLD process 
design, by an iterative process of transient screening and targeted application of synthetic 
biology tools. In it, analysis of expression after round one of transient screening of a new 
molecule would be used to inform synthetic design of an expression system for round two, 
allowing for the use of effectively targeted synthetic molecular biology tools. 
In this thesis, two such viable molecular biology tools have been developed: 5’TOP motifs for 
control of translation, and stability elements for control of mRNA stability. In an ideal case, 
the effect of 5’TOP motifs and stability elements could be user defined: predictably modifying 
expression characteristics to desired parameters. For instance, if the light chain of a mAb 
needed to be expressed at a 4:1 stoichiometry to the heavy chain, 5’TOP motifs could be 
assigned to grant its’ transcript a 4-fold greater rate of translation. At their current stage of 
development, neither 5’TOP motifs nor stability elements represent tools with the necessary 
predictability for this system. This imposes a small change: for optimisation of their respective 
target functions, multiple solutions should be screened, as shown in Figure 6.8. Fortunately, 
the relative simplicity of both of their implementation, incorporating between 5-34nt into a 
synthetic vector, render their production and testing in a high-throughput system viable. The 
large range of expression strengths they bestow demonstrate that they represent a powerful 




Figure 6.8  - A schematic of the generalised use of the molecular biology tools developed in this thesis. Whilst a 
single predictable user-defined solution is not yet possible, parallel testing of multiple tool variants may still be 
deployed in this system, to reduce R&D risk, and ensure a high success rate in cell line development for 
glycoprotein production. 
6.4. Conclusion 
Synthetic molecular biology tools present a powerful solution, to rationalising and de-risking 
the design and implementation of CLD for biopharmaceutical production. A lack of tools 
influencing mRNA dynamics have limited the scope of this toolbox.  
Investigation of novel RNA-binding effector proteins C1orf35 and HuR as such tools gave a 
set of initially promising results and interesting targets for future research. The association 
C1orf35 with stimulation of cell growth is consistent with the limited knowledge available on 
it. Similarly, observation of HuR stabilising mRNA and subsequently enhancing specific 
productivity are consistent with literature, and may imply the potential use of ARE-binding 
proteins in biopharmaceutical expression. However, the incongruities inherent to effector 
gene screening in cell lines between transient and stable expression systems rendered these 
tools inappropriate for a system predicated on transient-to-stable transferability of outcomes.  
The 3’UTR stability elements, specifically SE20, have been shown and validated to increase 
production of the SEAP model recombinant protein across several vector contexts and culture 
conditions. Moreover, its’ mechanism of action has been confirmed as extension of mRNA 
half-life. This use of the elements discovered in Oikonomou et al., 2014 is entirely novel. It 
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implies both the value in investigating the enhancement of biopharmaceutical titre via the 
3’UTR, and the potential power of omics-forward approaches to element discovery, even 
when a molecular mechanism isn’t apparent. The immediate next step should be to investigate 
whether SE20 presents a more general solution to mRNA stabilisation and titre enhancement, 
or whether its’ effects are more product, or context-dependent.  
5’TOP motifs have been shown to exert a high degree of control over the expression of 
recombinant protein. This has been validated across a number of vector contexts, culture 
platforms, and recombinant proteins, including an industry-standard transient screen of an 
scFP biotherapeutic molecule. Though 5’TOP motifs are relatively well characterised, and 
related molecular mechanisms such as mTOR overexpression and rapamycin treatment have 
been utilised in biopharmaceutical production, this direct use of 5’TOP motifs within 
expression vectors is entirely novel. The next step in the development of this tool will be to 
develop an understanding of the context-dependence of their effect on expression, thus 
making possible their predictable integration into a rationalised CLD process. 
When combined, together with synthetic promoter tools for control of transcription, these 
novel tools enable a wide array of expression strengths, enabling a  range of transient SEAP 
titres from 0.82-fold to 5.23-fold compared to an industry-standard vector, and behave in a 
synergistic modular fashion. Whilst a number of questions and developments will need to be 
solved to render each fully predictable in new contexts, this body of work has contributed two 
powerful, valuable synthetic biology tools toward the rationalisation of biopharmaceutical 
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Appendix A: Vector Maps and Construction 
TU1 
The basal TU1 vector is shown below, expressing SEAP as its’ CDS. The unique restriction 
sites, intended for cloning of vector elements in the transcription unit vector system (Patel et 
al., in press) are highlighted. Alternative genes were inserted by restriction/ligation cloning at 






TU1-SEAP-6xPP7bs, shown below, was generated by insertion of 6xPP7bs into the 3’UTR of 





FRT TO – PP7d Fusion 
Shown below is the FRT TO-PP7d-fusion expression vector, in this case encoding the PP7d-
C1orf35 fusion. This vector was first generated by insertion of PP7d, plus the SV40 NLS and 
HA tag, into the FRT TO vector, by Gibson Assembly. Genes were then inserted downstream 






To generate this construct, the C1orf35 CDS was inserted downstream of the 3xFLAG peptide 






The triple helices library was constructed by insertion of triple helices (in the example shown, 
MALAT1) downstream of the TU1-SEAP 3’UTR, in place of the SV40 PolyA, by SbfI/NotI 
restriction/ligation cloning. For constructs containing a PolyA, the SV40 PolyA was inserted 






Stability elements were inserted directly downstream of the SEAP CDS and SbfI restriction 







The TU1-Ef1α-SEAP expression vector (also referred to as TOP1-SEAP) was generated by 
insertion of the Ef1α promoter in place of the CMV promoter and 5’UTR in the TU1-SEAP 
vector, by EcoRI/PpuMI restriction/ligation cloning. Alternative genes were inserted by 
PpuMI/SbfI restriction/ligation cloning. 5’TOP sequences were inserted in place of TOP1, 
shown below, by site-directed mutagenesis. The Ef1α region upstream of the TATA box was 
designated as the proximal promoters, and synthetic proximal promoters inserted by 








The TU1-TCT expression vector was generated by insertion of the TCT motif, in place of the 
Inr motif, in the CMV core of TU1-SEAP. In the spacing variants, base pairs upstream of the 
TCT motif in the Ef1α promoter were inserted upstream of the TCT motif in this core. Taking 








To generate MGVT-Ef1α constructs, TU1-Ef1α transcription units (from BsaI sites upstream 
of the Ef1α promoter, and downstream of the SV40 PolyA) were inserted into the MGVT 
vector by Golden Gate cloning. 
 
 
 
